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Chronic pain is pain which persists beyond the normal physiological healing timeframe. It 
affects up to 20% of the Australian and New Zealand populations. Chronic pain is also costly, 
not only in terms of healthcare costs, but also in lost work days and decreased productivity. 
Surgery is one of the leading causes of chronic pain, highlighting the need to understand and 
prevent the transition from acute to chronic post-surgical pain. This study has documented 
the onset and development of subacute pain and the development of chronic pain. The 
undertaking of this study may have added to the arsenal of tools used to predict which 
patients will go on to develop chronic pain. By predicting chronic pain development in 
advance, interventions may be developed to prevent the development of persistent post-
surgical neuropathic pain. Considering the rising costs of healthcare, and the growing 
socioeconomic burden of chronic pain, strategies to prevent chronic post-surgical pain need 
to be carefully considered.  
Hypothesis:   
That one or more of the proposed factors measured perioperatively will predict continued 
pain at six weeks and three months after gynaecological surgery. 
Aims:    
1) To determine the prevalence of acute persistent pain at 6 weeks following surgery 
2) To determine the prevalence of chronic pain at 3 months following surgery 
3) To determine the extent to which (if at all) the perioperative factors measured 
predict continued pain at six weeks and three months. 
Methods:  
Patients were assessed at the Christchurch Women’s Hospital Pre-Admission clinic and 
approached for written informed consent. Those agreeing to participate were given 
validated questionnaires to complete in order to document their physical, emotional and 
functional state pre-surgery. In addition a cold pressor test was carried out to determine 




containing ice. The pain slowly builds until the participant can bear it no longer, at which 
point it is voluntarily removed from the stimulus.  
Intraoperative factors (anaesthetic techniques, surgical techniques, and analgesic use) were 
measured, as well as patient-controlled analgesia (PCA) use, and medications prescribed on 
discharge. 
At 6 weeks, participants were telephoned, and validated questionnaires completed. At 3 
months, all participants were again telephoned, and validated questionnaires were 
completed.  
Results and conclusions:  
Of the 54 participants 15.7% were deemed to be experiencing significant pain at 6 weeks 
post-operatively; 8.2% of participants were deemed to be experiencing significant pain at 3 
months postoperatively. The psychometric questionnaires used often found differences 
between those experiencing pain and those not experiencing pain at given observation 
points, but only the Brief Illness Perception Questionnaire (BIPQ) appears to be predictive of 
developing prolonged postoperative pain. The mean difference (7.4 on a 0-50) scale may 
even be enough to see it used clinically alongside other predictive measures. Many of the 
demographic factors correlated with the experience of pain at a given time point(s), but 
none were predictive of the development of prolonged pain to significant levels. 
The cold pressor test did not show any significant differences between those in pain at 
baseline, and those that are not in pain at baseline. However, pain threshold as measured 
by this test was shown to predict prolonged pain outcomes. Pain tolerance and pain 
endurance followed the same trend, but were not statistically significant.  
No surgical approach or group was significantly more likely to develop a prolonged pain 
state than the others. However, it did seem as though laparotomy may be associated with 
poorer pain outcomes, which is supported by the literature. Intraoperatively, those who 
would later develop prolonged pain states were less likely to receive opioids, but possibly 
likely to receive greater doses if they did. Perhaps worryingly, those who would later 
develop prolonged pain states were significantly more likely to receive tramadol 




discharge prescribing, however non-significant trends were noted across both in terms of 
prescription of specific non-steroidal anti-inflammatory drugs (NSAIDs) and weak opioids.  
Introduction to this thesis: 
Chapters One, Two, and Four of this thesis review the relevant literature for the following: 
the pathophysiology and epidemiology of pain (Chapter One); the tools currently available 
for the management of pain (Chapter Two); the tools used in this study to measure pain; 
and the tools used in this study to measure pain related behaviour (Chapter Four). Chapter 
Three gives a brief overview of the relevant aspects of the gynaecological surgical types 
used in this study. Chapter Five of this thesis outlines how the protocol for this study was 
designed and tested, while Chapter Six outlines the hypothesis, specific aims, and methods 
used in data collection and analysis. Chapter Seven details the results discovered using the 
aforementioned methods. Chapter Eight discusses the results found in Chapter Seven, the 
limitations and strengths of the present study, and draws conclusions based on these. From 
this, Chapter Eight makes appropriate recommendations for future research and notes 
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Chapter One – Pain 
 
1.1 Introduction to post-surgical pain 
The International Association for the Study of Pain (IASP) defines pain as: ‘An unpleasant 
sensory and emotional experience associated with actual or potential tissue damage, or 
described in terms of such damage’ (1). Pain is a subjective, multidimensional sensation with 
strong affective overlays (2). As stated, it is a result of potential or real tissue injury, and is 
considered the normal physiological end-point of this (3).  Pain can arise in the absence of 
tissue injury. This is indicative and demonstrative of strong psychological links in pain (4). The 
unconditioned response to pain is affectively negative. However, with conditioning an 
individual can become indifferent to, or even enjoy certain painful stimuli, such as different 
sexual behaviours, or the pain of physical exercise (2). The unconditioned negative response 
to pain serves a protective function (5), as the result is avoidance of painful (and, by proxy, 
injury-inducing) stimuli. This is best exemplified by sufferers with congenital or acquired 
insensitivity to pain, conditions in which serious tissue injury and/or death result from the 
sufferer’s lack of protective responses to injurious stimuli (5).  
Soft tissue injury and/or inflammation, such as that caused by surgery, is the archetypical 
cause of acute pain (2). In most cases, acute pain following surgery will decline in the days 
following surgery. Within weeks patients are free of pain, and able to go about their daily 
lives as they did prior to their surgery (6). However, around one in ten (7) (8) patients do not 
recover as uneventfully. Their pain persists beyond the accepted ‘normal’ duration, 
becoming chronic, and in many cases intense and disabling (9). Pain persisting after the 
surgical wound has healed is normally the result of nerve irritation. These sources of 
irritation can be exogenous to the nerve (such as inflammation), or endogenous to the 
nerve (such as nerve damage from the surgery) (7) (6) 
Psychological factors such as depression and stress correlate with chronic pain following 
surgical procedures (10). It is not yet known whether this relationship represents a cause or 
an effect, or simply a statistical association (11). However, the evidence for a correlation 
between Chronic Post-Surgical Pain (CPSP) and psychological and demographic (e.g. age, 




Genetic factors can play a large role in the differences between individuals in terms of pain 
perception, duration, and response to treatment (6) (13) (14). Changes in both the peripheral 
and central nervous systems alter an individual’s responses to both painful stimuli and non-
painful stimuli. Non-painful stimuli such as touch can be perceived as painful, a process 
known as allodynia. Painful stimuli are amplified and perceived as very painful, a process 
known as hyperalgesia. Internal factors (psychological, genetic, and neurochemical), and 
external environmental factors (such as social expectations) influence the severity and 
duration of an individual’s experience of pain (15). These advances in understanding of pain 
have caused the accepted view of pain to shift. Chronic pain can have the properties of a 
disease process in its own right, and not merely a symptom of an underlying problem (15).  
1.2 Acute Pain  
Acute pain is often thought of as a normal, predictable, protective response to noxious 
stimuli, such as chemical, mechanical, and thermal insults (3). Pain exists to ensure 
withdrawal from dangerous situations and to condition the individual to avoid future 
encounters with painful stimuli. This description over-simplifies the complex mechanisms by 
which pain is detected and interpreted, as each individual interprets diverse painful stimuli 
differently (2).  This suggests that ‘pain’ as a negative response to a given stimulus is not fixed 
in terms of perception or intensity between individuals, or even in the same individual in 
different situations. Inter-individual physiological and psychological factors largely influence 
the perception of pain. Intra-individual differences in pain perception in various situations 
have strong psychological overlays as well (1). 
1.2.1 Physiology 
There are three commonly accepted ‘types’ of acute pain. They are as follows; nociceptive 
(or ‘somatic’), visceral, and neuropathic (2) (16).  
Nociceptive or somatic pain involves the activation of the receptors of sensory nerve fibres 
known as nociceptors. There are two classes of nociceptors. The first class consists of the 
high-threshold mechanoreceptors (HTMs) which are thinly-myelinated nociceptors with free 
nerve endings that are activated in response to mechanical insults (17). The second class of 
nociceptors  are the polymodal nociceptors (PMN), which form a heterogeneous group 





The afferent nerve fibres which carry the pain impulses from their nociceptive endings to 
the brain are also split into two categories. There are the myelinated (A delta) fibres (known 
as ‘fast’ fibres), that carry the HTM nociceptors, and the unmyelinated (C) fibres (known as 
‘slow’ fibres), that carry the PMN nociceptors (2). The pseudo-unipolar neurones to which 
these fibres belong have cell bodies residing in the dorsal root ganglia (or the trigeminal 
ganglion), and their fibres terminate in the dorsal horn of the spinal cord (17). From here, the 
pain signals travel centrally via the neospinothalamic tract (for ‘fast’ pain), and the 
paleospinothalamic tract (for ‘slow’ pain). These axons terminate in the thalamus. From 
here are distributed widely throughout the brain, in particular to the cerebral cortex and 
limbic system (17). 
 
‘Physiological’ pain is caused by a high-intensity, transient, noxious stimulus causing 
activation of local nociceptors (19). ‘Pathological’ pain, however, occurs following damage to 
tissues (by ischaemia, or physical trauma), causing the release of inflammatory chemical 
mediators. As a result, regional nociceptors become sensitised to further noxious stimuli (19), 
resulting in peripheral hyperalgesia (20). 
  
Visceral pain is pain arising from an internal organ. These signals are mostly carried by C 
fibre axons (2). Visceral pain tends to be poorly localised for two reasons. Firstly, because the 
density of visceral nociceptors is lower than that found somatically. Secondly, it is poorly 
localised due to the highly diffuse central distribution of visceral nociceptive signals (16). As a 
result, pain arising from the viscera is often ‘confused’ with somatic pain along the spinal 
dermatomes (16). An example of this is the fact that pain is often experienced along the left 
lower cervical and upper thoracic dermatomes following a myocardial infarction.  
  
Visceral pain differs from somatic pain in terms of its subjective qualities (16). The pain 
sensations from visceral organs range from almost none (lung, liver), to pain in organs that 






The recent IASP Taxonomy working group has redefined neuropathic pain as ‘pain caused by 
a lesion or disease of the somatosensory nervous system’ (22). Neuropathic pain occurs as a 
result of abnormal functioning of a specific region of a part of the nervous system (2). In 
peripheral neuropathic pain, this malfunctioning usually occurs as the result of an external 
insult, such as mechanical trauma or severe temperature. This results in a negative shift in 
the balance of factors regulating excitatory and inhibitory signals. In partial injuries, this 
gives rise to increased excitatory activity that can lead to hyperalgesia due to the lowered 
threshold for nociceptive excitatory transmission (16). Central neuropathic pain occurs after 
damage (such as ischaemic injury) to regions of the central nervous system involved with 
somatosensory processing, leading to sensitisation of those neurones (2). For example, 
central neuropathic pain can develop from damage to the spinothalamic tract (23). 
  
Of course, no discussion of pain is complete without considering the psychological 
influences on the course of pain. Psychological factors influence not only the development 
and maintenance of pain, but the ability to cope with it. Pain, particularly when chronic, is 
associated with psychiatric disorders, such as depression and anxiety (24). Likewise, 
somatoform disorders can cause the experience of pain with little or no identifiable organic 
causes (24). As the IASP definition states, pain is “an unpleasant sensory and emotional 
experience associated with actual or potential tissue damage, or described in terms of such 
damage”. This describes the intertwined nature of the sensory and emotional aspects of the 
pain experience.  
 
1.2.2 Epidemiology  
As is to be expected after the physiological insult sustained when one’s body is sliced open, 
acute post-operative pain is very common among surgical patients. The severity and 
duration of this pain is dependent on the type of surgery and type of anaesthesia given (7), 
the adequacy of pain relief (25), and the patient’s inherent psychological and physiological 






1.3 Subacute Pain  
1.3.1 Physiology and pathology 
‘Persistent pain’ is a concept poorly defined in the literature, with some articles using the 
term almost synonymously with chronic pain (7), while others appear to use it as a stage 
occurring between acute pain and chronic pain (28). For the purposes of this study, the term 
‘subacute pain’ is viewed as a pain state in between acute pain and chronic pain that will be 
measured at six weeks postoperatively. This is to construct a reference point between 
‘acute postoperative pain’, and ‘chronic pain at three months postoperatively’. This provides 
a more valuable insight than the ‘acute versus chronic’ dichotomy.  
Because this pain state is loosely defined, the exact pathophysiological and 
psychopathological processes involved in the development of this pain state have not been 
studied per se. However, if subacute pain is viewed as a half-way point on a continuum from 
acute pain to chronic pain, it can be reasonably concluded that the pathological processes 
would resemble the process involved in the development of chronic pain.  
Chanda et al 2011 (29) describe the differing characteristics between a group (n=40) suffering 
‘subacute’ back pain (defined as 6-16 weeks duration), and a group (n=37) suffering 
‘chronic’ back pain (defined as >1 year duration). Three statistically significant differences 
were found. The authors noted that other factors were close to significant levels, but not 
detected due to lack of power.  
The three statistically significant findings were as follows: Firstly, and most relevant to this 
study, pain intensity. Interestingly, participants in the ‘chronic’ group scored significantly 
higher than the ‘subacute’ group on the Visual Analogue Scale (VAS). This is a 100mm line 
with zero being ‘No pain’ and ten being ‘Worst pain ever’. This indicates that pain intensity 
is higher among those with longer duration. It remains unclear whether this is because their 
pain worsens over time, or simply that those with greater pain intensity are more likely to 
progress to chronic pain. Similar results have been replicated in other studies (30) (31).  
The other two findings were specific to back pain (pain location, temporal dynamics of 





Most importantly, these findings suggest that subacute pain may not simply be an extension 
of acute or chronic pain; it may in fact form a distinct pain state. This thesis aims to further 
explore this idea, by repeating psychometric and pain score analyses at 6 weeks (‘subacute’) 
and at 3 months (‘chronic’) postoperatively, albeit limited by the timeframe available.   
1.3.2 Epidemiology  
Subacute pain is a relatively new and under-studied topic, making exact estimations of its 
prevalence difficult. However, if it is a pain state somewhere between acute pain and 
chronic pain, then the numbers experiencing subacute pain should be in between. The risk 
factors for developing chronic pain, such as surgical type, anaesthetic/analgesic technique, 
genetics, and socioeconomic factors (28) could logically be applied to subacute pain. For 
example, a patient undergoing a limb amputation, with all of the nerve damage and 
psychological factors involved, would likely have a longer recovery (in terms of pain as well 
as functionality) than a patient undergoing a laparoscopic hernia repair.  
It follows that the ‘risk’ of developing subacute pain should be higher than that of chronic 
pain, as by definition one must experience pain through the subacute period and beyond to 
be classified as being in chronic pain.  
The aspect of subacute pain that seems of the most practical importance is its transition to 
chronic pain. If more is learned about the differences between subacute and chronic pain, 
then perhaps controllable factors can be identified, and needless suffering prevented. In 
viewing pain as a three (or even more) step transition, rather than the ‘acute versus chronic’ 
dichotomy, perhaps more subtle insights can be gleaned.  
1.4 Chronic Pain  
Chronic pain, for all the research being carried out on it, is not overly well defined (2). The 
general consensus appears to be that it is pathological pain that continues beyond the 
‘normal healing period’ (32). What constitutes the ‘normal healing period’ remains a point of 
ongoing debate, with most cut-off points between three and six months (29) (33), with these 
time points being rather arbitrary. Regardless of its exact definition, chronic pain has 
become a significant problem, both in terms of individual suffering (34) (35), and in terms of its 




(8) (28) (36). Its incidence is higher in more invasive procedures such as thoracotomies, limb 
amputations, and mastectomies (28) (38).  
Chronic pain can result from many causes, not just surgery. In Australia, 17% of Australian 
males and 20% of Australian females report chronic pain, as do 16.9% of New Zealanders (39) 
(40). Chronic pain is costly, costing the Australian economy $34.4 billion per annum ($10,847 
per sufferer) (41). Large contributing factors are the cost of healthcare itself, absent workdays 
due to chronic pain, and reduced-effectiveness workdays. Chronic pain places the third-
largest financial burden on Australia's healthcare system, behind only cardiovascular 
diseases and musculoskeletal conditions. The latter is also associated with chronic pain, so 
some of the costs ascribed to musculoskeletal conditions are likely at least partially due to 
chronic pain. Surgery was found to be the second most common cause of chronic pain in the 
United Kingdom (42). This highlights the importance of identifying those most at risk, and the 
need to develop some preventative strategies. 
  
1.4.1 Pathophysiology 
The transition from acute to chronic pain is a complex process, an understanding of which is 
still in its infancy (34). Understanding of the pathophysiological processes behind this 
transition is crucial, as targets can be uncovered that can be used to halt the transition (43).  
Surgery, being a rather physiologically traumatic process, causes the release of a host of 
inflammatory mediators that sensitise peripheral nociceptors in the surrounding area (28). A 
series of reactive changes then occurs within the central nervous system, resulting in central 
sensitisation (34). These processes are likely protective, as increased pain sensations will 
naturally result in behaviour which reduces the risk of further damage, and allows healing. It 
has been suggested that chronic postoperative pain could be a failure of this system to 
‘reset’, resulting in ongoing (and possibly even compounding) hyperalgesia, driven 
particularly at central level (34). CPSP tends to closely resemble the characteristics of 
neuropathic pain. The surgical procedures with the highest risk of chronic pain tend to carry 
a high risk of major nerve involvement. Surgical injury to nerves contributes a significant 




Peripherally, as with any tissue injury, surgical procedures invoke an inflammatory response. 
The damaged tissues release pro-inflammatory substances (cytokines, prostaglandins, and 
histamine), triggering a localised inflammatory response. This sensitises local nociceptors 
and decreases the level of stimulus required to trigger them. The result is localised 
hyperalgesia (43). This is known as peripheral sensitisation (44). Peripheral nerve damage 
during surgery plays a major role in peripheral sensitisation, by creating hyperalgesia 
(excessive response to painful stimuli), and allodynia (a painful response to non-painful 
stimuli) (7). Damaged neurones can exhibit altered sodium ion channel expression, resulting 
in spontaneous activity, and altered sensation (34). In addition, within hours of the surgical 
trauma, afferent neurones exhibit (reversible) altered gene expression which results in an 
increase in excitatory neurotransmitters, and  a decrease in inhibitory transmitters (45) (46). 
Of course, inflammatory responses can be (and usually are) transient, and dissipate once the 
injury has healed. Major damage to a large peripheral nerve, however, is unlikely to ever 
fully return to its previous level of functioning. Nerve damage is far more likely to progress 
to chronic pain than inflammatory damage alone, although usually the peripheral 
component of chronic post-surgical pain would initially involve a combination of the two.  
At the interface of peripheral and central sensory systems lies the dorsal horn of the spinal 
cord. Peripheral nociceptive neurones synapse here, and their signals can be altered by 
several mechanisms, particularly involving the N-methyl-D-aspartate (NMDA) receptor (34), 
calcitonin-gene-regulated peptide (CGRP) and Substance P (44). Through these and other 
mechanisms, numerous intracellular alterations within the nociceptive afferents within the 
spinal cord, and result in increased sensitivity (28). This is partially responsible for the 
phenomenon known as ‘wind up’ (temporary summation) seen in central sensitisation.  
Peripheral sensitisation results in a large increase in the frequency and intensity of pain 
signals reaching the central nervous system from the periphery. The central nervous system 
correctly interprets this to mean that the body has been injured, and that protective 
measures need to be taken. Through diverse intracellular pathways resulting in ion channel 
and external receptor phosphorylation, these neurones become more excitable with a lower 
threshold for activation (7). Using similar mechanisms as in peripheral neurones, central 




The brain becomes more responsive to potentially harmful stimuli, and protective measures 
(such as rest, and guarding of the injured area) are adopted by the affected individual. If 
these responses become excessive or longstanding, neurones can become so sensitive that 
non-noxious stimuli are sufficient to trigger a nociceptive response (46). This gives rise to 
allodynia and secondary hyperalgesia (where uninjured areas become hypersensitive to 
painful stimuli) (28). 
1.4.2 Epidemiology and public health implications 
There are many factors known to influence the likelihood of developing chronic post-
surgical pain. Factors known to decrease the risk include: increased age (47), female gender 
(48), pre-operative pain (49), severe acute post-operative pain (50), genetics (51), certain 
psychological factors (13), the anaesthetic technique used (13), and surgical factors (such as 
duration, likelihood of nerve damage) (52).  
As previously stated, chronic pain develops in 5-60% of surgical patients. Not only the pain 
itself, but its flow-on effects, such as deleterious effects on mobility and cognition (53) (54), can 
have severe impacts on psychosocial (55) and workplace (53) functioning. In Germany, chronic 
pain (including that caused by surgery) costs an estimated 38 billion euro per year, in 
healthcare costs and in decreased work productivity (56). Despite this, the basic medical 
degree in most Australasian (and American) (57) medical schools is lacking in detailed training 
in the management of pain in painful conditions, and these conditions are seen as outside of 
the scope of general practitioners (53). As such, there is an increasing demand for 
practitioners who are trained in the management of complex pain, with Pain Medicine being 
recognised as a vocational specialty in its own right by the Medical Council of New Zealand 
in December 2012 (8). In New Zealand, the specialty is overseen by the Australia and New 
Zealand Faculty of Pain Medicine (FPM), which grew within the Australia and New Zealand 
College of Anaesthetists (ANZCA), but its development has had inputs from other colleges, 
such as the Royal Australasian College of Surgeons (RACS), the Royal Australian and New 
Zealand College of Psychiatrists (RANZCP), the Royal Australasian College of Physicians 
(RACP), and the Australasian Faculty of Rehabilitation Medicine (AFRM). The accreditation of 
Pain Medicine as a specialty in New Zealand has generated expectations for improved care 




Chapter Two – Management of Pain 
 
2.1 The clinical components of pain 
In order to effectively manage pain, an understanding should be gained of more than just 
physical nociception. Naturally the treatment of pain usually requires the selection of an 
appropriate analgesic agent. This selection would be assisted by knowledge of the 
nociceptive insult in question. However, pain is a multifactorial experience, and thus pain 
management must target more than just the physical nociceptive aspect.  
There are four accepted ‘clinical components of pain’ (2), namely, nociception, pain itself, 
suffering, and pain behaviour.  
2.2 Issues surrounding adequate peri-operative pain management 
The right to access effective pain management has been deemed a ‘basic human right’ (60). 
As pain could arguably be described as the most unpleasant physical and emotional aspect 
of the human experience, the vast majority of sufferers desire to decrease both the 
frequency and severity of their pain experience. Considering the powerful emotional 
responses involved in pain, it seems reasonable to expect others to empathise with the pain 
experiences of sufferers, and feel compelled to assist in alleviating their pain. It is likely that 
this has created our ethical views around pain management.  
Unfortunately opioids such as morphine and fentanyl that are the mainstays of inpatient 
treatment of acute pain (61) are potentially addictive, tolerance-forming, and subject to 
abuse. They are therefore tightly regulated (60). These factors accompanied by 
misconceptions of opioid administration from physicians and patients alike (such as ‘some 
pain is inevitable’, and ‘chronic opioid administration will certainly decrease quality of life’) 
(60) result in up to 50% of surgical patients receiving inadequate analgesia (62) (57). 
Inadequate management of acute postoperative pain increases the risk of adverse 
cardiovascular events (63), and enhances the risk of going on to develop chronic pain 
syndromes (60). Chronic pain is accompanied by an increased risk of depression, anxiety, and 




adds to sufferers’ impaired capacity for productivity (66). This highlights the need for 
effective peri-operative pain management.  
2.3 Pharmacological management of pain  
There is an ever-growing list of pharmacological agents available, with varying levels of 
evidence, used in the relief of pain. The choice of agent depends on the intensity and 
duration of the pain, and its aetiology. The major classes of pharmacological agents used for 
analgesic purposes are discussed below. 
2.3.1 Opioid analgesics 
No discussion of opioids in the literature appears complete without the famous quote 
‘Among the remedies which it has pleased Almighty God to give to man to relieve his 
sufferings, none is so universal and so efficacious as opium.’ 
(Thomas Sydenham, circa 1680) 
Opioids, in the form of the opium poppy Papaver somniferum have been used for analgesic 
purposes for thousands of years (67). The ‘archetypal’ opioid, to which others (natural, semi-
synthetic, and synthetic) are usually compared, is morphine (67).  
As with most drugs, opioids as a class mimic existing endogenous compounds (68). These 
endogenous compounds are referred to as ‘endorphins’, a term derived from the words 
‘endogenous’ and ‘morphine’ (69). There is a heterogeneous array of both the endorphins 
themselves and their receptors (the ‘main’ three being mu, kappa, and delta), produced 
largely in the pituitary gland (70). These substances are known to modulate pain and stress in 
the brain. They have several peripheral functions, and are involved in the regulation of 
blood pressure and of gastrointestinal motility (70) (68).  
All three opioid receptors are G-protein coupled. Their activation results in any of a number 
of intracellular cascades that largely lead to decreased neuronal excitability, and the 
resulting decreases in neurotransmission and neurotransmitter release (71) (72). Paradoxically 




The mu-opioid receptor, the main pharmacological target of morphine (by which it is 
named), and has both desirable effects (analgesia), and undesirable effects. Undesirable 
effects include physical dependence, respiratory depression, urinary retention, pruritus, and 
bradycardia. Other effects that could be classed as either desirable or undesirable 
depending on the circumstances of their use include euphoria (anti-depression), and 
constipation (anti-diarrhoeal) (71). The mu-opioid receptor is distributed widely throughout 
the brain, particularly in areas involved in the higher processing of perceiving, integrating, 
and forming emotional responses, such as the cerebral cortex and limbic system (72). It is 
also thought to decrease gamma-amino butyric acid (GABA) transmission in the 
periaqueductal grey (PAG). GABA is the major inhibitory neurotransmitter in the brain (74). 
The PAG plays a role in regulating the descending inhibitory pain pathway (75) (67). The 
decrease of GABA-ergic transmission results in increases in descending inhibitory signals in 
the PAG. These inhibitory signals sent down the descending inhibitory pain pathways 
decrease the perception of pain.  
The kappa-opioid receptor has analgesic properties as well. Unlike the euphoria produced 
by the mu-receptor, kappa-receptor activation results in dysphoria (72). Its side-effect profile 
largely limits the use of kappa-agonists. Its activation does not produce respiratory 
depression, but it is sedating and dissociating resulting in undesirable effects on cognition 
(72). This means that specific kappa-agonists are of limited clinical value. Once actions of 
each specific subtype can be elicited and their respective target genes can be identified, 
more specific pharmaceutical agents will likely be developed. 
The delta-opioid receptor has some analgesic properties, but can cause respiratory 
depression, potential convulsions, and physical dependence (71). Because its analgesic effects 
are not as pronounced as those of the mu-receptors (76), research is currently being focussed 
around its potential use as a pharmacological target for novel antidepressants (76) (77) (78) (79). 
The deduction of the chemical composition of morphine allowed the production of semi-
synthetic opioids such as oxycodone and heroin (diacetylmorphine), and later fully synthetic 
opioids, such as fentanyl and methadone (67). This was initially an attempt to retain 
morphine’s analgesic properties, but not its addictive ones (80). This remains a work in 




acts as a serotonin-noradrenaline reuptake inhibitor as well as being a weak mu-receptor 
agonist (81). Tapentadol is a newer, more potent mu-receptor agonist than tramadol. It is a 
noradrenaline reuptake inhibitor, but its serotonin reuptake inhibition is relatively weak (82). 
The need for opioids with lower dependence/misuse liability cannot be overstated. For 
example, in 2008 in the United States, it was estimated that roughly 4.8% of the population 
over twelve years of age had used prescription opioids for non-medical purposes (83). As well 
as directly searching for agents with inherently lower abuse/dependence liability, 
modifications to the methods of formulation are being developed. These include crush-
resistant or tamper-proof formulations rendering the drug unable to be insufflated or taken 
intravenously (84). 
Apart from the abuse/dependence potential, other adverse effects of opioids include 
respiratory depression, nausea and vomiting, pruritus and constipation. Acute opioid 
overdose is typically treated by administration of an opioid antagonist, such as naloxone or 
naltrexone (85). Naloxone acts as an ‘antidote’ to opioid agonist overdose by competing with 
the agonist for the mu-opioid binding site (it acts on kappa- and delta-receptors as well), 
without activating the receptor itself (71). 
In the management of acute pain, opioids are generally considered to be the gold standard 
and most effective agents in managing acute pain, particularly in the hospital setting (3). 
Their role in chronic pain becomes much more contentious (86) (87) (88). Even a Cochrane 
Collaboration review was unable to arrive at firm conclusions (89). There is a need for further 
investigations into their long-term analgesic efficacy, the adverse effects of opioids, and the 
impact of opioids on quality of life and functionality.  Unfortunately, as noted by the 
Cochrane Review (89), the follow-up period required renders the use of randomised 
controlled trials to be deemed impractical. This area will likely continue to rely on 
observational studies. In the meantime, the judgement of the individual clinician continues 






2.3.2 Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and steroids – The link between 
inflammation and pain 
The ‘Non-Steroidal Anti-Inflammatory Drugs’ (NSAIDs) are the most heavily-prescribed drug 
class on the planet (90). Brand names such as ‘Neurofen®’ (ibuprofen) and ‘Voltaren®’ 
(diclofenac) are likely to be the first pain reliever of choice for a consumer when confronted 
with mild to moderate pain. Unlike the opioids (of which only low-dose codeine, mixed with 
paracetamol is available over-the-counter in pharmacies in New Zealand) (91), many NSAIDs 
are readily available over-the-counter. As such, use of these medications is higher than that 
predicted by the prescription rate.  
It is presumed that the NSAIDs’ apparent analgesic qualities are largely due to their effects 
on inflammation. They do this by inhibiting the cyclooxygenase enzymes (COX-1 and COX-2), 
which in turn results in a decrease in prostaglandin synthesis, as the prostaglandins are 
involved in inflammation and pain signalling (92). 
The NSAIDS are broadly grouped into two classes, namely, those that ‘non-selectively’ 
inhibit both COX-1 and COX-2 (although naturally the extent to which each is inhibited 
depends on the individual agent), and those which are selective for COX-2 (celecoxib, 
etoricoxib, and paracoxib) (92). ‘Non-selective’ NSAIDs include ibuprofen, naproxen, 
diclofenac (93), and aspirin, although aspirin’s most common clinical use is as an anti-platelet 
agent to reduce the risk of cardiovascular incidents (92). The only COX-2 selective NSAID 
currently funded in New Zealand is meloxicam, although it shows COX-1 inhibition with 
increasing dose (94). 
The clinical profiles of these agents are largely dependent on which of the two COX enzymes 
the individual agent targets the most. COX-1 (along with the prostaglandins it produces) is 
found in endothelial tissue, platelets, in parts of the upper gastrointestinal tract, and in the 
kidney (95). As such it exerts control over platelet aggregation, renal blood flow, and mucous 
secretion in the upper gastrointestinal tract (95). From this, some of the actions, both positive 
and negative, of non-selective NSAIDS can be deduced. For example, aspirin’s anti-platelet 
effect is due to COX-1 inhibition in platelets. Likewise the negative gastrointestinal effects of 




protective mucous secretions, exposing the gastric mucosa to the low pH acidic fluid in the 
stomach. 
COX-2 is the enzymatic target by which NSAIDs largely have their desired clinical analgesic 
effects (92). COX-2 is found in white blood cells (macrophages, leukocytes), connective 
tissues, and joints (95). It is involved in inflammatory processes and in pain signalling, as well 
as in the inhibition of platelet aggregation (92). So while selective COX-2 inhibiting agents 
may some of the gastrointestinal effects associated with non-selective agents, they come 
with an increased risk of serious cardiovascular incidents, such as myocardial infarction (96). 
Paracetamol (acetaminophen) is one of the most commonly used analgesic and anti-pyretic 
agents worldwide (97). The mechanism of action is complex, combining peripheral and 
central COX inhibition, and inhibition of other important central pathways such as the 
descending serotonergic pathway, and perhaps even the cannabinoid system, among others 
(98). Although the precise mechanism of action remains unclear it becomes increasingly 
obvious that it is a central one (99). Paracetamol is generally considered to have a superior 
side-effect profile to the NSAIDs (94) (92) (97), with few or no adverse effects on the 
gastrointestinal tract (100), and no discernable effects on platelet function or on 
cardiovascular events (101). However, overdose of paracetamol is both more common, and 
more toxic than the NSAIDs (102). It has become the most common cause of acute liver 
failure in the United States (103). Nonetheless, it is recommended in New Zealand as a first-
line analgesic, with or without codeine or an NSAID, depending on the circumstances (94). 
Corticosteroids such as dexamethasone are often used as adjuvant analgesics (104), 
particularly in palliative care and in cancer management (104) (105). In peri-operative pain 
management a single preoperative 0.1 mg/kg dose of dexamethasone is anti-emetic and 
provides enhanced analgesia (106). Corticosteroids, like opioids, can mimic endogenous 
substances (107). Steroids are involved in the modulation of neuronal development and 
plasticity, which is of interest in terms of pain management (107). They are potent anti-
inflammatory agents by directly binding to Deoxyribonucleic Acid DNA (as a steroid-receptor 
complex) and by directly exerting effects on target genes, such as decreasing the synthesis 




creates a potent immunosuppressant effect limiting their use in the peri-operative situation 
(109). 
2.3.3 Adjuvant, novel, and secondary analgesics 
Secondary analgesics are described by Shipton in 1997, as “those agents having a pain-
relieving property as a secondary nature of their clinical activity. They can, however, be used 
as sole analgesic agents to treat various types of pain states” (110). As such, this definition 
essentially covers a variety of pharmacological agents not primarily used for their analgesic 
effects. It encompasses a diverse range of drug classes and individual agents. The 
aforementioned paper classes these agents by mode of action. As there are many different 
classes and agents, only the more commonly-used secondary analgesics will be discussed. 
-Antidepressants 
The tricyclic antidepressants, selective serotonin reuptake inhibitors (SSRIs), and serotonin-
norepinephrine reuptake inhibitors (SNRIs) have all found their way into the management of 
pain (110) (111) (112) (113). Not only do they have pharmacological actions with direct analgesic 
effects (112), it seems logical that given the strong psychological factors at play in pain, their 
anti-depressant effects would most likely indirectly decrease the pain perceived (111) (110). 
However, the efficacy of antidepressants in pain is limited, and restricted to certain pain 
syndromes. Only one of every three or four patients will experience a clinically significant 
reduction (50%) in pain (114) (115). 
The tricyclic antidepressants (TCAs) have several pharmacological actions that contribute to 
their clinical effects. They inhibit the presynaptic reuptake of serotonin and noradrenaline, 
as well as acting as antagonists at several serotonin receptors (5-HT2 in particular) (116), at α1-
adrenergic receptors (116), at H1-and H2-histaminergic receptors (117), and at muscarinic 
receptors (110) (111).  Two of the more commonly used agents, nortriptyline and amitriptyline, 
have slightly different effects. Amitriptyline causes a reasonably even reuptake inhibition of 
noradrenaline and serotonin, while nortriptyline favours noradrenergic reuptake inhibition 
(111). In addition, it is becoming increasingly evident that these agents function as neuronal 
sodium channel blockers, decreasing pain signal transmission (118) (119). These agents are 




Selective Serotonin Reuptake Inhibitors (SSRIs), as their name suggests, inhibit the synaptic 
reuptake of serotonin (5-hydroxytryptamine, 5-HT), resulting in an effective increase in 
central nervous system serotonin levels. It is by this mechanism and its downstream effects 
that the SSRIs are presumed to exert their anti-depressant effects (120). Their supposedly 
relatively benign side-effect profile is likely what led to interest in their use in pain (121) (114). 
Despite this, it appears that the analgesic effects of SSRIs are less consistent and much less 
efficacious than those of the TCAs (121) (114). This is perhaps somewhat surprising, given that 
knockout-mice studies have implicated 5-HT in inhibitory descending pain pathways (122) (123). 
As such it would seem that SSRIs should be reserved for those who cannot tolerate the 
TCAs. Speculation is that perioperative dosing with an SSRI might potentiate the analgesic 
effects of opioids and even decrease certain opioid side effects (124).  
Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs), like the SSRIs, inhibit the synaptic 
reuptake of serotonin. However, they also act to inhibit the reuptake of noradrenaline (114). 
By not binding to histamine, acetylcholine, or α1-adrenergic receptors, these agents have 
the potential to ‘side-step’ some of the common side-effects that can render TCAs 
intolerable to some patients (125). Venlafaxine, the most commonly-used SNRI, has been 
reported to be efficacious in case reports (125), and a review of the literature by Grothe et al 
(126) seems cautiously optimistic.  
Venlafaxine has been associated with a reduced incidence of chronic pain following 
mastectomy (127). There is reasonable evidence to support duloxetine’s efficacy in the 
treatment of painful diabetic peripheral neuropathy (128). It is likely that the SNRIs are more 
efficacious in the treatment of pain than the SSRIs due to their noradrenaline reuptake 
inhibition, as noradrenaline reuptake inhibition is considered to be the main mechanism by 
which TCAs and SNRIs relieve pain (115) (114).  
Bupropion is a ‘novel’ antidepressant, with a mechanism of action unlike TCAs, SSRIs, or the 
SNRIs. It is a noradrenaline-dopamine reuptake inhibitor (NDRI) (111). It appears to have some 
analgesic effects. Only a few trials have been conducted to date (129) (130). Only one double-
blind randomised controlled trial (conducted by Semenchuck et al) with a cross-over design 
showed promising results. Of the forty one participants, thirty (73%) described their 




phases. The changes in pain score were significantly greater following bupropion treatment. 
The authors described it as ‘well tolerated’ at the doses used. More research is needed, 
although promising early results and tolerability make it an option for those unable to 
tolerate other antidepressant treatments. 
-N-methyl-D-aspartate (NMDA) antagonists 
Glutamate is the main excitatory neurotransmitter in the human central nervous system (131) 
(132). As such, it seems reasonable to pursue ways of dampening certain glutamatergic 
systems to reduce pain signal transmission. There are an array of pharmacological agents 
known to antagonise the NMDA glutamate receptor, such as magnesium and ketamine (131). 
The NMDA receptor has been implicated in the neuronal changes in ‘wind-up’ and central 
sensitisation (133). It contributes to the development of opioid tolerance (134) (135), which 
potentially give NMDA antagonists a clinical role in the prevention of opioid tolerance. 
Ketamine is a non-competitive antagonist at the NMDA receptor, giving it analgesic and 
sedative effects through reduction of NMDA-mediated central sensitisation (136) (131). 
Ketamine also has the potential to produce psychomimetic effects (as a dissociative 
hallucinogen). A systematic review conducted by Subramanian et al (137) concluded that 
these effects were unlikely to occur at analgesic doses. Despite this conclusion, central 
nervous system adverse effects (such as dizziness, diplopia, dysphoria, dreams, 
hallucinations, disorientation, strange sensations, light headedness, sleep difficulties, and 
confusion (137)) occurred at a rate of 0.7%-18% in ketamine-treated patients, depending on 
route of administration. Another systematic review, conducted by McCartney et al (138) 
found that in the 20 of 24 studies examined, 12 studies documented no adverse effects. 
Seven studies showed adverse effects, but none were statistically significant between 
patients treated with ketamine, and controls. The review states that the remaining study 
reported psychomimetic effects, but that there were no incidences of hallucinations (139). As 
such, it seems likely that ketamine does not produce overt psychomimetic effects at doses 
required for analgesia. Those treated with ketamine for analgesia do not appear to show 
central nervous system symptoms at a higher rate than those treated with opioids alone.   
In the aforementioned review by McCartney et al (138), they reported that 58% of the studies 




pain after surgery). In a meta-analysis conducted by Ong et al (140) of preventative analgesia 
in the management of acute postoperative pain, seven studies met the inclusion criteria of 
being randomised, double-blind studies. This study grouped ketamine with another NMDA 
antagonist, dextromethorphan. Only two of the seven identified studies displayed a 
statistically significant positive effect on postoperative pain intensity. However, when the 
study results were combined the authors felt that NMDA receptor antagonists showed no 
analgesic benefits, and that their efficacy remained ‘equivocal’. 
So while ketamine’s role in preventative analgesia appears contentious, its use as an 
adjuvant to opioids appears promising. A systematic review conducted by Subramanian et al 
(137) identified thirty seven relevant double-blind, randomised controlled trials. The addition 
of ketamine to morphine patient-controlled analgesia (PCA) pumps did not improve 
analgesia (141). However, a single-bolus or perioperative continuous infusion appeared to 
reduce morphine requirements. The authors proposed that the relatively high number of 
studies showing no statistically significant results could be explained by the surgical 
procedures in question. They hypothesised that in surgery requiring relatively small to 
moderate doses of opioids to provide analgesia, existing pain relief strategies are sufficient, 
and that the addition of an adjuvant was unnecessary. In more major surgeries, requiring 
large opioid doses, the addition of ketamine should create more benefit.  
Much attention recently has been focussed on ketamine’s possible role as a rapid-acting 
anti-depressant (142) (143) (144) (145) (146). Given the links between depression and pain, 
particularly chronic pain, this raises the question of whether the use of ketamine in 
depressed chronic-pain patients could ‘kill two birds with one stone’. Its anti-depressant 
effects could decrease pain, or at least modulate an individual’s emotional response to it, 
and its analgesic effects could improve mood by the reduction or removal of the pain (147). 
Dextromethorphan is an NMDA receptor antagonist largely used as an over-the-counter 
cough syrup (131). It has fewer psychomimetic properties than ketamine, due to ketamine’s 
stronger binding affinity at the NMDA receptor (148). It is considered to be reasonably safe 
(with an over-the-counter status). In terms of efficacy, the McCartney et al review on 
preventative analgesics (138) reported dextromethorphan to be effective in a greater 




statistically significant positive results, compared with 58% of ketamine studies). They 
suggested that dextromethorphan exerted its effects in two ways. Firstly, it exerted its 
effects by reducing acute opioid tolerance, a notion supported by experimental evidence 
(149). Secondly, one study (150) reviewed showed statistically significant analgesic effects when 
dextromethorphan was administered alone as a premedication prior to surgery. This lent 
support to the notion that NMDA receptor antagonists directly reduced pain by decreasing 
central sensitisation.  
Magnesium as an ion functions as an NMDA receptor antagonist (131). However, it is 
debateable whether or not magnesium crosses the blood-brain barrier in sufficient 
quantities to produce NMDA receptor-mediated analgesic effects (151). Whilst it seems likely 
that magnesium potentiates opioids to a clinically-useful level (152) (153), the McCartney el al 
review (138) concluded that none of the four studies showed any preventative analgesic 
effects of magnesium.  
-Anticonvulsants 
Anticonvulsants are a group of medications, with varying pharmacological modes of action, 
which were developed primarily for the treatment of epilepsy. They have subsequently 
been clinically applied in bipolar disorder (154) (155), and in pain management (156) (157). These 
disorders all theoretically share similar neurophysiological pathologies, namely neuronal 
hyper-excitability (133) (158) (159), explaining the interest in expanding the use of 
anticonvulsants in these other disorders. In terms of pain management, application of these 
agents has been widely researched. They are used in the treatment of chronic pain (131) (156) 
(160). More recently interest has grown in their use in postoperative pain (131) (161). 
Carbamazepine acts on voltage-gated sodium channels, slowing their ‘recovery’ by slowing 
the rate of neuronal firing (162). Carbamazepine is chemically similar to the TCA’s (157) that 
may partially account for some of its actions. It is considered effective in trigeminal 
neuralgia (TN) with a suggestion by McQuay et al (156) that roughly seventy percent of 
patients could expect clinically significant benefits. Carbamazepine has some effects 
(although relatively weak) in diabetic neuropathy, but with less efficacy than in trigeminal 
neuralgia (158). There is weak evidence, largely from case reports, that carbamazepine may 




resulted in withdrawal in up to eleven percent of study participants, and tolerable adverse 
effects were reported in roughly half of those treated (157). Adverse effects included 
somnolence, changes in gait, dizziness, blurred vision, nausea, vomiting, and 
haematopoietic changes (133) (157) (158) (160). 
Phenytoin was the first anticonvulsant studied and used in neuropathic pain for its 
antinociceptive properties (157). Like carbamazepine, it acts on sodium channels. It might 
decrease synaptic glutamate by inhibiting its release (157) as well. Its efficacy appears to be 
more contentious, as shown in several recent guidelines in the American Journal of 
Medicine (163), in the Mayo Clinic Proceedings (164) , and in the National Institute for Health 
and Care Excellence (NICE) (165). 
Lamotrigine, valproic acid, and topiramate are three other popular anticonvulsants that 
have been studied to varying extents in the treatment of pain, but at present do not have 
particularly strong evidence bases (157) (158). Lamotrigine most likely acts by slowing neuronal 
sodium channels, and decreasing synaptic glutamate (158). It has shown promise as an add-
on therapy in TN (166), and as a stand-alone therapy in central neuropathic pain (167) and in 
diabetic neuropathy (168). However its lengthy titration period, necessitated by the risk of the 
potentially life-threatening dermatological condition Stevens- Johnson syndrome (169) (170) 
(171), appeared to be correlated with high drop-out from studies (158), which may limit its 
clinical use. Valproic acid acts to increase overall GABA levels in the brain, by increasing its 
production and decreasing its degradation (157). It also acts on sodium channels to prolong 
the ‘recovery’ phase (158), thus decreasing the rate of neuronal firing. There does not appear 
to be conclusive clinical evidence for analgesic or antinociceptive properties of valproic acid 
(172) (157) (158), despite promising pre-clinical findings in mouse studies (173) (174). Topiramate 
acts as a sodium channel blocker, up-regulates GABA release, and inhibits the α-Amino-3-
hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) and kainite glutamate receptors (157) 
(158). The research at present is inconclusive, with a study in central pain finding no positive 
effects in any subjects (175). Another study did not find significant benefit in chronic lumbar 
radicular pain (although some secondary outcome measures were significant) (176). 
Conversely, other studies in TN in multiple sclerosis patients (177), chronic low back pain (178), 
and diabetic neuropathy (179) have shown promising results. All three of these agents are 




Gabapentin is structurally a GABA analogue. However, it has no discernable activity at the 
GABA receptors, or apparent effects on GABA uptake or breakdown (180) (181). It appears that 
gabapentin increases GABA production and/or release, resulting in an increase in brain 
GABA (181). Gabapentin modulates calcium channels in the brain, and peripheral nerves by 
interacting with the α2δ-subunit of voltage-gated calcium channels (157) (158) (180) (181), that in 
turn may modulate downstream neurotransmitter pathways (181). It has a favourable side-
effect profile. This is usually limited to temporary sedation, dizziness, and pedal oedema (157) 
(158). It is excreted by the kidneys as the unchanged parent compound. It does not bind to 
plasma proteins, and does not affect hepatic enzymes (181) (182). These characteristics all 
decrease the likelihood of drug-drug interactions (183). So with a mechanism of action 
hypothetically capable of exerting analgesic and/or antinociceptive effects and a favourable 
side-effect profile, gabapentin could be of great clinical use.  
There is strong evidence for gabapentin’s role in the treatment of painful diabetic 
neuropathy (184) and in post-herpetic neuralgia (185) (186). It has also been shown to provide 
synergistic analgesic effects when given in combination with nortriptyline (187). A 2012 meta-
analysis by Clarke et al (188) suggests it is effective in the prevention of chronic post-surgical 
pain. It is results like these, along with its favourable side-effect profile, that have made 
gabapentin a first-line choice in treating many forms of neuropathic pain (133) (157) (158) (187).  
Pregabalin is, like gabapentin, is a structural analogue of GABA (157). Its mechanisms of 
action appear very similar to those of gabapentin, its main target being the α2δ-subunit of 
voltage-gated calcium channels (189). However, its binding affinity at this target is six times 
greater. As a result the required dose of pregabalin for pain is much lower than that of 
gabapentin (189). With its major reported side-effects being sedation and dizziness, and its 
renal excretion (189), its similarities to gabapentin are fairly obvious. A 2009 Cochrane 
Collaboration systematic review (190) found no evidence for pregabalin in the treatment of 
acute postoperative, or chronic nociceptive pain. However, it was deemed effective in 
neuropathic pain states, such as post-herpetic neuralgia, as well as fibromyalgia. Another 
systematic review found it to be effective in the prevention of chronic post-surgical pain (188). 
It is unsurprising that a drug that so resembles gabapentin, is effective in most if not all of 




Benzodiazepines are a group of anxiolytic, sedative-hypnotic agents which act at the GABAA-
receptor, up-regulating its response to GABA (191). It is not known whether the 
benzodiazepines possess any analgesic effects unrelated to their effects on anxiety and 
mood, either alone or as adjunct therapies (192). The only benzodiazepine which has been 
subjected to randomised controlled trial conditions is lorazepam (157) that was shown to be 
inferior to amitriptyline in post-herpetic neuralgia (193). Given the high abuse and 
dependence risk associated with benzodiazepine treatment (192), the lack of evidence of 
efficacy (192) (157), and indeed the evidence that benzodiazepines may actively antagonise 
opioid analgesia (194), there is no evidence strong enough in favour the use of 
benzodiazepines as analgesics in any pain condition. However, in pain caused muscle spasm, 
benzodiazepines and other ‘muscle relaxants’ may relieve the pain by reducing the spasm 
(110) (195). 
-α2 adrenergic agonists 
The α2 adrenergic system modulates pain both peripherally and centrally (110) (196). Their main 
site of action is the spinal cord that contains descending noradrenergic pain pathways (110). 
Thus α2 receptor–mediated inhibition of these pathways can produce powerful analgesia 
comparable to that mediated by opioids (197) They are usually limited to a role as adjunctive 
analgesics, as the systemic effects caused by α2 adrenergic antagonism include sedation, 
cardiovascular depression (bradycardia, hypotension), and hypothermia, as well as the 
desired analgesia and anxiolysis (108) (110). 
Clonidine is a α2 adrenergic receptor antagonist, which was initially developed for its 
cardiovascular actions, namely, for the control of heart rate and blood pressure (108) (131). As 
well as its adrenergic actions, evidence suggests it also acts as an imidazoline receptor 
agonist in the ventrolateral medulla that accounts for some of its hypotensive effects (198). In 
anaesthesia and pain medicine, clonidine is used for the following: sedation and anxiolysis 
pre-operatively (198); to decrease anaesthetic requirements intra-operatively (199); and as an 
analgesic (108) (131) (198). Clonidine is an effective analgesic and antinociceptive agent in its own 
right (198) (200) (201) by inhibiting the descending noradrenergic pain pathways (198). It is also 
likely to have some use as an adjunct analgesic, having been shown to decrease morphine 




epidurally and intrathecally, demonstrating analgesic effects on its own postoperatively (203) 
in an experimental setting (204). When delivered by these routes, it also acts to potentiate 
and increase the duration of opioid analgesia in the post-operative setting (205) (206) (207).  
Dexmedetomidine is a more potent α2 adrenergic receptor antagonist than clonidine (208). Its 
uses largely mirror those of clonidine, being used for pre-operative sedation and anxiolysis 
(198), intra-operatively to reduce anaesthetic requirements (209) and post-operative analgesic 
requirements (210). Postoperatively it is used to reduce analgesic requirements (211) (212), 
however more research is required before it can be recommended in the treatment of 
chronic pain (213). 
-Experimental and theoretical agents 
There are many other pharmacological agents used in the treatment of pain. These are 
largely dependent on the source, duration, and specifics pertaining to the individual patient. 
Many of the adjuvant treatments, as outlined above, are clinically effective in less than half 
of those who take them. As such, the search for more reliable treatments continues.  
Psychostimulants such as the attention-deficit hyperactivity disorder (ADHD) treatments 
dextro-amphetamine and methylphenidate, act as noradrenaline-dopamine reuptake 
inhibitors (214). When combined with opioids, psychostimulants have been found to decrease 
opioid requirements, decrease somnolence and respiratory depression, and improve 
cognition, mood, and quality of life (214) (215) (216). However, their clear potential for abuse and 
dependence has resulted in their use in pain management being restricted almost 
exclusively to end-of-life treatment such as cancer and Acquired Immune Deficiency 
Syndrome (AIDS) (110) (214) (215). Caffeine, a much less potent psychostimulant that acts as an 
adenosine receptor antagonist (217), is a first-line treatment for acute migraine headaches 
when combined with paracetamol (218). Even alone, it has been shown to have an analgesic 
effect on headaches (219). 
Opioid antagonists such as naloxone and naltrexone appear to be effective in central post-
stroke pain that occurs in 5-10% of stroke patients, and likely to be due to CNS vascular 
effects (110). Neuroleptics, also known as ‘anti-psychotics’ or ‘major tranquilizers’, may have 




and dopamine receptors (220) (221). Acetylcholine esterase inhibitors, such as neostigmine, 
increase pain thresholds by increasing the action of cholinergic neurones in the dorsal horn 
of the spinal cord (108). These have produced inconclusive results in humans thus far, with 
various mixtures and routes of administration providing different results (222) (223). 
2.3.4 Anaesthesia  
Pain management is a specialty that largely grew out of anaesthesia (8). Anaesthetic 
techniques can have a dramatic impact on perioperative pain (224). Anaesthesia is commonly 
thought of as simply a loss of consciousness or feeling. However, dependent on the 
surgical/procedural circumstances, there is often a need to combine unconsciousness with 
amnesia, analgesia, and muscle relaxation. This usually requires the use of multiple 
pharmacological agents, and often specialised equipment such as that used for respiratory 
support and monitoring (225). Anaesthesia is typically divided into general anaesthesia that 
induces a loss of consciousness in the recipient, and local or regional anaesthesia that 
reduces or removes sensation from a specific area (225).  
-General anaesthesia  
General anaesthesia (GA) is a state of unconsciousness induced in order to facilitate surgical 
procedures (226). The anaesthetist aims to monitor and maintain homeostasis across all 
major organ systems (renal, cardiovascular, respiratory, and neurological) in the process 
(225). Other goals of GA are amnesia, analgesia, and muscle relaxation. Amnesia, specifically 
anterograde amnesia (226), during the surgical procedure, is achieved in GA by the patient’s 
loss of consciousness. Only between 0.0068 and 0.9% of patients undergoing GA have been 
reported recall of the procedure (227). Despite the patient’s lack of consciousness, intra-
operative analgesia (with opioids, local anaesthetics) is an important part of GA, as it can 
decrease postoperative pain and recovery times (228). Muscle relaxation, also known as 
‘neuromuscular blockade’, produces immobility, which is naturally desirable during surgical 
procedures. 
There are three main ‘stages’ of GA. Induction, maintenance, and emergence. Induction is 
typically achieved using short-acting intravenous agents, classically barbiturates (thiopental) 




is often used if propofol is contraindicated (230). Maintenance of GA begins once the patient 
has lost consciousness, and typically requires a combination of agents. Typically, a volatile 
inhalational anaesthetic agent (such as sevoflurane), an intravenous induction agent (such 
as propofol), and an intravenous analgesic (such as fentanyl) are combined to provide 
‘balanced anaesthesia’ (225) (229). Intra-operative local anaesthesia, neuraxial blockade 
(epidural, spinal), and regional neural blockade are all useful tools in the pre-emptive 
reduction of postoperative pain (231). The emergence phase, as the name suggests, is the 
period during which the patient is re-awakened. During this phase, both physical and mental 
reactions can occur. Mentally, patients can be confused and disorientated, which can lead 
to problematic behaviour such as thrashing that risks complications such as suture rupture 
(232). Physically, there is a risk of ‘autonomic hyper-responsiveness’, where sympathetic 
excess results in hypertension and tachycardia (225). However, postoperative pain is almost 
certainly the most common clinical challenge encountered after awakening. This is usually 
combatted both preventively (in theatre) and once the patient is awake (233).  
In terms of adverse outcomes from GA, there are two main kinds, namely, the effects of the 
pharmacological agents used, and incidents that occur while performing anaesthetic-related 
procedures (such as intubation). Adverse events occur in approximately 5% of patients 
undergoing GA, the majority of which are cardiovascular (hypertension, tachycardia) and/or 
respiratory (respiratory failure, bronchospasm) (234). In terms of procedural adverse 
outcomes, some of the more common adverse outcomes include inadequate ventilation, 
and oesophageal intubation that can (rarely) lead to brain damage or death (235). The volatile 
anaesthetic agents, like any pharmacological agent, can have unwanted adverse effects. 
These are, however, considered rare (236). For example, rarely halothane has produced cases 
of hepatotoxicity (236). Volatile anaesthetic agents along with succinylcholine (a depolarising 
skeletal muscle relaxant) have been implicated in a life-threatening condition known as 
malignant hyperthermia (237). Between 1:5,000 and 1:100,000 patients undergoing GA will 
experience this condition. The increased bodily heat production is largely caused by muscle 
contractions (237). This is akin to how ‘shivering’ in response to cold will increase body 
temperature. The use of opioids during GA can result in typical opioid adverse effects, such 




will partially fail, and a patient will have some memory of the surgical procedure (227). This is 
known as ‘accidental awareness’.  
The importance of the perioperative period in the development of chronic pain has recently 
come to light (34) (44). A multimodal analgesic approach, both during and following a surgical 
procedure may reduce the risk of chronic pain development in certain surgical groups (224) 
(239). Ketamine appears useful in acute postoperative pain, but at subacute (measured at six 
weeks postoperatively) and chronic (measured at four months postoperatively) follow-up 
points ketamine does not appear to have any preventative effects (240).  
-Local anaesthesia  
Local anaesthetics are agents which cause a reversible loss of sensation in the area in which 
they are administered (241). They act by reversibly inhibiting ion channels and effectively 
prohibiting action potential propagation. This prevents peripheral signals (pain in particular) 
from reaching the CNS (242). Their main mechanism of action is through sodium channel 
blockade (242). While many chemical compounds (e.g. certain antidepressants) may have 
local anaesthetic properties, those used clinically tend to be aromatic compounds that 
contain either an ester or amide bonds (243). They are classed by these bonds, lignocaine 
being an example of an amide, and benzocaine an example of an ester local anaesthetic (244).  
Local anaesthetics can be administered using a variety of techniques:  
- Topical application tends to be reserved for more minor procedures/conditions (such as 
intravenous catheter insertion) (245). Newer evidence suggests topical lignocaine may have a 
place in the treatment of neuropathic pain conditions (such as post-herpetic neuralgia) (246).  
-Infiltration anaesthesia, whereby the local anaesthetic agent is delivered into the 
subcutaneous or intradermal layers of the skin. This is useful in the likes of minor skin 
surgery and for lumbar puncture (247) (248). Theoretically, any local anaesthetic agent could be 
used in this manner. Lignocaine is particularly popular as it is short-acting (249). The acidity of 
local anaesthetics can cause pain on administration, so sodium bicarbonate can be added to 
the solution to reduce this (250). Adding adrenaline to the solution will increase the duration 




-Intravenous regional anaesthesia such as the Bier’s block carries a somewhat higher risk of 
systemic toxicity than other methods of administration (251,252). Here, the local anaesthetic is 
delivered directly into the venous system of the body part in question, with a tourniquet 
(such as a tightly-inflated blood pressure cuff) proximal to the injection site. For obvious 
practical reasons, this procedure is largely limited to use in the limbs, in particular the upper 
limbs (249). Despite the risk of systemic toxicity due to tourniquet leakage, this technique 
remains popular, being seen as a more efficient alternative to GA for minor upper limb 
procedures (251).  
-Peripheral neural blockade involves selectively anaesthetising individual peripheral nerves 
(e.g. ulnar nerve block) and/or groups of nerves or a neural plexus (e.g. brachial plexus 
block) (249). ‘Central neural blockade’ is an extension of this, with the agents being delivered 
centrally, typically in the epidural or intrathecal spaces. This provides more widespread 
anaesthesia/analgesia (249). These blocks can be used in place of GA in certain patients, such 
as those at high risk of GA-related complications (e.g. the very elderly) (253). They can be 
administered either as a single injection, or as a continuous infusion (254). In order to block a 
peripheral nerve or neural plexus without causing neural injury, it should be accurately 
located. The larger peripheral nerves or neural plexuses are commonly in close proximity to 
large vessels. The consequences for inadvertently puncturing an artery or delivering local 
anaesthetics intravenously could potentially be disastrous. As such, these blocks are now 
commonly performed with guidance from the use of nerve stimulators and by ultrasound 
(255) (256). In nerve stimulation electrical impulses are sent to determine the location of the 
desired nerve. Stimulating the motor function component of a nerve will cause the 
innervated muscles to contract. The use of intra-operative epidural opioids (dependent on 
lipophilicity) and intrathecal opioids significantly decreases postoperative opioid 
requirements (257). A combination of intrathecal local anaesthetic and opioid has been 
successful in reducing both intra-operative and postoperative pain in caesarean section (258). 
Peripheral neural blockade remains popular and successfully used in the diagnosis and 
management of chronic pain (259,260,261,262,263). 
Adverse effects of local anaesthetics are uncommon if appropriate doses are given and 
administration protocols are followed (249). However, there is still potential for adverse 




(264). True ‘allergies’ to local anaesthetics are over-estimated, with other events often being 
incorrectly attributed to allergy (249) (264). Local tissue toxicity occurs when the local 
anaesthetic agent fails to dilute into surrounding tissue, resulting in a high intra-neural 
concentration that may result in prolonged or permanent neurological damage (249).  
Systemic toxicity from local anaesthetics occurs when the agent enters the circulation in 
sufficient concentration. The CNS is the most sensitive area to local anaesthetic toxicity (249). 
Early signs of toxicity are largely neurological. The inhibitory pathways of the CNS are more 
susceptible to local anaesthetic inhibition than the excitatory pathways (264).The first signs of 
local anaesthetic toxicity are often agitation and sensory disturbances, followed by 
generalised tonic-clonic convulsions (249). In severe overdose, CNS depression (particularly 
respiratory depression) soon follows (249). Management includes the immediate cessation of 
local anaesthetic administration, seizure control (with benzodiazepines such as midazolam), 
airway management, and intravenous lipid emulsion therapy and fluid administration (249).  
The cardiovascular system is subject to toxic effects from local anaesthetic agents as well. 
Local anaesthetics function as negative ionotropes, depressing cardiac contraction (265) and 
as peripheral vasodilators on vascular smooth muscle (266). Appropriate clinical management 
choices depend on the local anaesthetic in question, whether it was mixed with adrenaline 
(a vasoconstrictor), and other factors. Lipid emulsion therapy (intralipid®) appears to be 
highly cardioprotective in this setting (267). 
2.4 Non-pharmacological management of pain  
As chronic pain is increasingly being recognised as a multi-dimensional illness, non-
pharmacological management measures can be used alongside medication. Foremost 
among these are psychological interventions, and physical therapies (268). These combination 
approaches have been shown to be more effective than medical management alone (269). 
2.4.1 Psychological management of pain 
The focus of psycho-social interventions is based on the recognition of the subjective 
experience and chronicity of chronic pain (270). Psychological techniques focus on modifying 




the pain, rather than eliminating the pain itself (271). There are several main types of 
psychological intervention, each with its own focus: 
- Psychophysiological techniques attempt to bridge the gap between the psychological and 
physical aspects of chronic pain. For example, ‘biofeedback’ involves a patient learning to 
voluntarily control certain physiological processes, through understanding the results of 
physiological testing (272). For instance, methods of voluntarily exerting control over one’s 
blood pressure could be learnt. Relaxation techniques (such as diaphragmatic breathing and 
progressive muscle relaxation) show promise as well (268) (273).  
- Cognitive Behavioural approaches to pain management focus on identifying and 
challenging behaviours and emotions contributing to continued disability (268) (273). The aim is 
to modify the way patients view their pain and how they respond to it. The end goal is to 
increase a patient’s self-efficacy (274). Acceptance-based approaches such as ‘Acceptance 
Commitment Therapy’ are a form of this. This encourages patients to work through their 
pain experience and accept and embrace it, rather than modifying thought processes 
around it (275). 
- Operant Conditioning approaches, such as graded activation, are based around the basic 
principles of operant conditioning (positive/negative reinforcement and positive/negative 
punishment) (276). Here, positive behaviours are re-enforced and negative behaviours 
ignored. Following operant conditioning reasoning, maladaptive pain behaviours become 
conditioned over time. For example, if frequent verbal complaints of pain result in nurturing 
behaviours from others (positive reinforcement), the patient becomes conditioned to 
complain of pain in order to obtain nurturance. The reverse is true, in that therapies could 
be developed to condition patients into maintaining greater activity levels and less fear of 
pain, through graded exposure to each (268) (277). 
Highly prevalent emotional/psychological comorbidities, such as depression (278), can 
complicate the treatment of chronic pain. Such patients are often labelled ‘difficult’. The 
anger, sadness, and disappointment they often experience can worsen this perception (268). 
Patient expectations often exceed the realities of treatment, which if not properly 




2.4.2 Physiotherapy approaches to chronic pain 
Physiotherapy is widespread in the management of chronic pain (279). In back pain in 
particular, physiotherapy appears to improve quality of life (280). The use of physiotherapy in 
rehabilitation could provide significant savings to the health system (281). Physiotherapy is 
often administered alongside cognitive behavioural therapy, to help challenge maladaptive 
cognitive patterns such as fear-avoidance (282). Self-management of pain is of great 
importance in chronic pain (283). Exercises and techniques taught by physiotherapists assist 
with this. However, different clinicians appear to favour different approaches (284), without 
strong evidence to support one technique over another (279) (285). A systematic review 
suggests that ‘individually designed’ approaches might confer greater benefits. However, 
this systematic review acknowledges that it is sorely limited by the quality of available 
studies (286). Transcutaneous Electrical Nerve Stimulation (TENS) is an intervention whereby 
an electrical device on the skin delivers electrical pulse stimulation to the affected nerve(s). 


















Chapter Three – Gynaecological surgical types 
 
The reasons for surgery, surgical groups, and surgical techniques used on participants in this 
study are briefly discussed. 
3.1 Hysterectomy  
3.1.1 Background 
A hysterectomy is the removal of the uterus. The three main routes of surgical excision are 
laparoscopic, abdominal (laparotomy), and vaginal. Of the ‘major’ gynaecological surgeries, 
hysterectomy is the most frequently performed (288). In the United States, the abdominal 
route is the most common accounting for two-thirds of hysterectomies performed. The 
second highest is the vaginal route (21%), with laparoscopic route (12%) being the third. Of 
these, 0.9 percent were performed robotically, and the remaining 1.2% comprised ‘radical’ 
hysterectomies (289). Rates vary widely between countries (290). In New Zealand, nearly a 
quarter of women will have undergone hysterectomy by the age of 60 (291).  
3.1.2 Indications for hysterectomy 
About 70% of hysterectomies in New Zealand were performed to improve quality of life (291), 
freeing sufferers from symptoms of chronic illnesses such as endometriosis (292). The 
remaining procedures were performed to remove malignancies (292).  
3.1.3 Surgical approach 
Less invasive procedures typically result in fewer complications, and faster recovery times 
(293). The vaginal approach to hysterectomy, whereby the uterus is removed via the vagina 
without the need for abdominal incision, is considered the ‘ideal’ approach. However, this is 
not suitable for all patients (293). Laparoscopic surgery involves several small incisions, with a 
camera inserted through one so that the surgeon can visualise the internal organs. In the 
case of hysterectomy, it can be performed either to assist a vaginal hysterectomy (294), or as 
a stand-alone procedure (295). There is some contention as to the efficiency of laparoscopic 




a “waste of time” (296). Conversely, a meta-analysis found no significant difference between 
the two methods used (295). One randomised controlled trial found significantly lowered 
postoperative pain in the laparoscopic group (297). Abdominal hysterectomy is the most 
invasive of the hysterectomy techniques. It requires a large abdominal incision. It results in a 
higher rate of postoperative pain, and an extended recovery period, making it less 
preferable to laparoscopic and vaginal approaches (298).  
Following a hysterectomy, 4.7-31.9% of patients can be expected to develop chronic pain 
(299). Of note is that between 14.7% of the underlying female population in the United 
Kingdom and 24.0% of the underlying female population in the United States experience 
chronic pelvic pain (299). It is possible that hysterectomy cures the pain experienced by some, 
but it can create ongoing pain for others. Higher acute pain scores (300), any pre-operative 
pain (300), and a previous caesarean section (301) are associated with the development of 
chronic post-hysterectomy pain.  Surprisingly, the actual surgical approach has not 
previously been detected as a risk factor for the development of chronic post-hysterectomy 
pain (301). Considering the differences in tissue insult, acute pain, and healing period, this 
requires further study. Interestingly, gabapentin has shown promise in the prevention of 
chronic post-hysterectomy pain (302).  
3.2 Salpingo- and oophorectomy 
3.2.1 Background 
Oophorectomy is the surgical removal of the ovaries, while salpingectomy is the surgical 
removal of the fallopian tubes. In the United States, 26-68% of women undergoing 
hysterectomy undergo oophorectomy as well, particularly those close to or past menopause 
(303) (304) (305). Bilateral salpingectomy (BSO) is common during hysterectomy where the 
ovaries are conserved (306).  
3.2.2 Indications for salpingectomy and oophorectomy 
Salpingo- and/or oophorectomy (S/O) can be performed either in isolation, or during 
hysterectomy. Both primary ovarian and secondary metastatic neoplasms may require 
oophorectomy (307). Ovarian torsion (308), endometriosis (309), and pelvic adhesions (310) remain 




3.2.3 Surgical approach 
Salpingectomies and oophorectomies are performed laparoscopically or by laparotomy. 
When compared with laparotomy, laparoscopy offers fewer complications, shorter recovery 
time, and shorter hospital stays (311). In the acute postoperative period, laparoscopy results 
in significantly lower Visual Analogue Scale (VAS) pain scores, and a greater chance of being 
pain-free (312). This, along with the markedly smaller incision sites involved, makes 
laparoscopy the preferred approach. There does not appear to be any published literature 
outlining the incidence of chronic post-salpingectomy or post oophorectomy pain.  
3.3 Surgical management of endometriosis  
Endometriosis is a disorder characterised by the existence of ectopic endometrial tissue, 
generally found in the pelvis. It carries a large pain burden, with approximately 11% of pre-
menopausal women have evidence of endometriosis, and 71-87% of women suffering 
chronic pelvic pain as a result (313) (314). For those patients for whom medical management 
fails or is inappropriate or intolerable, surgical management becomes necessary (315,316). In 
the majority of cases, when the woman is still of child-bearing age, minimally-invasive, 
fertility-protecting approaches are used in laparoscopic ablation or excision (315,317). If both 
medical and minimally-invasive surgical techniques fail, hysterectomy with or without 
bilateral oophorectomy is usually indicated providing the woman does not plan on having 
future children (317). If the ovaries are conserved, there is a higher risk of continued pain that 
might require future surgery (318,319). The evidence behind the choice of surgical approach 
(laparoscopic versus laparotomy) is similar to that given for hysterectomy and salpingo-
oophorectomy, with laparoscopy remaining the preferred approach (320).  
3.4 Surgical repair of pelvic organ prolapse and pelvic floor defects 
Pelvic organ prolapse (largely vaginal vault prolapse, and pelvic floor defects in the present 
study) occur in 11-19% of women by the age of 80 (321). Of these 29% will require subsequent 
surgical repair (321). The greatest risk factors are parity and previous hysterectomy (322,323). 
For this indication, the abdominal approach is commonly performed, as it has a lower rate 
of prolapse recurrence (324). However, the price of the abdominal approach is the increased 
risk of complications, and longer recovery times (324). Laparoscopic surgery that is gaining 




many of the complications associated with abdominal surgery (325). Little published data 
exists on the incidence of chronic pain following these procedures. It has been suggested 
that some vaginal meshes are associated with chronic pain development in as many as 30% 























Chapter Four – Measurement of pain 
 
4.1 Introduction to the measurement of pain 
The obvious primary goal of any tool designed to measure an individual’s pain, or responses 
to pain, is to assist in diagnosis. It should potentially improve the clinical management of 
pain for that individual, leading to better pain outcomes and improved functionality. These 
tools also have implications for the scientific understanding of pain (327). Given the large 
psychological overlay in pain, psychometric questionnaires play a sizeable role in the 
assessment of pain. Other methods include physical testing of existing pain (such as moving 
a potentially painful limb on physical examination), or inducing pain to determine the limits 
of an individual’s pain threshold and tolerance by making use of electrical stimulation, or 
the cold pressor test.  
4.2 Psychometric Questionnaires 
4.2.1 Short form of the Depression Anxiety Stress Scale (DASS-21) 
The link between lengthy pain experiences and negative psychological states (such as 
depression and anxiety) is well established (328) (329).  
 
The DASS-21 (Short form of the Depression Anxiety Stress Scale) was designed (330)  to 
determine the extent to which the participant was experiencing the core symptoms of 
anxiety and depression, as well as stress (329). It is the short form of the forty two-item DASS 
questionnaire that contains three sections of fourteen questions, one for each psychological 
measure (330). The DASS-21 contains three sections of seven items, one for each 
psychological measure, as per its longer counterpart (330). Both the DASS and the DASS-21 
are self-report questionnaires (331). Each item of the DASS-21 is scored from ‘0’ (Did not 
apply to me at all) to ‘3’ (Applied very much, or most of the time), giving a total score out of 
sixty three, and scores out of twenty one for each of the three components. These scores 
are often doubled for the sake of comparison to the full-length DASS. 
The component of the DASS-21 labelled ‘depression’ assesses several of the core features of 




deprecation. The ‘anxiety’ component likewise assesses the core symptoms of anxiety, 
including physiological anxiety (such as autonomic arousal, and muscle tension), and 
psychological anxiety. The ‘stress’ component assesses a group of symptoms distinct from 
those measured by the depression and anxiety components. These include tension, 
irritability, and being easily distressed by stimuli considered minor stressors, or even stimuli 
not normally considered as stressors (332).  
The DASS and DASS-21 have been extensively validated in clinical (329) (332) and non-clinical 
(331) samples, and as such was included in this study as a potential predictor of pain 
outcomes. 
4.2.2 Short form of the Pain Anxiety Symptoms Scale (PASS-20) 
There is a relationship between the fear and resulting avoidance of pain, and the level of 
disability experienced in chronic pain (333). The PASS-20 (Short form of the Pain Anxiety 
Symptoms Scale) is designed (333) to measure pain-related anxiety. It assesses four of the key 
symptoms of pain-related anxiety. These are: cognitive anxiety, physiological anxiety, fear of 
pain, and escape/avoidance of pain and activities that may induce or worsen pain (334). It is 
the short-form of the forty-item PASS questionnaire, itself a twenty-item self-report 
assessing (like its longer predecessor) the aforementioned four key symptoms of pain-
related anxiety. Each item of the PASS-20 is scored from ‘0’ (Never) to ‘5’ (Always), giving 
section scores out of twenty five to each of the four key symptoms, and a total score out of 
one hundred. 
The ‘cognitive anxiety’ measure assesses an individual’s mental concerns, worrying, and 
other psychological symptoms (such as reduction in ability to concentrate). The component 
labelled ‘physiological anxiety’ is designed to measure the respondent’s somatic response to 
pain (or anticipation of pain). This largely involves symptoms relating to activation of the 
sympathetic nervous system, such as increased heart rate, sweating, and increased 
ventilation.  The ‘Fear’ measure assesses fearful thoughts related to pain, to the potential of 
pain, and to possible consequences of painful activities. Finally, the ‘escape/avoidance’ 




Like the DASS-21, the PASS-20 has been validated in both non-clinical (334) (335) and clinical 
(333) (336) (337) samples as a useful tool in the assessment of pain. This is the reason for its 
inclusion in this study. 
4.2.3 Short-form McGill Pain Questionnaire (SF-MPQ)  
 The Short-Form McGill Pain Questionnaire (SF-MPQ) is a measurement of perception of 
pain in adults suffering from chronic pain (338). It was developed (338) largely because its 
predecessor, the McGill Pain Questionnaire (MPQ) takes up to twenty minutes to complete 
(339), making it difficult to administer in clinical and research scenarios that often run on 
narrow timeframes. The SF-MPQ attempts to view pain in more depth than traditional pain 
intensity scales. It contains a total of 17 items. Eleven describe the sensory aspects of pain, 4 
relate to the affective aspects, there is a Visual Analogue Scale and a Present Pain Intensity 
Scale as well. The SF-MPQ lacks the ‘evaluative’ items contained within the full MPQ. It is 
roughly one fifth of the size of the full 70-item MPQ. Despite this, SF-MPQ scores have been 
shown to correlate well with MPQ scores (340).  
The eleven-item sensory dimension of the SF-MPQ includes adjectives such as ‘gnawing’, 
‘aching’, and ‘throbbing’ that describes the physical sensation experienced. The four-item 
affective dimension includes the adjectives ‘exhausting’, ‘sickening’, ‘fearful’, and ‘cruel-
punishing’; these document the emotional aspect of a person’s pain. Each of these items is 
scored from ‘None’ (0), to ‘Mild’, ‘Moderate’, and ‘Severe’ (4). The next item is the Visual 
Analogue Scale, which is a ten centimetre line with the left end marked ‘No pain’, and the 
right marked ‘Worst pain possible’, along which the participant is asked to tick where they 
would rate their current pain. The final item is the Present Pain Intensity Scale, which asks 
participants to rate their pain out of the following: ‘No pain’ (0), ‘Mild’, ‘Discomforting’, 
‘Distressing’, ‘Horrible’, and ‘Excruciating’ (6) (338). The fifteen adjective items are scored 
from zero to four, as discussed above. This gives a score out of forty four for the sensory 
dimension, and a score out of sixteen for the affective dimension, with a total descriptor 
score of sixty. The Present Pain Intensity can be scored out of six, and the visual analogue 
scale can be scored out of one hundred (millimetres) by measuring the distance along the 




The SF-MPQ has been widely used and validated (341) (342) (340) (339) questionnaire when used in 
patients suffering from chronic pain, leading to its inclusion in this study.  
4.2.4 Pain Catastrophizing Scale (PCS) 
Catastrophizing (excessive negative cognition surrounding pain) has been strongly 
implicated in the development of chronic pain states (277) (343) (344). The Pain Catastrophizing 
Scale (PCS) (345) measures an individual’s tendency to catastrophize in response to pain, or in 
response to the potential for pain.   
The Pain Catastrophizing Scale (PCS) (345) The PCS measures ‘catastrophizing’ across three 
categories. These are tendencies: to focus strongly on thoughts about pain (‘rumination’); to 
view oneself as helpless in dealing with pain-inducing situations (‘helplessness’); and to 
over-estimate the potential threat of stimuli which induce pain (‘magnification’) (345).  
The PCS is a 13-item self-report questionnaire. For each item the participant is asked to 
score how much that item applies to them, on a scale from zero (‘not at all’) to four (‘all the 
time’).  
  
The component ‘rumination’ has four items relevant to it, and as such is scored out of a 
possible sixteen. The component ‘magnification’ has three items relevant to it, and is scored 
out of a possible twelve. The remaining six items are relevant to the ‘helplessness’ 
component, giving a possible total of twenty four. The total PCS score is derived by the 
summation of the three individual component scores, and is scored out of a possible total of 
fifty two (346). The Pain Catastrophizing Scale has been widely used and validated (345) (344) 
(347), and as such has been considered to be a useful inclusion in this study. 
4.2.5 Pain Disability Index (PDI) 
The Pain Disability Index (PDI) (348) is a simple questionnaire for measuring the impact of pain 
on a person’s ability to undertake tasks and activities essential to their daily living. It is used 
clinically to determine patients’ disability due to pain over time, and to assist in evaluating 
the effectiveness of pain management therapies, particularly in chronic settings. 
The PDI measures the effect of pain on seven areas of an individual’s functioning, namely, 




support. There is one item for each area of functioning, and each item is ranked from zero 
(‘no disability’) to ten (‘total disability’). This gives an overall disability score out of a possible 
seventy (349). 
The PDI has been used in this study to assess the functional levels of participants post-
operatively, particularly as some of their number progress into chronic pain, a use for which 
it has been validated in peer-reviewed literature (348) (349) (350) (351).  
4.2.6 Brief Illness Perception Questionnaire (BIPQ) 
The Brief Illness Perception Questionnaire (BIPQ) (352) is a self-report scale designed to assess 
the respondent’s views on five dimensions of their illness. It is a shortened version of the 
Revised Illness Perception Questionnaire (IPQ-R), which is an eighty-item questionnaire, its 
length making it somewhat prohibitive in most clinical settings. As such, the nine-item BIPQ 
was developed as a more time-efficient alternative (352). 
Five of the nine items of the BIPQ aim to assess the five accepted core components of illness 
perception. These are ‘identity’, ‘cause’, ‘consequences’, ‘timeline’, and ‘cure/control’. 
‘Identity’ is the label assigned to the illness by the sufferer, and what they see as being a 
part of it. ‘Cause’ describes the factors attributed as the cause of their illness. 
‘Consequences’ are what the participant believes the outcome/s of their illness will be. The 
‘timeline’ is how long the participant expects to suffer their present illness.  ‘Cure/Control’ 
describes how strongly a participant believes they will be cured of their illness, or the extent 
to which symptoms can be managed.  
 
Two of the items assess emotional considerations, under the headings ‘emotions’ and 
‘concern’, with another representing the degree to which the participant comprehends their 
illness. The final item of the BIPQ is the item examining ‘cause’ (as described above). It is 
open-ended, and asks the participant to list, in order of significance, what they believe to be 
the three main factors that have caused their illness (352). The first eight items featured in 
this questionnaire are scored on a zero to ten scale, with zero being the negative response 
(e.g.: ‘No symptoms at all’), and ten being the affirmative (e.g.: ‘Many severe symptoms’).  
The BIPQ has been validated in asthma (352), diabetes (352), migraine (353), and allergic rhinitis 




predecessor (352) (353). It has predictive value for self-efficacy (355). This questionnaire has been 
chosen to investigate its usefulness in pain management, its correlation with self-efficacy, 
and to discover how illness beliefs change as levels and duration of pain change.  
 
4.2.7 Pain Self-Efficacy Questionnaire (PSEQ) 
The Pain Self-Efficacy Questionnaire (PSEQ) (356) is a self-report scale administered to 
sufferers of chronic pain which assesses their beliefs about their own self-efficacy.  
There are ten items ranked from zero to six, where 0 = ‘‘not at all confident’’ and 6 = 
‘‘completely confident’’. The total score is calculated by adding the scores for each question, 
yielding a maximum possible score of 60. A higher score indicates a stronger belief in their 
own self-efficacy. 
The PSEQ, like the PDI, is a well-validated (357) (356) (358), and has been shown to be a likely link 
in the relationships between chronic pain, depression, and disability (359). We have used it to 
investigate correlations between chronic pain, perceived self-efficacy, and more objective 
disability.  
4.2.8 Tampa Scale of Kinesiophobia – 13 (TSK-13) 
The Tampa Scale of Kinesiophobia - 13 (TSK-13, referred to hereafter as the TSK) (360) is a 
thirteen item self-report questionnaire assessing a patient’s fear of movement and/or 
reinjury, leading to what is known as pain avoidance behaviour. It is a shortened version of 
the seventeen-item TSK, with the four reverse-scoring questions removed. 
The TSK-13 items are all scored from one to four, where 1 = ‘Strongly disagree’ and 4 = 
‘Strongly agree’. The total score is calculated from the sum of all questions, giving a 
maximum possible total of 52. The higher the score, the greater the levels of kinesiophobia.  
The TSK has been shown to have excellent internal consistency and construct validity, and 
has been validated in several different chronic pain groups from low back pain (344), neck 
pain (361), shoulder pain (362) to temporomandibular disorders (363). It has been selected for 
use in this study because of the growing evidence base suggesting a possible causative link 




(363). We believe that a combination of the TSK, measuring kinesiophobia (which logically 
leads to avoidance behaviour in an effort to minimise risk of pain/reinjury), and the PSEQ, 
should provide valuable insight into the relationship between patient functionality and 
chronic pain 
4.2.9 Pain Treatment Satisfaction Scale (PTSS) 
The Pain Treatment Satisfaction Scale (PTSS) (364) is a sixty nine item self-report 
questionnaire assessing an individual’s level of satisfaction with their pain management. 
However, the length of this questionnaire, combined with the number of other 
questionnaires being used in this study, prohibited the use of the full questionnaire. As such, 
the version of the questionnaire used at the Burwood Pain Management Centre has been 
adopted that asks the questions most pertinent to the aims of this study. The version of the 
questionnaire used is comprised of 7 items, 5 of which are on a 0 to 10 scale, and 2 are ‘yes’ 
or ‘no’ questions. For example: “Was the treatment you received in line with what you 
expected at the beginning of treatment? Would you recommend this treatment to someone 
you know who has a similar problem?” 
4.3  The Cold Pressor Test 
The cold pressor test involves the participant placing their hand into a bucket of cold water 
(at 4 degrees centigrade), and removing it when they cannot bear it any more. The 
apparatus itself consisted of an 8-litre bucket, half-filled with ice, with a metal mesh over 
the ice to prevent ice burns. Cold water was then poured over the ice until it filled up above 
the mesh at a level deep enough for the participant’s hand. Once the participant’s hand was 
in the water, the participant informed the observer when the pain was first felt (the ‘pain 
threshold’) (365), and when the pain was unbearable (the ‘pain tolerance’) (365), at which point 
the limb was voluntarily removed. Pain endurance was the time difference between first 
feeling of pain (pain threshold) and the point at which the pain is no longer bearable (pain 
tolerance) (365). Perceived control over anxiety-inducing stimuli such as the cold pressor test 
increases pain tolerance and endurance (366). Given that the participant had total control 
over the cold pressor test, it is likely that pain tolerance and endurance in this test inflated 




As this perceived control over the cold pressor test existed in the same manner for all 
participants, it is unlikely that this produced any bias or confounders in the results. 
To the researchers’ knowledge, this test has not previously been carried out in comparable 
clinical research in New Zealand. However, the test is extensively documented in the 


























Chapter Five – Protocol Development 
  
5.1 Pilot study   
In order to best design and plan the main study detailed in this thesis, a pilot study was 
undertaken as part of the summer studentship program at the University of Otago, 
Christchurch. Ethical approval was obtained from the University of Otago Human Ethics 
Committee (Health) prior to commencing the study. This pilot study was designed under the 
assumption that the main study would comprise of a randomised controlled trial embedded 
into a cohort study. For clinical reasons beyond the control of the researcher, the 
randomised controlled trial element had to be discontinued, and the surgical population 
used altered. 
5.1.1 Aims and methods of the pilot study 
The aim of this pilot study was to design and partially pilot the proposed main cohort study 
of patients before and after surgery. Specifically, the aims were as follows: 
1) To pilot the use of the cold pressor test, and the questionnaires that were to be used 
in the main study. 
2) To determine the logistics of the main study, in terms of recruiting patients and 
performing the initial assessment at the pre-admission clinic at Christchurch 
Hospital. 
3) To determine the sample size available, and get an indication of the proportion of 











Inclusion Criteria: Exclusion Criteria: 
Aged 17 years or over Aged under 17 years 
Those undergoing elective surgery for limb 
amputation, thoracotomy,  and mastectomy 
surgery at Christchurch public hospital 
Informed consent withheld 
 Those with obvious cognitive impairments 
 Those on secondary analgesics (such as 
tricyclic antidepressants and the α2δ-sub-
unit voltage-dependent calcium channel 
blockers)1 
Table 1 Inclusion and exclusion criteria of the pilot study 
The rationale behind the inclusion and exclusion criteria chosen is outlined in chapter three 
of this thesis. 
There were 13 patients that met the study criteria, and gave their informed consent to 
participate. Another participant was identified but excluded due to receiving the secondary 
analgesic venlafaxine. Consenting participants were then taken to a private room in the pre-
admission clinic for assessment. The assessment piloted in this study was largely the same 
as that which was to be used as an initial assessment of participants in the main trial. It 
consisted of the following:  
Demographic data: Ethnicity, gender, level of education, and current work status were 
recorded for each participant. 
Validated questionnaires: The questionnaires2 used in this pilot study had all been 
extensively validated. These were the: Short Form McGill Pain Questionnaire (369) (370); Pain 
Disability Index (349); the Pain Self-Efficacy Questionnaire (371); the Depression and Anxiety 
Stress Scales-21 (372); and the Pain Anxiety Symptoms Scale-20 (336). 
                                                          
1 This exclusion criterion was put in place because the proposed main study involved a randomised control trial 
of two secondary analgesics. For logistical purposes, this component of the main study was dropped.  





Cold pressor test: The cold pressor test involved the participant placing their hand into a 
bucket of cold (at 4 degrees centigrade) water, and removing it when not being able to bear 
it any more. The apparatus itself was an 8-litre bucket, half-filled with ice and water, with a 
metal mesh over the ice to prevent ice burns.  
Explanation of main trial: The research student gave a detailed explanation of the proposed 
main trial (inclusive of the randomised controlled trial) to each participant. Participants 
were then asked to indicate whether or not they would, if eligible to participate in said trial, 
have given their informed consent.  
5.1.2 Relevant findings of the pilot study 
No participants recruited for this study were deemed to be in significant pain at the time of, 
or in the week prior to, assessment at pre-admission clinic. This meant that only the 
demographic information and the DASS-21 were completed by all participants. Only one 
participant indicated that they would not have participated in the main study if eligible to 
participate. 
Twelve participants in this study were undergoing mastectomy surgery; the one 
thoracotomy patient identified was undergoing an oesophagogastrectomy. No patients 
undergoing limb amputation were identified during the 10 weeks of the study. 
5.1.3 Using the pilot study to assist in designing the main study 
Over the 10-week course of this pilot study, 12 patients undergoing mastectomy, 0 patients 
undergoing limb amputations, and 1 patient undergoing a thoracotomy were identified at 
Christchurch Hospital Pre-admission clinic. This rate of patients acquired per week in the 
pilot study was substantially lower than that required for the main study. This led to a 
change in recruitment location from Christchurch Hospital Pre-admission Clinic to the 
Burwood Hospital Department of Orthopaedics, and then to the Christchurch Women’s 
Hospital Pre-admission clinic. Discussions with staff suggested that approximately 5 patients 
per week could be recruited from Christchurch Women’s Hospital Pre-admission clinic, 




Only 1 patient in an eligible surgical group was excluded from this pilot study, due to 
receiving the secondary analgesic venlafaxine (373). This was removed as an exclusion 
criterion for the main study, since it was no longer relevant once the randomised controlled 
trial aspect had been removed. No eligible participants failed the person-place-time 
orientation test. None were considered sufficiently cognitively impaired as to be 
incompetent to give informed consent. No eligible patients declined to participate in this 
pilot study, and only 1 of the participants of this pilot indicated that they would not have 
participated in the main study if eligible to do so. This boded well for participation rates 
once the study had been shifted to a department with greater numbers of potential 
participants. 
The design of the cold pressor test was not dramatically altered between the pilot study and 
main study, as it proved portable and functional. The way the study was introduced to 
















Chapter Six – Detailed Methods 
  
6.1 Hypothesis and aims 
6.1.1 Hypothesis  
As laid out in the literature review, all of the measures taken in this study have experimental 
or at least hypothetical evidence to suggest a relationship with prolonged pain states.  It was 
hypothesised that one or more of the measures taken (psychometric questionnaires, cold 
pressor test, clinical records, surgical and anaesthetic approaches) would predict pain at six 
weeks and three months postoperatively.  
6.1.2 Specific Aims  
1) The prevalence of acute persistent pain at 6 weeks postoperatively 
2) The prevalence of chronic pain at 3 months postoperatively 
3) The predictive value of the secondary measures collected, relating to each of the 
first two aims 
6.2 Review of literature 
Existing literature on the physiology, pathophysiology, and management of both acute and 
chronic pain was reviewed. Articles, reviews, and meta-analyses in peer-reviewed journals 
and textbooks were accessed, and the relevant information extracted. The search engines 
‘PubMed’ and ‘Google Scholar’ were used to extract relevant articles. Physical copies of 
textbooks were accessed at the University of Otago, Christchurch (UOC) medical library, and 
the University of Otago Christchurch’s Department of Anaesthesia.  
6.3 Ethical approval  
Ethical approval for the project required an extension of an existing proposal. This extension 
was granted by the University of Otago Research Human Ethics Committee (Health) on 8th 
May 2014 (reference number HE13/07). Locality authorisation for the project to be 
undertaken at Christchurch Women’s Hospital was granted by the Canterbury District 
Health Board (CDHB) Research Office (Research Office allocated number 14082). 




undertaken. It was suggested that ethnicity data should be collected - that was already the 
case. In addition that those Māori participants are explicitly made aware that consent given 
for this research project was for the purposes of this study only. This was done not only with 
Māori participants, but extended to all other participants as well. 
6.4 Study design 
The study design was piloted in the summer before the main study took place. The 
methodology and results of the pilot study can be found in chapter five. 
A prospective cohort study was undertaken in the Preadmission Clinic at Christchurch 
Women’s Hospital (CWH). From here, patients who were undergoing gynaecological surgery 
and requiring at least an overnight stay at either CWH or Southern Cross Hospital (SCH) 
(under CDHB contract) were approached. Once informed consent had been obtained, 
participants were subjected to the cold pressor test, and filled in the baseline 
questionnaires. At six weeks, and three months following their surgery, participants were 
contacted by telephone, were asked about their pain (if any), and completed further 
questionnaires.  
Following an individual’s surgery, every effort was made to access the relevant records 
relating to their surgery.  
 Sample size  
The planned sample size for the original iteration of the study was 140 participants. This was 
the number judged realistic from a logistical standpoint. As calculated by GPower 3.13, an a2 
= 0.05, and power of 80% , it would allow detection of correlations of 0.21 between baseline 
measurements and pain levels at follow-up The original design was a randomised controlled 
trial of gabapentin and nortriptyline for the prevention of CPSP, embedded within a 
prospective cohort study. The detectable Cohen’s d for this study was 0.85. Ethical approval 
from the Ministry of Health’s Health and Disability Ethics Committee was obtained, as was 
locality authorisation from the Canterbury District Health Board, and permission was 
granted by the Head of Department for the Department of Orthopaedics at Burwood 
Hospital. However, before the first participant could be recruited, several senior clinicians in 





the Department of Orthopaedics actively resisted having their patients involved in any 
research study. Their wishes were respected, and the study was moved to the specialty with 
the second highest number of potentially eligible patients: gynaecology. The resulting time 
delay in repeating the required approvals and the limited timeframe of the B.Med.Sc. (Hons) 
meant that the randomised controlled trial component unfortunately had to be removed, 
and fewer participants were able to be recruited. With the 3 month follow-up period of this 
study taken into consideration, approximately 10 weeks only could be allocated to 
recruitment. Based on the figures given by the Department of Gynaecology, it was decided 
that it could be reasonably expected that approximately 5 participants could be recruited 
per week. As a result, a target of 50 participants was set. This would allow detection of 
correlations of 0.34 between baseline measurements and pain levels at follow-up. Four 
extra participants were recruited in the 11th week to account for loss to follow-up. 
6.5 Recruitment and consent  
Selection  
Patients were approached at Christchurch Women’s Hospital pre-admission clinic by the 
research student or nursing staff. They were given a brief outline of study, and asked if they 
were interested in hearing more. If they expressed interest, they were taken to one of the 
rooms in pre-admission clinic once pre-admission had been completed. 
Written informed consent  
The trial and the requirements of participation were fully explained. Participants were given 
an information sheet to take away with them. They were encouraged to ask any further 
questions. The investigators’ contact details were supplied (on the participant information 
sheet) should any questions occur at a later stage. They were reminded them that they 
retained the right to withdraw from the project at any stage without any disadvantage to 
them. Informed consent was obtained by the signing of the consent form. 
The participants consented to the following: 1) Pre-operative assessment; 2) Access to their 
(relevant) clinical records; and 3) Consent to being contacted at 6 weeks and 3 months post-





6.6 Inclusion and exclusion criteria 
Inclusion Criteria                
All of the following criteria had to be met in order to enter the study, providing no exclusion 
criteria existed. They were:                        
1) To undergo gynaecological surgery requiring at least an overnight stay at Christchurch 
Women’s Hospital or Southern Cross Hospital (under CDHB contract) 
2) 16 years of age or older   
3) To grant informed consent 
Exclusion Criteria 
Any potential participant would be ineligible to enter the study if one or more of the 
following criteria existed: 
1) <16 years of age 
2) Cognitively impaired  
3) Withholding informed consent 
4) Any person whose proficiency in English was such that they would require an interpreter 
to fully understand the study 
Inclusion criteria (as listed above) were that patients were aged 16 years or older, and 
would be undergoing gynaecological surgery at Christchurch Women’s Hospital. The age 
limit was placed in order that patients could give their own informed consent. The surgical 
groups were chosen because the gynaecological surgical group were a large surgical group 
carrying a large overall pain burden. There were 54 participants recruited. 
Exclusion criteria (as listed above) were the following: patients aged less than 16 years 
(reasoning as above); those who withheld informed consent; those with obvious cognitive 
impairments that might render them incompetent to give informed consent; and any person 
whose proficiency in English was such to require an interpreter to fully understand the 




and time orientation. The questions used to determine this were as follows: 1) ‘Can you 
please tell me your full name? 2) ‘Can you please tell me where we are at present? 3) ‘Can 
you please tell me what year it is, and what day of the week it is?’. As the follow-up 
assessments were conducted over the telephone, it was not practical to include anyone 
whose English proficiency was not sufficient to complete the questionnaires without an 
interpreter. 
6.7 Baseline assessment  
The baseline assessment was carried out in pre-admission clinic. It comprised three parts, 
namely: the collection of demographic data; the administration of validated questionnaires 
to determine the participant’s pre-operative psychological state; and the cold pressor test 
to determine the participant’s pain threshold, tolerance, and endurance.  
6.7.1 Demographic information, and validated questionnaires 
The questionnaires aimed to potentially identify which (if any) psychological states (as 
measured by these questionnaires) would predict pain outcomes postoperatively. Multiple 
measures were taken, as a single questionnaire could not globally assess a person’s 
psychological state. The characteristics measured by these questionnaires were as follows: 
DASS-21: Depression, anxiety, and stress, which are known to correlate with chronic pain 
states. 
BIPQ: Participant perceptions and beliefs surrounding illness and pain. 
SF-McGill: The severity and character of pain. 
PTSS: How well a participant believed their pain was being managed. 
PSEQ, TSK, PDI: Level of functioning, and how the pain is affected their daily lives. 
The questionnaires used in the initial assessment for the main study were largely the same 
as those undertaken in the pilot study. All had been extensively validated. They were 




Participants were asked to indicate if they were in any pain that was distressing or 
functionally impairing (3/10 or above on the verbal analogue scale) at any time in the week 
immediately preceding the assessment, and was related to the reason for their surgery.    
In pain DASS-21 BIPQ Demographic 
information 




DASS-21 BIPQ Demographic 
information 
Figure 1 Data collected at baseline for each group 
 
Demographic data: Ethnicity, age, gender, level of education, and current work status were 
recorded for each participant. These factors are known to be related to depression, anxiety, 
illness perception, and the experience of pain. Participants were asked to indicate their 
smoking status, and alcohol and recreational drug use, as these are known be related to the 
progression of pain.  
All participants were asked to indicate the appropriate day and time of day for follow-up 
telephone calls, and whether or not they would like to receive a copy of the results. Home 
phone, cell phone, email, other contact details were collected as well.  
6.7.2 The cold pressor test 
Pain threshold (time taken to feel pain) and pain tolerance (total time hand is submerged) 
were recorded. From these, pain endurance (pain tolerance minus pain threshold) was 
calculated. The water temperature in the tank was set at 4 degrees Centigrade. No 
distractions were allowed during the test, as these are proven to enhance pain tolerance 
(374,375). 
The cold pressor test was carried out before the participant completed the questionnaires, 
in order that the observer could not subconsciously influence the subject’s performance 
based on their pain versus no pain status, or on their psychological measures. 
Participants were aware that a test limit existed for their safety. However, they were 
blinded to the actual said limit. For safety reasons, the test was terminated after 4 minutes 
if the participant had not already removed their hand. The test limit of 4 minutes was 




6.8 Perioperative assessments  
Complete perioperative data proved difficult to obtain for many participants due to 
incomplete files, and due to files being held by other District Health Boards. The following 
were searched for:  
6.8.1 Surgical and anaesthetic techniques 
Surgical approach (laparoscopic, laparotomy, per-vaginal); type of surgical procedure; the 
type and amount of all medications used; duration of surgery; and any perioperative 
surgical or anaesthetic complications. 
6.8.2 Recovery room assessment  
Analgesia given was recorded. Any complications occurring were recorded.  
6.8.3 Postoperatively  
The following were recorded:   
- The amount of morphine/fentanyl used every 24 hours (obtained from Patient Controlled 
Analgesic pumps), and the weak opioid/NSAID/steroid use. 
- The appearance of postoperative red flags (infection, bleeding, rupture of sutures) 
- The analgesic medications on discharge from the hospital 
The following were searched for on the clinical records database:  history of chronic pain; 
any chronic medical condition; any chronic psychiatric condition; and the number of 
previous admissions/referrals to tertiary health centres.  
6.9 6-weeks postoperatively  
Participants were contacted by telephone at an appropriate time to respond to the 
questionnaires. If participants did not answer within 48 days of their surgery, they were 
considered lost to follow-up, and were not contacted at 3 months. 
Participants were asked to indicate if they were in pain at any time of the week immediately 

























Figure 2 Data collected at 6 weeks for each group   
*: ‘In pain’ – any pain which, in the participant’s eyes, has caused distress or functional 
impairment over the preceding week. The pain must be the direct result of their surgery, 
and must be greater than or equal to 3/10 on the Verbal Rating Scale (VRS). 
For all participants: 
1) They were then informed that the researcher would contact them in another 6 weeks, 
and asked to indicate an appropriate time. 
2) Information about late complications from their surgery (e.g. wound opening, after 
discharge infections, re-hospitalisation, etc.) were recorded. 
6.10 3-months postoperatively 
Participants were contacted by telephone at an appropriate time to complete the 
questionnaires. If participants did not answer within 48 days of their surgery, they were 
considered lost to follow-up. 
Questionnaires:   
1) For those with pain at 6 weeks (n=1) 
For the patient still in pain, the same questionnaires as at week 6 were administered. 
For those patients not in pain (n=7), the following was recorded: the date the pain stopped; 
and the reasons it stopped (if they had reasons). The DASS-21 questionnaire was 
administered. 
2) Those with no pain at 6 weeks (n=43) were asked if, since the last contact by telephone, 
they had experienced any pain that they attributed to their surgery  
-3 participants identified that they had developed pain in the time since the 6 week 




only during menstruation). They were asked to complete the DASS-21, and SF-McGill 
questionnaires, and a verbal scale of pain intensity. The remaining participant, who had 
experienced ‘sub-threshold’ pain at 6 weeks (2/10 verbal scale of pain intensity), now 
experienced pain ranging from 3-7/10 on the verbal scale of pain intensity. She was asked to 
complete the DASS-21, PASS-20, PDI, PTSS questionnaires, the verbal scale of pain intensity, 
and the functional measures (TSK, PSEQ).  
- For the rest with no pain at 6 weeks (n=40), only the DASS-21 questionnaire was 
administered. 
Participants were informed that they would not be contacted again; they were reminded 
that they could request a copy of the results, or contact the research team if they had any 
questions. Participants were then thanked for their participation. 
All efforts were made to ensure all participants received adequate care. At the cessation of 
the study, it was planned that any participant experiencing debilitating chronic pain would 
be referred to the Burwood Pain Management Centre for treatment. However, fortunately 
none of our participants experiencing continued pain were considered appropriate for 
referral, and were followed-up by their own General Practitioner.  
6.11 Analysis of data   
As previously noted, the sample size was limited by the following: the timeframe of the 
B.Med.Sc. (Hons) course4; several setbacks that resulted in a delayed start; the number of 
eligible patients seen at Christchurch Women’s Hospital, and the number of eligible patients 
the research student was able to recruit. This rather small sample size resulted in limited 
statistical power to detect some of the less common outcomes and smaller associations.  
Initially it was planned to calculate correlations between baseline measures and pain scores 
at 6 weeks and 3 months postoperatively. However, the change from orthopaedic to 
gynaecological patients meant that far fewer of the patients were in pain at baseline, and 
fewer still at follow-up, than expected. This meant that it was inappropriate to use 
correlations, as too many participants had pain scores of zero. Instead those patients in pain 
                                                          





were compared with those patients not in pain at each observation point. Baseline 
characteristics of those who progressed into prolonged pain states were compared with 
those who did not. 
Data was entered into Microsoft Excel spreadsheets, and then into OpenEpi (Dean, A.G. et 
al, Open Source Epidemiologic Statistics for Public Health) for quantitative analysis. Any 
participants not completing follow-up point(s) were excluded from analyses relating to 
those point(s). There were 95% Confidence intervals (95% CI) calculated using the Score 
(Wilson) method. T-tests (dependent and independent) were used for comparisons of 
means and two-tailed p-values were used throughout. Chi-squared tests were used for 
comparisons of proportions. Linear regression was attempted to impute pain endurance on 
the cold pressor test in patients who reached the time limit of 240 seconds. Significance was 

















Chapter Seven – Results 
 
Participants were recruited from pre-admission clinic at Christchurch Women’s Hospital 
from 5th May 2014 until 31st July 2014. They were then followed up by telephone for their 6-
week and 3-month assessments that ended on the 29th October 2014.  
7.1 Participant flow 
 
Figure 3 Participant flow. Note: All three participants lost to follow-up at 6 weeks had been in pain at baseline. Both 
participants lost to follow-up at 3 months had been pain-free at 6 weeks.  
Ideally, data would have been collected about those who chose not to participate or were 
rendered ineligible by the exclusion criteria. Due to the clinical responsibilities of the nursing 
staff, a large number of patients were ‘vetted’ before the research student was even made 
aware of these patients. The research student was therefore unable to gather accurate data 
about non-participants. Conversations with the nursing staff revealed three main reasons 
why the staff would choose not to pass a patient on to the research student:  
1) The nursing staff considered the patient too vulnerable or scared (for example those 
with significant comorbidities or malignancies or the very anxious). 
2) The patient flagrantly failed an inclusion criterion, such as being very cognitively 
impaired, or unable to speak English.  
3) Those patients who indicated they would not provide informed consent. 
Due to the busy clinical environment, the nurses were often too busy to provide this 
information. The research student did not know how the study was introduced to patients 
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make any accurate conclusions about the number of non-participants. Of the 61 patients 
personally approached by the student, 54 consented without meeting any of the exclusion 
criteria. Of the remaining 7 patients, 4 patients initially indicated interest, but either forgot 
or changed their minds, and left after their pre-admission was complete. Two patients 
refused to take part, and 1 patient was deemed too cognitively impaired. A number of 
patients under the age of 16 came through the pre-admission clinic. None of these were 
approached. This might have impacted the data as explained later. 
7.2 Baseline characteristics  
7.2.1 Demographic information and relevant history 
For all participants, the following were recorded: ethnicity; age (date of birth); gender; level 
of education; and current work status. Participants were also asked to circle any given 
conditions they had suffered. Their smoking status and use of alcohol and recreational drugs 
















 Not in pain at 
baseline (n=26) 




Ethnicity    
NZ Māori 3 (11.1%) 2 (6.9%) 5 (9.3%) 
NZ European 21 (77.8%)   23 (79.3%) 44 (81.5%) 
Other 3 (11.1%) 4 (13.8%) 7 (13.0%) 
Mean age (years) 48.4 (SD 12.9) 36.3 (SD 10.7) 42.1 
History of:    
Chronic pain 8 (30.8%) 19 (67.9%) 27 (50%) 
Mental illness 4 (15.4%) 9 (32.1%) 13 (24.1%) 
Surgery 20 (76.9%) 17 (60.7%) 37 (68.5%) 
Smoking    
Present (mean 
pack years) 
7 (26.9%) (16.9 pack 
years, SD 9.7)  
4 (14.3%) (5.3 pack 
years, SD 3.1) 
11 (20.4%) (10.8 
pack years)  
(95% CI 4.3, 17.3) 
Former (mean 
pack years) 
6 (23.1%) (20.3 pack 
years, SD 12.7) 
5 (17.6%) (8.9 pack 
years, SD 6.9) 
11 (20.4%) (14.4 
pack years)  
(95% CI 6.4, 22.4) 
Never 13 (50%) 19 (67.9%) 32 (59.3%) 
Consume alcohol 14 (53.8%) 21 (75%) 35 (64.8%) 
Yes (standard 
drinks per week) 
3.7 3.4 3.6 
Currently working  22 (84.6%)  22 (78.6%) 44 (81.5%) 
Level of education    
University 5 (19.2%) 8 (28.6%) 13 (24.1%) 
Other post-
secondary 
9 (34.6%) 12 (42.8%) 21 (38.9%) 
Secondary school   7 (26.9%) 6 (21.4%) 13 (24.1%) 
Unanswered 5 (19.2%) 2 (7.1%) 7 (12.9%) 
Table 2 Demographic and relevant medical information at baseline. *Two participants identified themselves with two 
ethnicities, and so for the purposes of ethnicity, percentages shown are percentage reporting each ethnicity, and sum to 
more than 100%. 
Age and ethnicity  
All 54 participants in this study were biologically female, and all identified themselves as 
such. The ‘Not in pain’ (NP) group were a mean of 12.1 (95% CI 5.7, 18.6) years older than 
the ‘In pain’ (IP) group, which was a significant difference (p < 0.001). In the NP group, the 
youngest participant was 25 years of age, while the oldest was 73.  By comparison, the 
youngest participant in the IP group was 20 years of age, and the oldest 67.  
Table 2 shows that it is clear that both groups had similar distribution of ethnicities, with the 




participants selected multiple ethnicities, and in accordance with New Zealand Census 
reporting (379), each ethnicity stated was recorded, producing a total of over 100%. In the NP 
group, ‘Other’ ethnicities recorded were Latino-American, British, and Filipino origin. In the 
IP group, ‘Other’ ethnicities recorded were Irish, Dutch, Spanish, and unspecified European 
origin. The 2013 New Zealand Census (379) recorded 8.1% of the Canterbury region as NZ 
Māori, 86.9% as NZ European, and 14.1% as other ethnicities. This compares with the 7.4% 
(NZM), 80.6% (NZE), and 12% (Other) in this study, suggesting a representative spread of 
ethnicities within the study.  
Relevant history 
There were 27 participants (50%) that reported a history of chronic pain, defined as ‘pain 
lasting longer than three months’. Those in the IP group were significantly more likely than 
those in the NP group to have had a history of chronic pain (p= 0.01). This is unsurprising, as 
many of the IP group would be undergoing surgery to relieve longstanding pain. The 
prevalence of chronic pain in the underlying New Zealand population is 16.9% (39).  
A history of mental illness seems likely to go under-reported on a simple self-reporting 
questionnaire, due to embarrassment or inaccurate recall. It is possible that some 
participants thought the question was only relevant to current disorders, and did not report 
past issues. There were 13 participants (24.1%) that reported a prior or current mental 
illness; this was higher in the IP group than in the NP group, but not significantly (p= 0.15). 
Both groups individually as well as in total, are all lower than the lifetime prevalence for 
‘Any disorder’ (39.5%) found in Te Rau Hinengaro: The New Zealand Mental Health Survey 
(380). This survey asked specifically about symptoms of many disorders, and so was more 
sensitive than the question in this this study about a history of mental illness. 
With the category of ‘surgery’ being broad, it has been difficult to find lifetime risk reports in 
the literature, particularly for New Zealand. One study from the United States reports a risk 
of intra-abdominal surgery by the age of 60 of 43.8% (381), while two others report female 
lifetime risks of prolapse and/or urinary stress incontinence surgery of 19% (382) and 20% 
(383), respectively. Naturally, with a mean age of only 41.5 years, the women in this study are 
not representative of a ‘lifetime’ risk. However, with an overall record of 37 participants 




further surgery. Interestingly, participants in the IP group were non-significantly more likely 
than those in the NP group to have previously undergone surgery (p = 0.20). If this is a true 
association, it could be at least in part due to the 12.1 year mean age gap between the two 
groups.  
The comparison of self-reported mental illness, chronic pain, and surgical history with 
mental illness recorded in medical files will be discussed later. 
Smoking  
Despite appearing higher in the NP group, a Chi-squared at a significance level of 0.05 did 
not find a significant difference in the number of ‘current smokers’ (p = 0.25), or ‘former 
smokers’ (p = 0.63) between the two groups. However, a two-tailed independent t-test 
found that those currently smoking in the NP group had a significantly longer pack-year 
history. The same could not be said for the ‘former smokers’, with the 20.3 years vs. 8.9 
years difference being not significant at 95% confidence  interval (p = 0.10). The longer pack-
year history in the NP group might at least be partially explained by the 12.1 year mean age 
gap between the two groups. 
Recall bias likely affected reporting of the duration of smoking history for some participants. 
It is not known how this would affect the overall results. The prevalence of current smokers 
in New Zealand adults is 19.9% (18.8% of current smokers are adult females) (384).  Of the 
female population, 18.6% were regarded as ‘ex-smokers’ in 2006/2007 (385). It is worth 
noting that the prevalence of New Zealand female smokers in the 30-39 age bracket (in 
which the IP mean falls) is 21.5%; it is 22.3% in the 40-49 age bracket, (in which the NP 
mean falls) (386).  
Illicit drugs 
Only one participant (1.85%) admitted to recreational drug use other than alcohol, 
compared to 23.8% of the adult New Zealand population (387). It is likely that illicit drug use 
was under-reported in this study. This could possibly be due to fear that, despite assurances 
to the contrary, divulging the information could negatively affect some aspects of their 




much lower rate of illicit drug use. In absence of a plausible explanation it seems likely that 
this is either a case of under-reporting, or a statistical anomaly.  
Alcohol use 
Of the 54 total participants, 35 (64.8%) consumed alcohol at least once per week. Those in 
the IP group were more likely than those in the NP group to report that they consume 
alcohol at least once per week, but not significantly (p= 0.10). The New Zealand average for 
females, as measured by the 2007/2008 New Zealand Alcohol and Drug Use Survey (388) is 
43.2%. Using the Statistics New Zealand population indicators (389) there were 2,271,800 
females in the New Zealand population as of 31st December 2013. Using these data, a Chi-
Squared test for population proportions found that the 54 participants in this study were 
significantly more likely to consume alcohol at least once per week than the average New 
Zealand female (p < 0.001).  
This study asked participants to record the number of standard drinks they consumed per 
week (NP 3.7, IP 3.4, total 3.6). The 2007/2008 New Zealand Alcohol and Drug Use Survey 
(388) did not ask about this, but rather focussed on whether or not people were likely to drink 
to excess in a single sitting. New Zealand population data on standard drinks consumed per 
week is not available in a form comparable to the data collected in this study. 
Employment and education  
A total of 44 participants (81.5%) were employed in either part- or full-time work. There was 
no statistically significant difference between the two groups in terms of the proportions 
employed in each group (p = 0.57). The ‘Labour force participation rate’ reported by 
Statistics New Zealand for the June 2014 quarter is 68.5% (390). 
In terms of highest level of education, 13 (24.1%) participants had received tertiary 
education, 21 (38.9%) participants that had undertaken other post-secondary study, and 13 
(24.1%) others that had at least one secondary school qualification. Five participants (19.2%) 





There were no significant differences in education between those in pain and those not in 
pain on a Chi-squared test, namely: tertiary qualification, p = 0.42; other post-secondary 
qualification, p = 0.54; and secondary qualification, p = 0.64. In 2013, 76.2% of the adult 
population (aged 25-64 years) had at least one secondary school qualification, with 26.1% 
holding a Bachelor’s degree or higher (391). In 2007, 41% of all adults (aged 25-64 years) had 
received tertiary education (included all post-secondary education) (392).  
In this study, 63.0% of participants (28.6% tertiary education, and 38.9% ‘other post-
secondary’ education) had completed post-secondary education (even when assuming that 
all 7 non-respondents had not). The lower confidence limit was found to be greater than the 
number given by the New Zealand government (49.6% versus. 41%), indicating that the 
participants in this study were significantly more likely than the underlying population to 

















7.2.2 Validated questionnaires and pain score means (standard deviations) 
 Not in pain at 
baseline (n=26) 






DASS-21     
Depression 1.5 (1.8) 3.9 (3.5) 2.7 (3.5) 0-21 
Anxiety 1.8 (3.0) 3.9 (4.2) 2.9 (3.4) 0-21 
Stress  3.6 (3.2) 7.5 (5.4) 5.6 (4.8) 0-21 
Total 6.9 (6.5) 15.3 (18.9) 11.2 (10.5) 0-63 
BIPQ* 33.4 (10.2) 41.1 (7.6) (n=27) 37.3 (9.7) 0-50 
‘In pain’ 
questionnaires: 
    
SF-McGill  (n=27)  (95% CI)  
Sensory - 5.5 (5.3) (3.4, 7.6) 0-44 
Affective - 1.6 (2.4) (0.7, 2.5) 0-16 
PPI - 1.8 (1.2) (1.3, 2.3) 0-6 
Total - 8.9 (8.0) (5.7, 12.1) 0-66 
VAS - 2.1 (2.0) (1.3, 2.9) 0-10 
PCS  (n=25)   
Rumination - 7.2 (4.4) (5.4, 9.0) 0-16 
Magnification - 3.5 (2.6) (2.4, 4.6) 0-12 
Helplessness - 8.5 (4.4) (6.7, 10.3) 0-24 
Total - 19.2 (10.1) (15.0, 23.4) 0-52 
PDI - 26.7 (14.5) 
(n=26) 
(20.8, 32.6) 0-70 
PASS-20  (n=27)   
Cognitive - 13.0 (5.2) (10.9, 15.1) 0-25 
Escape - 11.0 (5.9) (10.7, 15.3) 0-25 
Fearfulness - 5.0 (4.5) (3.2, 6.8) 0-25 
Physiological 
arousal 
- 8.2 (5.2) (6.1, 10.3) 0-25 
Total - 37.2 (17.0) (30.5, 43.9) 0-100 
VAS Scores     
Pain high - 7.3 (2.9) (n=26) (6.1, 8.5) 0-10 
Pain low - 2.1 (1.7) (n=27) (1.4, 2.8) 0-10 
Usual pain - 3.5 (2.0) (n=26) (2.7, 4.3) 0-10 
Table 3 Validated questionnaires at baseline. *The 'Causal categories' section of the BIPQ is not included in this table. When 
one or more participant has not answered a given questionnaire, the number of respondents is given in the table as (n=X). 
DASS-21  
Each section of the DASS-21 has 7 items (0-3 scale), with a maximum possible score in each 
section of 21, and maximum total score of 63. All DASS-21 section scores were significantly 




Using a two-tailed t-test for independent group means depression scores were significantly 
higher in the IP group than in the than the NP group [mean difference 2.4 (95% CI 0.9, 3.9) 
(p= 0.01)]. The normative data (norm) from 1,724 United Kingdom adults (372) for the 
depression subscale was 2.8 (SD 3.9). The 95% confidence interval for the IP group is (CI 2.5, 
5.3), and the difference between the IP group and the published norm is not significant on a 
two-tailed independent t-test (p = 0.11). 
Anxiety scores were significantly higher in the IP group than in the NP group [mean 
difference 2.1 (95% CI 0.1, 4.1) (p=0.02)]. The norm (372) for the anxiety subscale is 1.9 (SD 
3.0), so the difference between the IP group and the published norm is significant (p = 0.02).  
Stress scores were significantly higher (p = 0.002) in the IP group than the ‘NP group [mean 
difference 3.9 (95% CI 1.5, 6.4) (p= 0.002). The norm (372) for the stress subscale is 4.7 (SD 
4.2), so the difference between the IP group and the published norm is significant (p = 0.01). 
Total DASS-21 scores were significantly higher in the IP group than in the NP group [mean 
difference 8.4 (95% CI 0.6, 16.2) (p= 0.002)]. The norm (372) for the DASS-21 is 9.4 (SD 9.7), so 
the difference between the IP group and the published norm is significant (p= 0.002). 
BIPQ 
The BIPQ contains 8 items (0-10 scale), with a maximum possible score of 80. The mean 
BIPQ score in the IP group (41.1) was significantly higher (p = 0.003) than the NP group 
(33.4) on a two-tailed t-test for independent means, with a mean difference of 7.7 (95% CI 
2.8, 12.7). This indicates a more threatening view of illness in the IP group that seems logical 
given their higher anxiety and stress scores. Some examples of published norms are as 
follows: common colds 36.6; ‘pre-diagnosis’ chest pain 42; asthma 45.8; myocardial 
infarction 49.3; and diabetes mellitus 52.4 (352). In terms of threats to their health, this would 
see the cohort as a whole (mean 37.3) viewing their illnesses as somewhere between the 
common cold, and undiagnosed chest pain The BIPQ also asked participants to rank-order 
the 3 most important factors they believe caused their illness. Participants filled in 
anywhere from 0 to 3 factors, with a total of 61 answers recorded. For the sake of analysis, 
these answers were grouped into categories. Twelve participants (19.7%) believed their 




but stated they had ‘no idea’ of the cause of their illness; 10 participants (16.4%) blamed 
their lifestyle or other self-controlled factors; 9 participants (14.8%) blamed childbirth; 9 
participants (14.8%) blamed other assorted biological factors; 6 participants (9.8%) believed 
their age had a role to play; there were 3 4.9% that believed their illness was caused by 
chance or poor luck. Ten (18.5%) of the 54 participants did not answer this section of the 
BIPQ. ‘Norms’ for this section of the BIPQ do not appear to have been published for 
gynaecological patients. 
SF-McGill, PCS, PDI, and PASS-20 scores 
The means, standard deviations, and 95% confidence intervals for the SF-McGill, PCS, PDI, 
and PASS-20 scores are shown in Table 3. Naturally no comparisons can be made at baseline 
given that only patients in pain at baseline completed them.  
The SF-McGill has an 11-item ‘sensory’ sub-scale, and a 4-item ‘affective’ sub-scale. Each 
item is scored out of 4, giving a maximum possible score of 44 for the ‘sensory’ sub-scale, 
and 16 for the ‘affective’ sub-scale. It has a ‘present pain indicator’ (PPI) which is scored out 
of 6, bringing the maximum possible total score to 66. The PCS is scored out of a total of 52, 
with 13 items (0-4 scale). The ‘Rumination’ ‘Magnification’ and ‘Helplessness’ sub-scales 
comprises of 4, 3, and 6 items respectively, with a resulting maximum possible scores of 16, 
12, and 24. The PDI is a 7-item questionnaire, with its items scored on a 0-10 scale, giving a 
maximum total score of 70. The PASS-20 is a 20-item questionnaire, each of its items being 
scored from 0-5. Each of its 4 sub-scales (cognitive anxiety, escape/avoidance, fearfulness, 
and physiological arousal) has maximum scores of 25, with the overall maximum score being 
100. 
SF-McGill  
The norms for the sensory and affective scales of the SF-McGill in patients with chronic back 
pain (n=188) are 11.9 (SD 0.9) and 3.0 (SD 0.6)5, respectively (339). These are both higher than 
the 5.5 (p < 0.001, two-tailed independent t-test) and 1.6 (p < 0.001). The PPI and VAS 
                                                          




scores naturally differ vastly between clinical circumstances, and a valid published 
comparison (for pre-operative or gynaecological patients) could not be found. 
PCS  
Women are reported to have significantly higher levels of pain catastrophizing (as measured 
by the PCS) than men both overall, and in the rumination and helplessness sub-scales (345). 
As such, normative data for women (n=302) was used for comparison with this all-female 
cohort. The following calculations are two-tailed independent t-tests, using the norms6 
published by Sullivan et al (345). This cohort only significantly differed from the norms in the 
helplessness sub-scale [helplessness 8.5 (SD 4.4) versus 7.2 (SD 3.0) (p = 0.046)]. The other 
sub-scales and the overall scores did not significantly differ. The cohort means are given 
first, namely: rumination 7.2 (SD 4.4) versus 8.8 (SD 3.6) (p = 0.09); magnification 3.5 (SD 
2.6) versus 3.6 (SD 2.1) (p = 0.85); and total 19.2 (SD 10.1) versus total 19.5 (SD 8.5) (p = 
0.89). These norms are for a pain-free cohort of psychology students, who were asked to 
recall a recent painful experience while completing the questionnaire. 
PDI 
Tait et al (349) report results from 401 chronic pain patients that were separated into ‘low’ 
and ‘high’ disability, based on which side of the median (46) they fell. The means for the 
‘low’ and ‘high’ groups were 34.5 (SD 9.3) and 55.9 (SD 5.8), respectively. The mean for this 
study’s ‘In Pain’ cohort was 26.7 (SD 14.5). For the sake of comparison, a 95% confidence 
interval was calculated using a two-tailed independent t-test for the 204 ‘low disability’ 
participants in the Tait et al study, and was based on the mean of 34.5 and a standard 
deviation of 9.3. This study’s ‘In Pain’ cohort was shown to significantly differ from the 
published norm for ‘low disability’ chronic pain patients: mean difference 7.4 (95% CI 3.7, 
11.9) (p < 0.001). However, this study noted that women reported significantly less disability 
than men, but did not state the extent to which this occurred. Given how close the upper 
arm of the ‘In Pain’ group’s CI comes to the lower arm of the Tait group (32.6 versus 33.2), it 
is likely that this is due to either the gender differences, or the fact that this compares 
patients from a chronic pain unit to pre-surgical patients likely to be suffering lower levels of 
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pain. It is quite possible to be a real difference, as people actually specifically undergoing 
treatment for chronic pain would likely be more disabled by it than those who are not.  
PASS-20  
The norms for each of the sub-scales of the PASS-20 are as follows: 12.3 (SD 6.7) for 
cognitive anxiety; 12.8 (SD 6.1) for escape/avoidance; 7.4 (SD 6.4) for fearfulness; 6.2 (SD 
5.7) for physiological arousal; and a total of 38.6 (SD 20.4) for a cohort of n=282 (333). With 
the exception of fearfulness, where our cohort scored significantly lower, these do not differ 
significantly from our cohort on two-tailed independent t-tests. These results are as follows: 
cognitive anxiety mean difference 0.2 (p = 0.85); escape/avoidance mean difference 2 (p = 
0.07); fearfulness mean difference 2.4 (p = 0.02); physiological arousal mean difference 2 (p 
= 0.07); and total mean difference 0.4 (p = 0.91).  
In the ‘In Pain’ group, 1 participant did not fill in the BIPQ (so n=27); 1 participant who did 
left two questions blank. In the ‘Not in Pain’ group, 1 participant had left three questions 
blank. One participant did not complete the SF-McGill (so n=27), 3 did not complete the PCS 
(so n=25), 2 did not complete the PDI (so n=26), and 1 did not complete the PASS-20 (so 
n=27). These scales have been analysed by the number who completed them (for example, 
the SF-McGill was analysed with n=27, not n=28). One person who filled out the PDI left the 
‘sexual’ question blank. After discussion with a Consultant Biostatistician, it was decided 
that the sample size in this study, and the likely effect of the missing data points, was not 
great enough to warrant logistical regression.  
Of the ‘In Pain’ group, the mean VAS scores were out of 10, where 10 indicates the worst 
pain possible. The VAS scores were as follows: highest pain 7.3 (SD 2.9); lowest pain 2.1 (SD 
1.7); and usual pain 3.5 (SD 2.0). Twenty-seven of the 28 participants gave ‘lowest pain’ 








7.2.3 Cold pressor test results (means, in seconds) 
 Not in pain at 
baseline (n=26) (SD) 




Threshold 57.0 (59.4) 50.8 (47.1) 6.2 (-23.0, 33.4) 
Tolerance 119.6 (73.4) 112.43 (88.0) 7.15 (-37.3, 51.6) 
Endurance 87.5 (84.9) 77.9 (100.1) 9.6 (-60.2, 41.0) 
Number who hit the 
test limit (240 sec) 
5 (19.2%) 7 (25%) Total: 12/54 (22.2%) 
Table 4 Cold pressor test results (means, in seconds). Maximums of 240 seconds are included 
Table 4 shows the mean scores and standard deviations in scores from the cold pressor test 
at baseline. The mean differences between the two groups and confidence intervals for 
each difference are displayed as well. 
The NP group scored non-significantly higher on average in all three measures, but a greater 
percentage of the IP group reached the 240 sec limit of the test (25% vs. 19.2%).  
None of these results were statistically significant. The confidence intervals for mean 
difference in threshold (-23.0, 33.4), tolerance (-37.3, 51.6) and endurance (-60.2, 41.0) all 
included zero. All p-values were shown by a two-tailed t-test for independent means to be > 
0.05 (threshold p-value 0.67; tolerance p-value 0.75; endurance p-value 0.71). It would 
seem likely that those already in pain at the time of a pain-inducing test react differently to 
those who were not. It is conceivable that a true difference exists, but that it is smaller than 
this study was powered to detect.  
It is worth noting that the 240 second time limit of the test is a ceiling which artificially 
lowered the tolerance and endurance scores for 7 participants (25%) in the IP group, and 5 
participants (19.2%) in the NP group. It is impossible to know how much this will have 
lowered the ‘true’ tolerance and endurance for each group. Given the comparable rates in 
each group, it seems likely that this could have caused similar underestimations in both 
groups. A linear regression was undertaken to in an attempt to more accurately compare 
the pain endurance scores between the groups. Unfortunately, those who reached the 240 
second time limit did not have threshold scores different to those who did not, so the 
imputed data was nonsensical. The imputed tolerance data points were all lower than 240 
seconds, while clearly these individuals’ tolerances were all at least 240 seconds. As such, 




time limit. These individuals were not excluded from the analysis, as this would have further 
underestimated the scores.  
Those with a threshold and/or tolerance of 240 seconds were given an endurance of 240 
seconds. This is because many had artificially-small endurances, for example, if a participant 
had a pain threshold of 230 seconds and then their pain tolerance reaches the 240 second 
limit, their observed pain endurance is 10 seconds.  
Two participants in the NP group demonstrated pain thresholds greater than 240 seconds, 
compared to no (0) participants in the IP group. As there was no way of estimating the ‘true’ 
pain thresholds of these participants, their pain thresholds have been left unadjusted, and 
analysed as 240 sec. There were also 4 other participants in the IP group and 2 participants 
in the NP group with identical pain thresholds and tolerances (i.e. they removed their hand 
at the same moment as their first indication of pain). It seems unlikely that many of these 
people are completely incapable of enduring pain, although given the full participant-
control of the cold pressor test it is possible they simply did not want to endure any pain, or 
more likely that they simply misunderstood the test. 
 



























  Figure 5 Pain threshold vs. pain tolerance – 'Not in pain' 
Figures 4 and 5 show the relationship between pain tolerance and pain threshold. It used 
the relationship between the pain thresholds and pain tolerances of those who did not 
reach the 240 second limit to predict the pain tolerances of those who did reach the 240 
second limit, based on their pain threshold.  
7.3 Surgical records 
Patient surgical records were obtained, with informed consent, for all patients. However, 
many of the records were found to be incomplete, with factors such as anaesthetic and 
Post-Anaesthetic Care Unit (PACU) data unable to be located for 7 of the participants.  
From these records, several factors were extracted. The main factors examined were as 
follows: the surgical method; the duration of surgery; the complications during or following 
the surgery; and the pre-operative, intra-operative, and postoperative pharmacological 
management (including the anaesthetic technique). Also noted was the location of the 
surgery (either Southern Cross Hospital or Christchurch Women’s Hospital), as well as the 





























7.3.1 Surgical data 
 Not in pain at 
baseline (n=26) 
(%) 
In pain at baseline 
(n=28) (%) 
Total (n=54) (%) 
(95% CI) 
Surgical route    
Laparoscopy  12 (46.2%) 24 (85.7%) 36 (66.7%) (53.4%, 
77.8%) 
Laparotomy/abdominal 5 (19.2%) 2 (7.1%) 7 (13.0%) (6.4%, 
24.4%) 




   

















10 (38.5%) 0  10 (18.5%) (10.4%, 
30.8%) 
Other 2 (7.7%) 6 (21.4%) 8 (14.8%) (7.7%, 
26.6%) 
Surgical duration  
(minutes) 
94.8 (SD 43.9) 
(n=20) 
78.6 (SD 27.3) 
(n=22) 
86.3 (SD 36.6) (95% 
CI 74.9, 97.7) 
Hospital (n=21) (n=25)  
Christchurch Women’s 15 (71.4%) 18 (72.0%) 33 (71.7%) (57.5%, 
82.7%) 
Southern Cross 6 (28.6%) 7 (28.0%) 13 (28.3%) (17.3%, 
42.6%) 
Table 5 Surgical factors identified from participants’ patient records. 
For the ‘In Pain’ group, 3 participants undergoing hysterectomy and/or oophorectomy 
(theoretically curative for endometriosis) underwent excision of endometriosis at the same 
time. They were categorised by their ‘primary’ indication or underlying/causative pathology. 
One participant undergoing hysterectomy underwent pelvic floor repair as well. Where a 
certain factor has not been identified for one or more participants, the number identified is 




Those in pain at baseline were significantly more likely to undergo laparoscopic surgery, 
with the limits of each 95% confidence interval non-overlapping (in pain 68.5%, 94.3% 
versus not in pain 28.8%, 64.5%, p = 0.002). Neither group was significantly more or less 
likely to undergo laparotomy [95% confidence intervals of 2.0%, 22.6% (IP) versus 8.5%, 
37.9% (NP), and p = 0.187]. For vaginal surgery, a Chi-squared test showed a p value of 
0.012, indicating statistical significance. However, when 95% confidence intervals are 
calculated for each group using the Score (Wilson) method, the ‘Not in Pain’ group’s lower 
limit (19.4%) crossed the upper limit of the ‘In Pain’ group (22.6%), suggestive of a lack of 
statistical significance.  
There were little differences between the two baseline groups in terms of the surgical 
groups to which they belonged. The 95% confidence intervals for the two groups overlapped 
for hysterectomy [3.7%, 27.2% (IP) versus 13.7%, 46.1% (NP), p=0.13], hysterectomy with 
salpingo- and/or oophorectomy [12.7%, 43.4% (IP) versus 11.0%, 42.1% (NP), p=0.87], and 
salpingectomy and/or oophorectomy [2.0%, 22.6% (IP) versus 6.2%, 33.5% (NP), p=0.34]. 
The IP group was more slightly more likely to undergo excision of endometriosis; although 
the 95% confidence intervals for the groups overlapped, a significant p-value was found on a 
Chi-squared test [17.9%, 50.7% (IP) versus 2.1%, 24.1% (NP), p=0.03]. No IP participants 
underwent pelvic floor/vaginal vault repair, while 10 (38.5%) of the NP participants did. This 
result is statistically significant, with no overlap of 95% confidence intervals [0%, 12.1% (IP), 
22.4%, 57.5% (NP)] and p < 0.001. Six participants (21.4%) in the IP group underwent ‘other’ 
types of surgery; four of these participants underwent ovarian cystectomy, 1 underwent a 
diagnostic laparoscopy, and 1 underwent an adhesiolysis. Two participants (7.7%) in the NP 
group underwent ‘other’ surgical type surgery, 1 a tubal ligation, and the other a diagnostic 
laparoscopy. 
In terms of surgical duration, the mean difference between the two groups was 19.8 
minutes [95% CI -2.8, 42.4 (p= 0.083) two-tailed independent t-test] that was not 
statistically significant. 
The past medical histories recorded in the patients’ files were compared to those given at 
the baseline assessment. This comparison revealed that 14 participants (compared to 13 




(compared with 37 self-reported) had a record of previous surgery. Recall bias is likely to 
have played a large role in this, especially for surgeries undertaken a long time ago. Only 14 
participants (compared with 27 self-reported) were found to have documented chronic 
pain. This indicates that much of the chronic pain these people experience is either not 
detected by the medical system, or is dealt with at a primary health care level. 
7.3.2 Analgesic use 
 Not in pain at 
baseline (n=26) 





(n=23) (n=24)  
Opioids (any) 21 (91.3%) 23 (95.8%) 0.53 
Opioid equivalents 
given (1 mg oral 
morphine) 
 67.2mg  71.8mg See text 
Clonidine 5 (21.7%)  7 (29.2%)  0.56 
Paracetamol 13 (56.5%)  8 (33.3%)  0.11 
Parecoxib 18 (78.3%)  15 (62.5%)  0.24 
Lignocaine 2 (8.7%)   2 (8.3%)   0.97 
Post-op analgesics: (n=23) (n=24)  
Opioid equivalents 22 (95.7%) (48.1mg) 
(n=22)* 
23 (95.8%) (64.1mg) 
(n=22)* 
0.98 
Clonidine  3 (13%)  2 (8.3%)  0.60 
Paracetamol 21 (91.3%)  22 (91.7%)  0.97 
Ibuprofen 7 (30.4%)  11 (45.8%)  0.28 
Diclofenac 5 (21.7%)  4 (16.7%)  0.66 









   
Codeine  13 (50%) 13 (46.4%) 0.80 
Tramadol 9 (34.6%) 11 (39.3%) 0.72 
Paracetamol 23 (88.5%) 25 (89.3%) 0.92 
Ibuprofen 11 (42.3%)  15 (53.6%) 0.41 
Diclofenac 8 (30.8%) 9 (32.1%) 0.91 
Table 6 Intra- and post-operative, and discharge analgesic use between baseline groups. *Several missing individual pieces 




Table 6 shows the use of intra-operative and postoperative analgesics as a comparison 
between the baseline groups (IP, NP). Opioid use has been standardised to units of ‘1 mg of 
oral morphine’ using a Faculty of Pain Medicine of the Australian and New Zealand College 
of Anaesthetists opioid equivalency chart that is yet to be released to its Fellows. Where a 
certain factor has not been identifiable for one or more participants, the number identified 
is shown as (n=X).  
Inpatient (intra-operative and postoperative) medication charts could be found for 23 
participants (88.5%) in the NP group, and 24 participants (85.7%) in the IP group. Discharge 
medication information could be found for all participants, as recorded from both their files 
and participants themselves (during the 6 week phone call). However, medication dosage 
and duration could not be reliably discovered for the majority of participants, and as such 
has been omitted from analysis.  
As can be seen in Table 6, none of the medications were significantly more likely to be given 
to either group intra-operatively, postoperatively, or on discharge (all p-values > 0.05). It 
would appear that pre-operative pain does not greatly alter the pharmacological pain 
management intra-operatively, postoperatively, or upon discharge from hospital. Pain 
scores could not be reliably recovered from the records, so it is impossible to know whether 
this represented truly equal pain between the groups, or inadequate analgesia in the IP 
group (or, conversely, excessive analgesia in the NP group).  
The mean doses of opioids charted have been shown. For many participants it was difficult 
to ascertain from the notes the doses given, and whether a drug was actually given or 
simply charted. The doses given have all been standardised to the equivalent of 1 milligram 
of morphine. This has been calculated from a range of different medications, and often the 
route of administration (e.g. intravenous, oral) is not stated in the notes. As such, much of 
the calculations behind the standardised opioid dosages given here have been deduced, and 
should be interpreted with caution. As there were only 5 participants per group who were 
identified as having a patient-controlled analgesia pump, and the fact that the dosage data 
for one of the participants in the IP group could not be found, emphasises cautious 





7.4 6-week assessments  
7.4.1 Prevalence of subacute pain 
During the 6 week follow-up assessments, 3 patients could not be reached by telephone. 
After multiple attempts at making contact, they were considered lost to follow-up. All of 
these participants had been in pain at baseline. Of the remaining 51 participants, 8 
participants (15.7%) (95% CI 8.2%, 28.0%) were deemed to be experiencing continued 
disruptive or distressing pain. A further 10 participants (19.6%) (95% CI 11.0, 32.5%) 
continued to experience pain, but only intermittently and of a low-grade (never exceeding 
3/10 on the verbal analogue scale). Of the 8 participants categorised as ‘In Pain’ at the 6 
week follow-up point, 6 of these participants (75%) had been classed as ‘In Pain’ at the 
baseline assessment.  
7.4.2 Psychometric questionnaires and pain scores 
Results of DASS-21 and PTSS questionnaires, means (standard deviations) 
 Not in pain at 6 
weeks (n=43) 
In pain at 6 
weeks (n=8) 
Difference 




    
Depression 1.9 (3.2) 2.8 (2.8) 0.9 (-1.5, 3.3, 
p= 0.43) 
0-21 
Anxiety 2.1 (2.5) 3.1 (3.6) 1.0 (-2.1, 4.1, 
p= 0.47) 
0-21 
Stress  3.6 (4.2) 6.0 (4.4) 2.4 (-1.3, 6.1, 
p= 0.18) 
0-21 





    
Depression 2.6 (3.5) 3.4 (3.5) 0.8 (-2.2, 3.8, 
p= 0.57) 
0-21 
Anxiety 2.6 (3.4) 4.4 (3.0) 1.8 (-0.8, 4.4, 
p= 0.16) 
0-21 
Stress 5.5 (5.0) 6.1 (4.2) 0.6 (-3.1, 4.3, 
p= 0.73) 
0-21 
Total 10.7 (10.6) 14.9 (9.2) 4.2 (-3.8, 12.2, 
p= 0.27) 
0-63 
PTSS (6 weeks) 44.9 (5.7) 42.3 (6.8) 2.6 (-3.2, 8.4,  
p = 0.34) 
0-50 




DASS-21    
When the DASS-21 was re-administered at 6 weeks, those ‘In pain’ at the 6 week 
assessment (IP6) scored higher in every sub-scale of the DASS-21 than those ‘Not in pain’ at 
the 6 week assessment (NP6). However, none of these differences were significant. When 
the baseline DASS-21 scores of the IP6 group were compared to those of the NP6 group, the 
same non-significant trends were found.  
The cohort’s overall DASS-21 scores did not change significantly between baseline and 6 
weeks on a two-tailed dependent t-test, from which the three participants lost to follow-up 
were excluded, the mean difference was 2.41 (95% CI -2.3, 6.3 t = 1.217, p = 0.229). 
PTSS  
Given that the version of the PTSS used in this study is a modified one (used by the Burwood 
Pain Management Centre), no normative data are available. The PTSS used is a 7-item 
questionnaire, 5 items being 0-10 scale questions (with a possible maximum of 50), with the 
other 2 items being ‘yes or no’ questions. Those not in pain at 6 weeks scored their surgical 
experience higher, but not significantly. Overall, 48 (94.1%) participants answered ‘yes’ to 
the question - ‘Was the treatment you received in line with what you expected at the 
beginning of treatment’ ( there was 1 ‘no’ from those in pain,  and 2 from those not in pain). 
Forty –six participants (90.2%) answered ‘yes’ to the question - ‘Would you recommend this 
treatment to someone you know who has a similar problem?’ (2 answered ‘no’ from those 
in pain, and 3 answered ‘no’ from those not in pain). Our participants scored a mean of 43.8 
(SD 8.5) for the PTSS. This would seem to be a high level of satisfaction with the pain 










Comparison of the ‘In pain (baseline)’ and ‘In pain (6 weeks)’ groups – psychometric 
questionnaires 
 In pain (baseline) 
(n=28) 
In pain (6 weeks) 
(n=8) 
Possible range 
TSK - 13.8 (9.8) 0-52 
PSEQ - 36.4 (15.8) 0-60 
SF-McGill (n=27)   
Sensory 5.5 (5.3) 13.3 (2.3) 0-44 
Affective 1.6 (2.4) 2.3 (1.9) 0-16 
PPI 1.8 (1.2) 1.4 (1.1) 0-6 
Total 8.9 (8.0) 16.9 (3.9) 0-66 
VAS/VRS 2.1 (2.0) 2.1 (1.9) 0-10 
PCS (n=25)   
Rumination 7.2 (4.4) 5.6 (3.5) 0-16 
Magnification 3.5 (2.6) 1.6 (1.6) 0-12 
Helplessness 8.5 (4.4) 4.8 (3.2) 0-24 
Total 19.2 (10.1) 12.0 (6.8) 0-52 
PDI 26.7 (14.5) (n=26) 14.1 (9.1) 0-70 
PASS-20 (n=27)   
Cognitive 13.0 (5.2) 10.6 (4.7) 0-25 
Escape 11.0 (5.9) 8.6 (5.8) 0-25 
Fearfulness 5.0 (4.5) 4.9 (2.8) 0-25 
Physiological arousal 8.2 (5.2) 6.8 (3.4) 0-25 
Total 37.2 (17.0) 30.9 (14.0) 0-100 
VAS/VRS Scores    
Pain high 7.3 (2.9) (n=26) 5.4 (1.5) 0-10 
Pain low 2.1 (1.7) (n=27) 2.6 (1.7) 0-10 
Usual pain 3.5 (2.0) (n=26) 3.9 (1.3) 0-10 
Table 8 Comparison of the baseline 'in pain' and 6 week 'in pain' groups - 'In pain' questionnaires 
Table 8, and this section as a whole, shows the characteristics of patients in pain at each 
time point, rather than tracking individual patients over time. Due to the telephonic style of 
the 6 week follow up, the VAS used in the SF-McGill and baseline questioning had to be 
replaced with a Verbal Rating Scale (VRS). The VRS is scored from 0-10, and correlates well 




calculated, as the groups were not independent as required for an independent t-test. Not 
much would be gained from dependent t-tests, as only 6 participants would have met the 
requirements. The Table shows the difference between the scores of the two groups as 
wholes, not simply the change in the scores of those 6 who were in pain at both points. Of 
the ‘In pain’ group at 6 weeks (IP6), 25% were not in pain at baseline; only 21.4% (6 
participants) of the ‘in pain’ group at baseline (IP) developed subacute pain, meaning the 
other 22 IP data points could not be matched to a 6 week equivalent.  
On the SF-McGill, the IP6 group scored higher on the sensory and affective subscales, as well 
as on the total SF-McGill score. The reverse was true of the PPI, although insubstantially 
(mean difference 0.4). VAS/VRS scores did not differ between the groups. The identical VAS 
and VRS scores (2.1, 2.1) and very similar standard deviations (2.0, 1.9) between the groups 
supports the interchangeable use of scores from these two scales. This notion does not 
seem unreasonable given that they are the same scale, with the reporting method being the 
only difference. The published norms for the SF-McGill are 11.9 and 3.0 for the sensory and 
affective scales, respectively (339). On two-tailed independent t-tests, the IP6 group scored 
significantly higher on the sensory sub-scale [mean difference 1.4 (95% CI 0.7, 2.1), p < 
0.001], but significantly lower on the affective scale [mean difference 0.7 (95% CI 0.2, 1.2), 
p= 0.01] than these norms.  
On the PCS the IP group scored higher than the IP6 group on all 3 subscales. Overall, the IP 
group scored higher than the IP6 group on the PCS (mean difference 7.2). The IP6 group 
scored significantly lower on the rumination (norm 8.8, SD 3.6, p=0.04) and magnification 
(norm 3.6, SD 2.1, p= 0.01) sub-scales than the published norms (345) on two-tailed 
independent t-tests. The differences between in scores on the helplessness (norm 7.2, SD 
3.0, p=0.07) and total PCS score (norm 19.5, SD 8.5, p= 0.40) were not significant. 
PDI scores in the IP group were higher than those of the IP6 group. The IP6 group scored 
significantly lower than the published norm (348) [mean difference 20.4 (95% CI 12.7, 28.1), p 
< 0.001] on a two-tailed independent t-test. The norm for the ‘low disability’ group is 34.5.  
The means of every sub-scale, and the total PASS-20 score, were higher in the IP group than 
in the IP6 group; cognitive (mean difference 2.4); escape (mean difference 2.4); fearfulness 




difference 6.3. In two-tailed independent t-tests, the IP6 group scores did not significantly 
differ from the published norms (333) on any sub-scale; fearfulness (norm 7.8, SD 6.4, p= 
0.27), cognitive anxiety (norm 12.3, SD 6.7, p=0.35); and the escape (norm 12.8, SD 6.1, p= 
0.08) sub-scales. The IP6 group scores were higher than the published norms on the 
physiological arousal (norm 6.2, SD 5.7, p= 0.64) sub scale, but not significantly. For the total 
PASS-20 score, the IP6 group scored lower than the published norm, but not significantly 
(norm 38.6, SD 20.4, p=0.20).  
In terms of VAS/VRS scores the IP group scores were greater than those of the IP6 group for 
‘highest pain’ (mean difference 1.9). For ‘lowest pain’ (mean difference 0.5) and ‘usual pain’ 
(mean difference 0.4), the IP6 mean scores were higher.  
7.5 3 month follow up 
7.5.1 Prevalence of chronic pain 
During the 3 month follow-up assessments, 2 participants could not be reached by 
telephone. One had been in pain at baseline, but neither of the two was in pain at 6 week 
follow-up. After multiple attempts at making contact, they were considered lost to follow-
up. All participants had been in pain at baseline. Of the remaining 49 participants, 2 
participants (4.1%) (95% CI 1.1%, 13.7%) were deemed to be experiencing continued 
disruptive or distressing pain on a daily basis. Both had been in pain at baseline, and one 
had been in pain at 6 weeks. Another 2 participants (4.1%) (95% CI 1.1%, 13.7%) described 
continuous intermittent moderate to severe pain (one upon micturition, the other during 
menstruation). Neither of these participants had been in pain at baseline measurement or 
at 6 weeks. The fact that only one of the four had been in pain at 6 weeks questions the pain 
of the other three was a late result of their surgery, or was unrelated. Therefore only the 2 
participants experiencing daily disruptive or distressing pain were asked to complete the 







7.5.2. Psychometric questionnaires and pain scores 
Results of 3-month questionnaires, means (standard deviations) 
 Not in pain 
(n=45) 
In pain (n=4) Total  
(n=49) 
Possible range 
DASS-21*     
Depression 0.5 (1.1) 4.5 (3.1) 0.9 (1.7) 0-21 
Anxiety 0.5 (1.2) 2.8 (2.5) 0.8 (1.6) 0-21 
Stress  1 (1.5) 6.8 (1.3) 1.6 (2.4) 0-21 
Total 2.1 (3.5) 16.5 (5.4) 3.3 (5.2) 0-63 
TSK (n=2) - 12 (scores: 12, 
12) 
- 0-52 
PSEQ (n=2) - 48 (scores: 46, 
50) 
 0-60 
SF-McGill     
Sensory - 10.5 (4.7) - 0-44 
Affective - 2.3 (0.5) - 0-16 
PPI - 2.5 (1) - 0-6 
Total - 15.3 (4.6) - 0-66 
VRS - 2.3 (1.7) - 0-10 
PCS (n=2)     
Rumination - 6 (scores: 5, 7) - 0-16 
Magnification - 4 (scores: 4, 4) - 0-12 
Helplessness - 6 (scores: 4, 8) - 0-24 
Total - 16 (scores: 15, 
17) 
- 0-52 
PDI (n=2) - 14.5 (scores: 6, 
23) 
- 0-70 
PASS-20 (n=2)     
Cognitive - 5 (scores: 5, 5) - 0-25 
Escape - 4 (scores: 4, 4) - 0-25 
Fearfulness - 2.5 (scores: 2, 3) - 0-25 
Physiological 
arousal 
- 5 (scores: 7, 3) - 0-25 
Total - 16.5 (scores: 15, 
18) 
- 0-100 
VRS Scores     
Pain high - 6.3 (2.2) - 0-10 
Pain low - 0.5 (0.6) - 0-10 
Usual pain (n=2) - 4.5 (scores: 4, 5) - 0-10 
Table 9 Results of 3-month questionnaires. *One participant excluded from analysis, as explained in the text 
DASS-21 
For the purposes of reporting the DASS-21 results, all 4 participants experiencing continued 




One person ‘Not in Pain’ was in a relapse of major depressive disorder (MDD) relapse at the 
time of follow-up and scored as follows: D = 12; A = 4; S = 13, with an overall DASS-21 score 
of 29 (10 times the ‘Not in Pain’ mean of 2.9). As such, they have been excluded from 3-
month DASS-21 score analysis as an outlier. Two-tailed t-tests revealed significantly higher 
depression scores in the ‘In Pain at 3 months’ (IP3) group than the ‘Not in Pain at 3 months’ 
(NP3) group [mean difference 4 (95% CI 2.6, 5.4, p < 0.001)]. Likewise for anxiety [mean 
difference 2.3 (95% CI 0.9, 3.7, p = 0.002)]; for stress [mean difference 5.8 (95% CI 4.2, 7.4, p 
< 0.001)]; and the overall DASS-21 score [mean difference 14.4 (95% CI 5.6, 23.2, p = 0.014)].  
As with the comparisons between the IP and IP6 groups in the section above, t-tests could 
not be carried out on much of this data, as the groups were not mutually exclusive.  
For the depression sub-scale, the NP3 group scored lower than both the NP6 group (mean 
difference 1.4) and the NP group (mean difference 1.0). The IP3 group scored higher than 
both the IP6 group (mean difference 1.7) and IP group (mean difference 0.6). The very small 
(n=4) size of the IP3 group means that a large effect size would be needed to be reliably 
detected, and the influence of chance on samples this small cannot be understated. 
For the anxiety sub-scale, the NP3 group again scored lower than both the NP6 group (mean 
difference 1.6) and the NP group (mean difference 1.3). The IP3 group scored lower than 
both the IP6 group (mean difference 0.3) and the IP group (mean difference 1.1). 
For the stress sub-scale, the NP3 group again scored lower than both the NP6 group (mean 
difference 2.6) and the NP group (mean difference 2.6). The IP3 group scored higher than 
the IP6 (mean difference 0.8) but lower than the IP group (mean difference 0.7).   
Overall, the NP3 group scored lower than both the NP6 group (mean difference 5.2) and the 
NP group (mean difference 4.8). The IP3 group scored higher than the IP6 group (mean 
difference 4.6), but lower than the IP group (mean difference 1.2).  
SF-McGill  
While all 4 participants that were deemed to be experiencing distressing or disruptive pain 
at 3 months were asked to complete the SF-McGill. This remains a very small sample size, 




with caution. On the sensory sub-scale, the IP3 group scored lower than the IP6 group 
(mean difference 2.8), but higher than the IP group (mean difference 5.0). On the affective 
sub-scale, the means of the IP3 and the IP6 groups were identical (2.3), both marginally 
higher than the IP group (mean difference 0.7). On the PPI, the IP3 group scored higher than 
both the IP6 group (mean difference 1.1) and the IP group (mean difference 0.7). Overall, 
the IP3 group scored lower than the IP6 group (mean difference 1.6), but higher than the IP 
group (mean difference 6.4). The VAS/VRS scores (and SD’s) were nearly identical [IP 2.1 (SD 
2.0), IP6 2.1 (SD 1.9), IP3 2.3 (SD 1.7)].  
The VAS/VRS scores asked outside of the SF-McGill were as follows: In terms of ‘highest 
pain’, the IP group scored higher than the IP3 group (mean difference 1.0), who, in turn, 
scored higher than the IP6 group (mean difference 0.9). In terms of ‘lowest pain’, the IP6 
group scored higher than the IP group (mean difference 0.5), who, in turn, scored higher 
than the IP3 group (mean difference 1.6). In terms of the ‘usual pain’, only 2 IP3 participants 
answered (as the other 2 had intermittent pain, giving a ‘usual pain’ of 0). Their scores were 
4 and 5, respectively on the VRS, both marginally higher than the IP mean of 3.5 and the IP6 
mean of 3.9. 
Other questionnaires   
Only 2 participants answered the TSK, PSEQ, PCS, PDI, and PASS-20 at the 3 month 
observation. Informal comparisons to the IP and IP6 groups can be cautiously explored. For 
the TSK, both IP3 participants scored 12, similar to the mean of 13.8 scored by the IP6 
group. Both scored higher (46, 50) on the PSEQ than the IP6 group mean of 36.4. Yet the 
95% confidence interval of 23.2, 49.6 for the IP6 group suggest it is possible that both IP3 
group scores fit within a similar range as the IP6 scores. On the PDI, the IP3 scores of 6 and 
23 are difficult to interpret, as so dissimilar. Both are lower than the IP group mean of 26.7; 
they fall either side of the IP6 group mean of 14.1. 
For the PCS, IP3 scores could be compared with both the IP, and IP6 groups. On the 
rumination sub-scale, the IP3 scores (5, 7) were comparable to the IP mean (7.2) and the IP6 
(5.6) mean. On the magnification subscale, the IP3 scores (4, 4) were comparable to the IP 
mean (3.5), but were above the upper limit of the 95% confidence interval for the IP6 group 




of small sample sizes. On the helplessness subscale, the IP3 scores (4, 8) were comparable 
to, or slightly lower than the IP mean (8.5), but once more were slightly higher than the IP6 
mean of 4.8. Overall for the PCS, the IP3 scores (15, 17) were slightly lower than the IP mean 
of 19.2, but slightly higher than the IP6 mean of 12.0.  
Similar to the PCS, the PASS-20 scores could be compared across all three observation 
points. The IP3 pair appeared to score lower on every subscale (and overall). On the 
cognitive subscale, the IP3 scores of 5 and 5 were both lower than the IP mean of 13.0 and 
IP6 mean of 10.6. Similarly, on the escape subscale, the IP3 scores (4, 4) were lower than the 
IP mean of 11.0 and the IP6 mean of 8.6. On the fearfulness subscale, the IP3 scores of 2 
and 3 were both lower than the IP mean of 5.0 and the IP6 mean of 4.9. On the 
physiological arousal sub-scale, the IP3 scores (7, 3) were again lower than the IP mean of 
8.2, although the score of 7 was similar to the mean of 6.8 for the IP6 group. Overall, the IP3 
scores of 15 and 18 were both roughly half of the IP mean of 37.2, and of the IP6 mean of 
30.9.  
7.6 Predictive value of secondary measures on prolonged post-surgical pain 
Given the small number of participants experiencing pain at 6 weeks (n=8) and at 3 months 
(n=4), it was decided to include all of these n=11 (one was in pain at both points) into a 
‘prolonged pain’ group. Seven (63.6%) (95% CI 35.4%, 84.8%) of these participants had been 
in pain at baseline, compared to 28 (51.9%) of the cohort at baseline.  
7.6.1 Predictive value of baseline demographic data 
In terms of ethnicity, 9 of the ‘prolonged pain’ group identified themselves as New Zealand 
European, and 2 identified themselves as ‘Other’ (Latino American, and British). None of 
those who experienced ‘prolonged pain’ self-identified as NZ Māori at baseline, although 5 
(8.9%) of the baseline ethnicities stated they were NZ Māori, and 11 (20.4%) of the 54 total 
participants were deemed to be in ‘prolonged pain’ (20.4% of 5 being roughly one 
participant). 
The mean age of those who experienced ‘prolonged pain’ was 43.8 (SD 11.5). When their 
ages are removed from the rest of the cohort (so that n=43), the cohort mean age is 41.7 




(63.6%) of those experiencing ‘prolonged pain’ had a self-reported history of chronic pain, 
compared with 20 (43.5%) of the rest of the cohort that was not a significant difference (p = 
0.313). Three (27.3%) of those experiencing ‘prolonged pain’ had a self-reported history of 
mental illness as compared to 10 (21.7%) of the rest of the cohort that again was a non-
significant difference (p = 0.779). Of the prolonged pain group, 9 (81.8%) reported previous 
surgery, not significantly different from the 28 (65.1%) of the rest of the cohort (p = 0.289). 
Those experiencing ‘prolonged pain’ were not significantly: more or less likely to consume 
alcohol weekly (9 versus 26, p = 0.187); to have ever smoked (6 versus 16, p = 0.298); 
presently employed (8 versus 36, p = 0.401); have completed post-secondary education (5 
versus 29, p = 0.177).  
7.6.2 Predictive value of baseline psychometric questionnaires 
The means for the baseline cohort (n=43) in the DASS-21 were as follows: depression 2.6 (SD 
3.5); anxiety 2.5 (SD 3.4); stress 5.5 (SD 5.0); and total 10.3 (SD 10.8). Despite the ‘prolonged 
pain’ group scoring higher on all three subscales (and overall) at baseline, there was no 
significant difference as measured by two-tailed independent t-tests on the depression 
subscale 3.7 (SD 3.3) [mean difference 1.1 (95% CI -1.3, 3.5 p = 0.344)], the anxiety subscale 
4.2 (SD 3.0) [mean difference 1.7 (95% CI -0.5, 3.9 p = 0.121)], the stress subscale 6.2 (SD 
3.8) [mean difference 0.7 (95% CI -2.2, 3.6 p = 0.617)], or the total DASS-21 score 14.0 (9.1) 
[mean difference 3.7 (95% CI -3.0, 10.4 p = 0.263)].  
Ten of the 11 participants in ‘prolonged pain’ answered the BIPQ. Their mean score was 
43.3 (SD 9.8), compared with the mean score of the rest of the baseline cohort (n=43) of 
35.9 (SD 9.3). This result was significant at 95% confidence [mean difference 7.4 (95% CI 
0.01, 14.8, p = 0.049)], indicating a more threatening view of illness at baseline in those who 
would later go on to develop ‘prolonged pain’. All but one of the 4 participants that 
experienced ‘prolonged pain’ who had not been in pain at baseline had scores higher than 
the mean of 32.4 (SD 9.6) for the rest of the ‘Not in Pain at baseline’ group (n=22) (21, 37, 
43, 54). Similarly, all but 1 of the 6 participants (one participant did not answer the 
questionnaire) in ‘prolonged pain’ who had experienced pain at baseline had scores higher 
than the mean of 39.7 (SD 7.6) for the rest of the ‘In Pain at baseline’ group (n=21) (38, 42, 




Only 6 of the 7 participants in prolonged pain in pain at baseline completed the SF-McGill at 
baseline, with means of 3.7 (SD 2.1) and 0.8 (SD 1.3) for the sensory and affective subscales, 
respectively. By comparison, the means for the rest of the IP cohort were 6.0 (SD 5.8) and 
1.9 (SD 2.5), respectively. The difference in sensory scores was not significant [mean 
difference 2.3 (95% CI -0.8, 5.3, p = 0.136)], neither was the difference in affective scores 
significant [mean difference 1.1 (95% CI -0.4, 2.6 p = 0.149)].  
Baseline comparisons for other questionnaires: means (standard deviations) 







(95% CI, p) 
Possible range 
PCS  (n=20) (n=5)   
Rumination 7.0 (4.8) 8.4 (2.3) 1.4 (-1.8, 4.6  
p = 0.362) 
0-16 
Magnification 3.5 (2.9) 3.6 (1.4) 0.1 (-1.8, 2.0  
p = 0.913) 
0-12 
Helplessness 8.6 (4.9) 8.2 (1.3) 0.4 (-2.2, 3.0  
p = 0.750) 
0-24 
Total 19.1 (11.2) 20.2 (3.6) 1.1 (-5.1, 7.3  
p = 0.716) 
0-52 
PDI  28.2 (15.6) 20.2 (5.9) (n=5) 8 (-1.0, 17.0  
p = 0.080) 
0-70 
PASS-20   (n=6)   
Cognitive 13.8 (4.8) 10.0 (5.6) 3.8 (-2.1, 9.7 
p = 0.175) 
0-25 
Escape 12.1 (6.0) 7.3 (4.0) 4.8 (-9.4, -0.2  
p = 0.041) 
0-25 
Fearfulness 5.7 (4.8)   3.2 (1.4) 2.5 (-5.0,-0.04 
p = 0.046) 
   0-25 
Physiological 
arousal 
9.0 (5.1) 5.3 (4.5) 3.7 (-1.2, 8.6  
p = 0.119) 
0-25 
Total 40.5 (16.5) 25.8 (13.6) 14.7 (-0.04, 9.4 
p = 0.051) 
0-100 
Table 10 Comparisons of baseline scores between the prolonged pain group and the remainder of the IP group 
Table 10 shows comparisons between the baseline questionnaire scores of those in 
prolonged pain who experienced pain at baseline and those for the remainder of the IP 
group. Mean differences, and the 95% confidence intervals and p-values around these were 
calculated using two-tailed independent t-tests. Where any participant had not completed a 




None of the differences between the two groups were significant at 95% confidence on the 
PCS or the PDI. However, on the PASS-20 all scores were lower for the ‘prolonged pain’ 
group, reaching significance on the escape (p = 0.041) and fearfulness (p = 0.046) subscales. 
The difference in total PASS-20 scores nearly reached significance (p = 0.051, upper arm of 
the 95% confidence interval around the mean difference 0.04).  
In terms of VAS pain scores at baseline, there were no significant differences between those 
who went on to develop ‘prolonged pain’, and those who did not. Where any participant(s) 
from either group did not give a certain score, this is reflected by the (n=X). Lowest pain 
scores for those who developed ‘prolonged pain’ (n=7) were 2.0 (SD 1.0) versus 2.1 (SD 1.9) 
for those who did not (n=19) [mean difference -0.1 (95% CI -1.3, 1.1 p = 0.864)]. Highest 
pain scores for those who developed ‘prolonged pain’ (n=7) were 7.6 (SD 1.0) versus 6.8 (SD 
2.6) for those who did not develop ‘prolonged pain’ (n=20) [mean difference 0.8 (95% CI -
0.6, 2.2 p = 0.260)].  The usual pain scores for those who developed ‘prolonged pain’ (n=6) 
were 4 (SD 1.1) versus 3.3 (SD 2.2) for those who did not develop ‘prolonged pain’ (n=19) 
[(mean difference 0.7 (95% CI -0.7, 2.1 p = 0.314)]. Two-tailed independent t-tests were 
used for these analyses. 
7.6.3 Predictive value of the cold pressor test 
The cold pressor test results between the prolonged pain group and the rest of the cohort 
were as follows: Tolerance: the rest of the cohort’s (n=43) mean of 123.6 (SD 78.4) was 
higher than the ‘prolonged pain’ group’s (n=11) mean of 86.5 (SD 85.0), but not significantly 
so [mean difference 37.1 sec (95% CI -23.3, 97.4) (p = 0.209)]. Threshold: the rest of the 
cohort’s mean 61.4 (SD 56.3) was higher than the ‘prolonged pain’ group’s mean of 24 (SD 
17.7), this time significantly so [mean difference 37.4 sec (95% CI 17.1, 57.7) (p < 0.001)]. 
Endurance: the rest of the cohort’s mean of 85.4 (SD 93.6) was higher, but not significantly, 
than the ‘prolonged pain’ group’s mean of 70.9 (SD 90.4) [mean difference 14.5 sec (95% CI 
-50.7, 79.8 (p = 0.64)]. 
7.6.4 Predictive value of peri-operative data 
Much of the surgical information could not be located for various individuals. Totals for each 




Three (27.3%) of the 11 participants experiencing ‘prolonged pain’ had a self-reported 
history of mental illness, as compared to 10 (22.7%) of the rest of the cohort (n=44). This 
result is not significant (p = 0.750). Seven (63.6%) of those in ‘prolonged pain’ reported 
previous experience(s) of chronic pain, as compared to 20 (45.5%) of those for the rest of 
the cohort who did not that is not significant (p = 0.280). Ten (90.9%) of those in ‘prolonged 
pain ‘reported previous surgery, as compared to 27 (61.4%) of those for the rest of the 
cohort. This result was did not reach significance, but was the closest of the three in its 
reach (p = 0.061). 
Those who experienced ‘prolonged pain’ were so spread out across the surgical groups that 
formal statistical analysis essentially became impossible. Information on surgical group 
could only be found for 10 of the 11 participants. The surgical groups were as follows: 
hysterectomy (1); hysterectomy and salpingectomy and/or oophorectomy (3); 
salpingectomy and/or oophorectomy (1); excision of endometriosis (4); pelvic floor repair 
(1); and other surgery (1). Four participants in the ‘prolonged pain’ group, and 7 participants 
in the rest of the cohort underwent excision of endometriosis, a difference that was almost 
significant (p = 0.087). This difference is likely confounded by the fact that the 3 who 
underwent hysterectomy and excision of endometriosis simultaneously were classed as 
hysterectomies, and that none of these 3 experienced ‘prolonged pain’. If, for the sake of 
argument, they are included as ‘excision of endometriosis’, the difference is 4/10 versus 
10/44, p = 0.258. 
It was found that 63.6% of those who experienced ‘prolonged pain’ (n=11) underwent 
laparoscopic surgery, as did 29 (65.9%) of those who did not (p = 0.803). Three (27.3%) in 
the ‘prolonged pain’ group and 4 (9.1%) in the remainder of the cohort underwent 
laparotomy (p = 0.075). Two (18.2%) in the ‘prolonged pain’ group, and 9 (20.5%) in the rest 
of the cohort underwent per-vaginal surgery (p = 0.976). 
The mean duration of surgery in the ‘prolonged pain’ group (n=10) was 88.5 minutes (SD 
48.3), and 86.6 minutes (SD 33.1) in the rest of the cohort (n=32) that was not significant 
difference [mean difference 1.9 (95% CI -33.7, 37.5, p = 0.909)]. Eight (80%) of those in 
‘prolonged pain’ for whom location of surgery could be discovered, had their surgery 




cohort (n=37) (p = 0.373). The remaining 2 (20%) of those in ‘prolonged pain’ and 11 (29.7%) 
in the rest of the cohort had their surgeries performed at SCH. 
Analgesic use between the prolonged pain group and the rest of the cohort 
 Rest of cohort 
(n=43) 
Prolonged pain (n=11) p-value  
Intra-operative 
analgesics: 
(n=37) (n=10)  
Opioid equivalents 
(1 mg oral 
morphine) 
36 (97.3%) (70.5 mg) 8 (80%) (93.9 mg) 0.047 
Clonidine 8 (21.6%) 4 (36.4%)  0.238 
Paracetamol 17 (45.9%)  4 (36.4%)  0.728 
Parecoxib 26 (70.3%)  7 (63.6) 0.984 
Lignocaine 4 (11.8%)  0  0.276 
Post-op analgesics: (n=37) (n=10)  
Opioid equivalents 36 (97.3%) (43.7 
mg)* 
9 (90%) (106.7 mg)*  0.313 
Clonidine 4 (11.8%) 1 (9%)  0.944 
Paracetamol 34 (91.9%) 9 (%) 0.849 
Ibuprofen 12 (32.4%) 6 (60%)  0.112 
Diclofenac 9 (24.3%) 0 0.084 




8 (21.6%) (mean** 
177.4mg)  





   
Codeine  23 (53.5%) 3 (27.3%) 0.121 
Tramadol 11 (25.6%) 6 (54.5%) 0.064 
Paracetamol 38 (88.4%) 10 (90.9%) 0.810 
Ibuprofen 18 (41.9%) 8 (72.7%) 0.067 
Diclofenac 16 (37.2%) 1 (9.1%) 0.073 
Table 11 Analgesic use between the prolonged pain group, and the rest of the cohort. *Several missing data points where 
opioids were given, but doses not noted. **1 patient’s PCA records did not contain volumes, so n=7 for this mean 
Intra-operatively, the only statistically significant difference in analgesics between the 
groups was the number of participants in each group given opioids. It was found that 36 
(97.3%) of the 37 ‘rest of the cohort’ participants for whom intra-operative data could be 
found, received opioids intra-operatively. By comparison, 8 (80%) of the 10 ‘prolonged pain’ 




who would go on to develop’ prolonged pain’ received a mean difference of 23.4 mg more 
oral morphine equivalents in theatre. Due to the difficulties converting the various opioids 
into oral morphine equivalents, and the difficult data (some missing, some illegibly hand-
written) it would be rash to attempt to draw significant conclusions from the differences in 
oral morphine equivalents between these groups. Interestingly, those given opioids in the 
‘prolonged pain’ group (n=8) were significantly more likely (p = 0.014) to receive tramadol 
than those given opioids in the rest of the cohort group (n=36). This significance remained 
even when those who had not received opioids in theatre were factored in (p = 0.046, two-
tailed t-test). 
Postoperatively, there were no significant differences in the analgesics received by either 
group. As stated above, it is difficult to analyse the opioid doses between the groups. If 
anything, this data was even more poorly recorded. It was often difficult to tell which 
medications had simply been charted, and which had actually been given. However, the 
means of 106.7 mg (‘prolonged pain’ group) versus 43.7 mg (‘rest of the cohort’ group) 
appear strikingly different. Another interesting point postoperatively was the use of 
diclofenac. Although it did not reach levels of significance (p = 0.084), none of the people 
who went on to develop ‘prolonged pain’ received diclofenac postoperatively, as compared 
to 9 (24.3%) of those who did.  
On discharge, none of the medications prescribed to one group significantly differed from 
the other group. With that said, the two weak opioids (codeine and tramadol) were 
prescribed almost inversely to each group. Codeine was prescribed on discharge to 53.5% of 
the ‘rest of cohort’ versus 27.3% to the ‘prolonged pain’ participants (p = 0.121). Tramadol 
was prescribed to 25.6% of the ‘rest of cohort’ group versus 54.5% of ‘prolonged pain’ 
participants (p = 0.064). The same trend held for the two of the most popular NSAIDs, 
ibuprofen and diclofenac. Ibuprofen was prescribed to 41.9% of the ‘rest of cohort’ 
participants versus 72.7% of the ‘prolonged pain’ participants (p = 0.067). Diclofenac was 
prescribed to 37.2% of the ‘rest of cohort’ participants versus 9.1% of ‘prolonged pain’ 





Chapter Eight – Discussion and conclusion 
 
The study which had been planned over four months, and gained approval from all 
necessary parties such as the national Health and Disabilities Ethics Committee (HDEC), the 
University of Otago, and the relevant departments, was never to recruit a single participant. 
This study had planned to use orthopaedic patients (namely hip and knee arthroplasties). It 
included a randomised controlled trial embedded within the cohort study, whereby half of 
the participants still experiencing significant pain six weeks postoperatively would be given a 
combination of gabapentin and nortriptyline. Unfortunately, several senior individual 
clinicians within the Department of Orthopaedics actively resisted the study due to concerns 
about the medications being trialled, and loss of control over the management of their 
patients enrolled in the study. While both of the proposed medications are widely regarded 
to be safe and efficacious, the concerns of these clinicians were respected, and another 
department had to be chosen. 
The specialty then identified to have the second-highest number of potential participants, 
was Gynaecology. The head of department, and the individual staff, were all more than 
happy to facilitate the study. The protocol was adapted, and the large chain of paperwork 
(ethics, locality authorisations… etc.) started up again. Unfortunately, due to the twelve 
month time constraint, it was not considered plausible to recruit enough participants to 
conduct a statistically meaningful randomised control trial. The resultant study was 
essentially a fleshed-out, extended version of the pilot study outlined in Chapter Six of this 
thesis. It is strongly believed that a randomised controlled trial of these (or similar) 
medications in the prevention of chronic post-operative pain should be conducted in future. 
8.1 Interpretation of results 
The sample sizes, for reasons outlined previously, were not as large as originally planned. 
This limited interpretations of the formal statistical analyses, and can result in many type II 
errors (failure to correctly reject the null hypothesis). The calculations have been performed 




small cohort (n=54), and resultant smaller individual groups, rendered it difficult to detect 
small to medium effect sizes, and are subject to bias and sampling error. 
8.1.1 Prevalence of subacute and chronic pain 
Of the 8 participants who were identified as experiencing clinically significant pain at 6 
weeks following their surgery, 6 participants had been classified as ‘in pain’ at the baseline 
assessment. Their SF-McGill scores on the sensory scale, but not the affective scale, were 
significantly different (p < 0.001 and p = 0.41, respectively) to their baseline scores. These 
differences in the sensory scale suggest that the pain experienced by these participants was 
unlikely to have been simply a symptom of their underlying condition, as it was significantly 
different in nature. As such, it seems reasonable to assume this pain was largely a result of 
the surgery. However, the student researcher who conducted all interviews at all three 
points was not sufficiently experienced in gynaecology to make detailed judgements. The 
limited information gathered by the questionnaires and the nature of the follow up 
assessments (by telephone) could still limit such judgement. 
Of the 4 participants who were identified as experiencing clinically significant pain at three 
months following their surgery, only one of these had been identified as in ‘subacute’ pain 
at the six week follow up point. However, 2 of the remaining 3 participants had reported 
sub-threshold pain at that time that was recorded, and 2 of these 4 participants had been in 
pain at the baseline assessment. On the sensory scale of the SF-McGill, the scores of these 2 
participants had changed sufficiently between baseline (4, 6) and 3 months (10, 17) to 
consider them likely to be an effect of the surgery. As with those in pain at 6 weeks, their 
affective scores did not appear to differ from baseline to 3 months (0, 3 to 2, 2).  
Given the small number in pain at the follow-up points, the decision was made to analyse 
them (n=11) as one ‘prolonged pain’ group. Seven participants (63.6%) in this group had 
been in pain at baseline, 1 (9.1%) was in pain at both 6 weeks and 3 months. It is worth 
noting that smaller (n < 300), single-centre studies have been shown to find lower CPSP 






8.1.2 Factors influencing the risk of developing subacute and chronic postoperative pain 
Does the presence of pain pre-operatively predict postoperative pain states? 
Over half of the participants, 28 of 54, were deemed to be in clinically significant pain at the 
baseline preoperative assessment. Participants who were in pain at baseline were slightly 
more likely than those who were not to experience pain at either follow-up point, but not 
significantly (6 weeks and/or 3 months) (7 of 11, or 63.6%, p= 0.48). This suggests that those 
experiencing preoperative pain are possibly more likely to develop postoperative pain 
persisting to the subacute and then chronic phases. At an individual level, however, this 
would not seem to be a strong predictive factor. As such, the results of this study cannot 
support the clinical use of this as a predictive factor in the absence of further evidence.  
Does the presence of subacute pain predict the development of chronic pain? 
Eight of participants were identified as experiencing subacute pain when followed-up six 
weeks postoperatively. Four of the participants were identified as experiencing chronic pain 
when followed up six weeks postoperatively. One participant experiencing subacute pain 
developed chronic pain, while 7 did not. By comparison, 3 participants who were not 
experiencing pain at 6 weeks developed chronic pain at 3 months, while 45 remained pain-
free at 3 months. This is not necessarily the expected result, as it would seem logical that 
one would have to pass through the subacute stage to reach a chronic pain state. However, 
as mentioned earlier, 2 of the remaining 3 participants had reported sub-threshold pain at 
that time that was recorded. It is therefore possible that either sub-threshold pain is more 
important than previously thought, or the way sub-threshold pain was differentiated from 
‘above threshold’ pain in this study was not entirely accurate. As previously stated, smaller 
(n < 300), single-centre studies have shown lower CPSP rates (394), so it is possible, indeed 
likely, that sample size has impacted on these results. It still seems logical to aggressively 
treat and follow up, those still experiencing pain 6 weeks postoperatively. Not only will they 
benefit from the pain management in the short-term, but it may prevent them going on to 
develop chronic pain. Further research is needed into subacute pain, and its relationship 





Psychometric questionnaires  
As discussed in the literature review, psychological and social factors such as depression, 
anxiety and gender (12,10) are known to influence (and be influenced by) pain (both acute and 
chronic). In this study, many psychosocial factors were analysed through the use of the 
psychometric questionnaires. These are described in Chapter Four, and can be found in 
Appendix One.  
In the ‘In Pain’ group, baseline depression, anxiety, stress, and total DASS-21 scores were all 
higher than in the ‘Not in Pain’ group. This reinforces the association between pain and 
negative affect, even if no direction of causality can be directly established from this data. 
The effect of this higher level of psychological distress on perioperative clinical outcomes 
warrants further investigation. Of interest was the overall drop in the cohort’s mean DASS-
21 scores. The cohort at 3 months scored lower than it had at 6 weeks (mean difference 4.7) 
and at baseline (mean difference 7.9). This reflects the true shift in the proportion of the 
cohort who were in pain, and the resulting effect on affective scores. Also, the ‘not in pain’ 
group at 3 months scored lower on every sub-scale than either of the previous ‘not in pain’ 
groups. This would indicate the change in the proportion of the cohort who were in pain not 
to be the sole factor resulting in improved affective scores. 
Depressive, anxiety, and stress symptom scores, as measured by the DASS-21, were 
associated with the pain state at all 3 follow-up points. DASS-21 scores in all subsections 
were higher in those who progressed into ‘prolonged pain’ states, but not significantly so. 
Depressive scores were the closest to reaching significance, but still had p=0.34. It is 
possible that the effect these scores can detect remains too small for the sample size (and 
therefore too small to use clinically on individual patients), or that another affective 
questionnaire might have greater predictive value. Taking into account this data and the 
data in the literature, it seems likely that depressive symptoms are associated with the 
postoperative development of lasting pain states. The early detection and management of 
these symptoms could beneficially affect pain outcomes, as well as distress levels. Even in 
the absence of pain, it seems logical that thorough detection and management of 




It would appear from the BIPQ results that those who go on to develop prolonged pain after 
surgery have a more threatening view of their illness before their surgery than those who do 
not. This appears to conflict with the results of the PASS-20. Two of the PASS-20 subscales 
escape, and fearfulness were even scored significantly lower at baseline by those who 
developed ‘prolonged pain’ than those who did not. This would appear to indicate that 
patients who go on to develop prolonged pain states postoperatively identify their illness as 
particularly threatening, but are no more (if anything, they are less) emotionally distressed 
by their illness (and/or pain) than those who do not develop prolonged pain states. This 
seems to be backed up, although not to significant levels, by the sensory and affective scales 
of the SF-McGill; those who went on to develop prolonged pain states scored lower in these 
scales. Those who would develop prolonged pain also scored lower, almost at significant 
levels in the PDI, suggesting it is possible that these people are less disabled by their pain 
pre-operatively. PCS scores were so similar between the groups making it difficult to draw 
any conclusions from the available data.  
Wildly extrapolating from the data from the psychological questionnaires could paint the 
clinical picture of the ‘archetypal’ person at higher risk of developing prolonged post-
surgical pain. This person may be reasonably functional (PDI scores) with a slightly lowered 
affect (DASS-21 scores), who identifies their illness as particularly threatening to their health 
(BIPQ scores), but without appearing unduly concerned by it (PASS-20, PCS scores). VAS pain 
scores at baseline did not differ statistically significantly, nor were the raw means widely 
separated (the greatest being a mean difference of 0.8 for ‘highest pain’). This makes it 
unlikely to be a clinically useful tool for predicting prolonged pain states. Of course, the 
sample sizes involved severely limit conclusions drawn from formal statistical analysis. 
Differences that do not truly exist may appear to, and ones that do exist may be missed.  
The only factor that could realistically be interpreted from these data as a potential 
‘screening’-type tool for the risk of developing prolonged pain is the BIPQ. With a mean 
difference of 7.4 (95% CI 0.01, 14.8, p = 0.049) on a 0-50 scale, if this is a ‘true’ difference it 
would imply a mean of 14.9% higher scores in those at risk of developing prolonged pain. 
While this is not a great enough difference to predict accurately each individual who could 
develop prolonged pain, it could provide a ‘piece of the puzzle’ in guiding clinical practice. 




predicting prolonged postoperative pain. More research is needed regarding predictive 
abilities of each of the other questionnaires. In order to claim that none existed on the basis 
of this small sample study could potentially throw the baby out with the bathwater. 
Any correlation of the characteristics measured by these questionnaires with lasting pain 
states implies that these symptoms should be detected and managed early. Simple tools 
such as the questionnaires used in this study could be used to screen preoperative patients, 
to enable early detection and intervention, not only to influence pain outcomes, but 
psychosocial and functional outcomes as well. In patients identified as having ‘at risk’ 
factors preoperatively, follow up several weeks postoperatively could potentially prove 
useful in the secondary prevention of chronic pain, by intervening at the subacute (or acute 
persistent pain) phase. This should be investigated in future studies. This study simply may 
not have had the statistical power to show the associations between the likes of the SF-
McGill or the DASS-21 on pain progression; else unknown biases and/or confounding factors 
might have influenced the outcomes. It is also possible, although unlikely, that there simply 
was no association between these questionnaires and the measured outcomes in this 
population. Perhaps the measures did not fit the methods. In a study of this size, it is likely 
to be a combination of these factors. 
Demographic information 
Overall, none of the demographic factors (age, ethnicity, education, work status, smoking 
status, and alcohol intake) or relevant histories (self-reported chronic pain, mental illness, or 
surgery) differed significantly between those who progressed into prolonged pain states, 
and those who did not. Given the relevant literature (12,11,28,2,6) surrounding this issue, it 
seems likely that this study was simply not sufficiently powered to detect the effects of 
these.  
In terms of ethnicity, there were no significant differences between the groups at baseline, 
and the cohort appeared to be in line with the 2013 New Zealand Census data for 
Canterbury. None of those experiencing prolonged pain self-identified as New Zealand 
Māori. It seems likely this is due to sample size, or under-reporting of pain by the New 




rates of inferior prolonged pain outcomes among New Zealand Māori patients undergoing 
moderate to major gynaecological surgery at CWH (or at SCH under CDHB contract). 
The literature suggests that younger (6) and female (28) patients are at increased risk of 
developing postoperative chronic pain. As this study was conducted on gynaecological 
patients, all of whom self-identified as ‘Female’ (from the options ‘Male’, ‘Female’, and 
‘Other’), it is not possible to draw comparisons between the genders from the results of this 
study alone. In terms of age, the mean age of participants in this study was 42.1 (SD 13.2). 
Age was not a significant factor in predicting who would develop prolonged pain, so these 
results can therefore neither support nor reject the hypothesis that age influences the 
development of chronic pain. However, it is possible that the relationship between age and 
likelihood of developing prolonged pain may not be linear. As this study was also 
undertaken using a group of patients who were largely over 30 years of age, it cannot be 
concluded from these results whether teenagers or younger adults are at increased risk of 
developing prolonged pain compared to other age groups and developmental periods. 
There is evidence that components of the brain do not complete development until the age 
of the mid-20’s (395). As the subjective experience of pain is almost entirely in the brain, it 
seems plausible that different developmental stages may influence pain experience and 
behaviour.   
Participants who experienced ‘prolonged pain’ had increased rates of self-reported chronic 
pain, mental illness, weekly alcohol consumption and former or current smoking. Also, their 
rates of employment and completed secondary education were lower. However, none of 
these results were significant. As one could reasonably expect all of these trends (2,28) it 
appears likely that the small sample size has resulted in type II errors.  
Perhaps unsurprisingly, given the long-term pain caused by conditions such as 
endometriosis, the preoperative cohort had a much higher likelihood of a history of chronic 
pain (50%) than would be expected in the underlying population (16-20%). Furthermore, a 
history of chronic pain may indicate a psychological and/or physiological predisposition 
towards developing prolonged pain states (6). It seems reasonable to cautiously suggest that 
those who have previously experienced chronic pain would be more likely to repeat this 




The preoperative cohort was less likely to report a history of mental illness than would be 
expected in the underlying population. This is most likely to be due to the simple wording of 
the question, when compared to the more detailed questions and broader range of 
questions asked in the likes of Te Rau Hinengaro (380). Given the association between pain 
and certain mental illnesses (396), it seems likely that the non-significant trend of increased 
rate of mental illness observed in those at higher risk of developing prolonged pain, may be 
a true one. 
The participants in this study were all, necessarily, undergoing surgery. A greater proportion 
of this cohort than would be expected from the admittedly limited evidence (68.5% vs. 19-
43.8%) (381) (382) had undergone surgery in the past. Of particular note is that these sources 
stated lifetime risk, while the mean age of women in this study was only 41.5 years. This 
would point to previous gynaecological surgery being a risk for requiring further 
gynaecological surgery, whether through surgical failure or complications, recurrence of 
disease, or through chronic post-surgical pain. This study did not observe all relevant factors 
relating to the risk of requiring gynaecological surgery, so it is possible that there are other 
factors causing the observed association.  
The increased proportion of smokers, and greater pack-year history seen amongst those 
‘not in pain’ at baseline, is likely to be due to the higher mean age of more than a decade. 
This is more likely than smoking being protective against pain, as evidence (397) clearly 
suggests an association between chronic pain and smoking. This supports the observed 
trend of the increased likelihood of smoking in those who would go on to develop prolonged 
pain. This cohort was significantly more likely to consume alcohol at least once weekly than 
the average adult female in New Zealand (64.8% vs. 43.2%). For this too, the evidence (397) 
shows an association between chronic pain and alcohol, supporting the observed trend of 
increased frequency of alcohol consumption in those who would go on to develop 
prolonged pain.  
This cohort was more likely to have completed secondary school (87.1% vs. 76.2%), and to 
have completed post-secondary education (58.7% vs. 41%) than the average New Zealand 
adult. The use of the term ‘Labour force participation rate’ by the Statistics New Zealand 




was employed in full- or part-time work than the average New Zealand adult population 
(81.5% vs. 68.5%). This may be due to the inclusion of younger adults in the Statistics New 
Zealand findings, while the cohort used was largely comprised of middle-aged and older 
adults. These comparisons may reflect some of the inequities of health distribution in New 
Zealand in that the better educated and the employed have greater opportunities to receive 
tertiary health care. Those who are employed and those with higher educational 
qualifications are less likely to experience chronic pain (398), lending weight to the trends 
observed here. 
Predictive value of the cold pressor test  
The cold pressor test was chosen for the study because of its ease of use, and relatively high 
reliability in predicting an individual’s pain tolerance (399). At baseline, ‘those in pain’ scored 
slightly lower (but not significantly so) than ‘those not in pain’ on all measures. However, for 
those who experienced prolonged pain (at 6 weeks and/or 3 months), the lower baseline 
cold pressor test scores appeared to predict the likelihood of experiencing prolonged pain 
across all 3 measures. The pain threshold was the only significant measure, with the mean 
difference for this measure being in excess of 30 seconds (37.4 seconds), a potential 
difference large enough for clinical use. Pain tolerance and pain endurance were not 
significantly predictive, and had mean differences of 35.6 and 14.5 seconds, respectively. 
Analysis of pain tolerance data and pain threshold data (in a few), but in particular pain 
endurance data was severely limited by the 240 second threshold, resulting in 
underestimations of unknown size. For threshold and endurance this simply results in a cut-
off. However, because endurance is derived from these two scores (tolerance minus 
threshold), if an individual’s threshold is high and their tolerance reaches the test time limit, 
their derived pain endurance would appear to be very low. It is of note that those who 
would not go on to develop prolonged pain had higher mean scores in all three areas. If a 
way can be found to neutralise the effect of the time limit, a preoperative cold pressor test 
could be a useful clinical tool in predicting prolonged pain experience following surgery. It 
would need to be combined with other known predictive factors and the patient’s clinical 
picture. It is concluded that the cold pressor test could be a useful clinical tool in the 
prevention of chronic postoperative pain. By preoperatively identifying those most at risk, 




accordingly. This could result in the secondary prevention of the development of chronic 
postoperative pain.  
Perioperative factors  
Intraoperative factors  
Several aspects of the surgery itself were examined. Firstly, participants were grouped by 
surgical groups. These were as follows: excision of endometriosis, hysterectomy, 
hysterectomy and salpingectomy and/or oophorectomy, salpingectomy and/or 
oophorectomy, pelvic floor/vaginal wall repair, and other surgeries which were undergone 
by 8 patients (14.4%). Those in the ‘prolonged pain’ group were grouped too sparsely for 
formal statistical analysis, if anything this indicates that they were evenly spread across the 
groups. Surgical approach was also noted. There were 36 patients (66.7%) that underwent 
laparoscopic surgeries, 7 patients (13.0%) underwent laparotomies, and 11 patients (20.4%) 
that underwent per-vaginal surgeries. Laparotomy appeared to be most strongly correlated 
with adverse pain outcomes, with 27.3% of those in prolonged pain versus 9.1% of those not 
in prolonged pain, having undergone laparotomy. This difference was only just non-
significant on a Chi-squared test (0.075). An argument could be made for the use of a one-
tailed test when the existing literature (400) and clinical understanding points towards a 
higher risk of prolonged pain states following laparotomy. This would make a baseline 
assumption, and give a statistically significant p-value of 0.038. However, given the sample 
sizes involved, even a ‘significant’ result would have to be interpreted with caution, and as 
such the two-tailed test is likely to be more accurate. With a mean difference of 1.9 minutes 
(p = 0.909) between those who later developed prolonged pain and those who did not, 
duration of surgery appeared non-predictive of poorer pain outcomes. That is not to say 
that duration of surgery beyond a certain length of time could not prove to be a useful 
predictor, although the results of this study do not support this. 
All of the surgeries were performed under general anaesthesia. Interestingly, a greater 
proportion of those who would not no go on to develop prolonged pain received intra-
operative opioids (p = 0.047). Whether this is simply due to sample size, or whether use of 
opioids in theatre is protective against prolonged pain cannot be stated from this data. 




greater doses of opioids intra-operatively; they received a mean of 23.4 mg of oral 
morphine equivalents more than the rest of the cohort did. Due to difficulties converting 
doses, and difficulties recovering data, the dosage data is difficult to draw conclusions from. 
However, it is possible that these increased doses are in fact a risk factor for prolonged pain, 
rather than the previous conclusion of ‘receiving opioids at all’ being protective. Further 
research is required into the relative merits and demerits of intra-operative opioids. Of 
note, those who would go on to develop prolonged pain were significantly more likely to 
have received tramadol intra-operatively (p = 0.014). This study was not geared towards 
examining the safety and efficacy of intra-operative tramadol. However in the absence of 
explanations to the contrary, this is a potentially disquieting result. More detailed study into 
the long-term effects of intra-operative tramadol should be undertaken to rule it out as a 
risk factor for prolonged pain states. 
Postoperative factors    
The Post-Anaesthetic Care Unit (PACU) data was briefly examined. In the clinical records, 
duration of PACU stay was not stated frequently enough to enable any conclusions to be 
drawn. Analgesic use was better recorded in PACU. The analgesic use in PACU was 
combined with analgesic use on the wards to give one set of ‘inpatient, postoperative’ 
values.  While there were no statistically significant differences between the groups, it was 
interesting to see that ibuprofen was prescribed more often to those who would go on to 
develop prolonged pain (60% versus 32.4%), while the opposite was true of diclofenac (0 
versus 24.3%). Discharge analgesics were largely limited to weak opioids such as codeine (26 
patients) and tramadol (20 patients), paracetamol (48 patients), and NSAIDs such as 
ibuprofen (26 patients) and diclofenac (17 patients). There were 41 patients that were 
discharged on opioid medications (codeine and/or tramadol). None of the prescribing on 
discharge was significantly predictive of progression to prolonged pain states. However, 
there was a trend of more ibuprofen being prescribed to those who would go on to develop 
prolonged pain (72.7% versus 41.9%), and an opposite trend for diclofenac (9.1% versus 
37.2%). Somewhat in keeping with the more frequent use of intra-operative tramadol in the 
‘prolonged pain’ group, patients were more likely to be prescribed tramadol on discharge, 
although this result was not significant (54.5% vs. 25.6%). It seems plausible that this could 




(27.3% versus 53.5%, p = 0.121), resulting in a similar proportion receiving a weak opioids. 
There appear to be a trend of prescribing in terms of both NSAIDs and weak opioids on 
discharge from hospital associated with the development of prolonged pain states. 
However, these results are not significant. Future work could focus on whether this is a true 
association with larger samples (and other surgical types) or not. Future work could also 
concentrate on discovering whether this potential association can be explained by other 
factors (e.g. a risk factor for prolonged pain could also be an indication for tramadol) or not.  
Location of surgery could be identified for 47 of the participants. Thirteen of the surgeries 
were performed at Southern Cross Hospital, and 34 of the surgeries were performed at 
Christchurch Women’s Hospital. The IP and NP groups were split evenly between the 
hospitals, with 7 (28%) of ‘those in pain’ at baseline, and 6 (28.6%) of ‘those not in pain’ at 
baseline having their surgery performed at Southern Cross Hospital. 
Three participants were noted to have moderate to severe adverse postoperative 
outcomes: one presented to the Emergency Department 13 days postoperatively with a 
suspected postoperative infection; one presented to the Emergency Department several 
days postoperatively with vomiting and intense pain; one suffered an accidental uterine 
perforation intra-operatively and required an extra night in hospital as a result. The first of 
these 3 experienced subacute pain at 6 weeks, but was pain-free by 3 months. The second 
patient had no pain at either follow-up point, and the third patient was lost to follow-up at 
the 6 week assessment. It would seem likely that complications such as these increase the 
risk of developing prolonged pain issues. 
8.2 Limitations of the study 
As has been previously stated, this study faced many challenges from the outset. Time 
limitations and the wishes of individual senior clinicians meant that the planned randomised 
controlled trial of nortriptyline and gabapentin in those in pain at six weeks had to be 
excised from the study protocol. In itself, this meant that several aspects of study planning 
had to be compromised, and follow-on errors may have adversely affected the accuracy of 
the results. For example, the specialty with the second highest (the highest having been 
orthopaedics) number of eligible patients was gynaecology. While the staff in gynaecology 




there tended to be more minor than those planned to be used (hip and knee arthroplasties) 
with resultant lower rates of postoperative chronic pain (299) (401). So the time limitations 
caused by the several-month delay while the project was redesigned resulted in fewer than 
the optimal number of participants being recruited. This combined with a patient group 
with lower rates of prolonged postoperative pain meant that study power was somewhat 
compromised. As such, it seems likely that a (or several) type II error(s) exists in this study. 
Chronic pain is usually arbitrarily defined as pain lasting >3 or > 6 months (402), so time 
constraints forcing the time point at which pain was  defined as ‘chronic’ to be 3 months 
had little effect. On the other hand, if chronic pain is defined as ‘pain persisting beyond the 
accepted period of healing’, three months is well beyond this point. 
In terms of study methodology, as with essentially every study ever conducted, flaws 
occurred for the sake of practicality. As highlighted earlier, the structure of the pre-
admission clinic necessitated assistance from the nursing staff for the purposes of 
recruitment. Of course, their clinical duty to the patient came before the study, and so some 
potentially eligible participants were ‘shielded’ by them. From conversations with the staff, 
it seems these patients were largely the very anxious, and/or those with significant medical 
comorbidities. This likely skewed the baseline characteristics of participants in favour of 
those having less psychological and physiological distress. Given the correlation between 
psychological state and the experience of pain (65), it is likely that any sampling bias related 
to psychological distress would have impacted the pain scores at baseline, and potentially at 
the later follow-up points. 
Some of questionnaires used were designed and only validated for use in chronic pain 
patients, so their accuracy in those in acute pain has not yet been validated. However, the 
associations between the depression and anxiety scores and pain in this study points to the 
questionnaires having a wider scope than their current use. It was felt that questionnaires 
developed for pain would be more useful in a pain-based study than some of the more 
general screening questionnaires. The quality of answers to the questionnaires may have 
been compromised during the six week and three month follow up calls. This is mere 
conjecture, but a large number of participants answered ‘straight zeros’ to the DASS-21 by 




to answer sensitive/embarrassing questions to a 21 year-old male may have resulted in 
some participants answering ‘zero’ to all questions to avoid embarrassment.  
The same observer recruited all patients, conducted all baseline assessments, and all 
patients at both follow-up points. It therefore stands to reason that any subconscious 
bias/biases that this observer possessed would have been distributed equally to each 
participant. In one sense, this is a good thing, because if said bias/biases can be identified, 
then the correction/s can be applied much more easily than for multiple potential biases 
from multiple observers. On the other hand, if said bias/biases cannot all be identified, 
which it is likely some have not been, then the results may be systematically skewed in a 
certain direction. In terms of follow-up, obviously every effort was made to contact all 
participants. This is evidenced by only three participants being lost to follow-up at the six 
week stage. At the three month stage, however, it is possible that ‘those in pain’ at six 
weeks were subconsciously deemed ‘more important’ to the study, and pursued more 
intensely. The single observer was not clinically experienced in the field of gynaecology. As a 
result, participants’ reports of pain may have been inaccurately attributed to their surgery, 
when it is possible that some participants’ pain was unrelated to the operation (such as a 
recurrence of their original condition). This was mitigated somewhat by comparing the 
subjective nature of the pain at each time point, using the information gathered by the SF-
McGill. If the subjective nature of the pain was significantly different, it seems likely the 
cause of the pain was different as well. 
Loss to follow-up was not a large problem, with only five of fifty four participants (9.3%) 
dropping out. All five dropouts were unreachable by telephone despite multiple attempts to 
contact them. Three were lost at the six week stage, with another two being unreachable 
during the three month assessments. It is of note that four of these participants (and all the 
three lost at six weeks) had been identified as being ‘in pain’ at the baseline assessment; the 
remaining one suffered from an unspecified mental illness. This raises suspicion that those 
lost to follow-up at this point were potentially more likely to develop lasting pain states. 
Only eight participants (14.8%) were identified as experiencing clinically significant pain at 
the six week follow-up point. Given the characteristics of those who were lost, it seems that 
this is an underestimate, and the true number would probably lie between 14.8-20.4%, 




8.3 Generalisability and applicability 
The underlying population from which this cohort was recruited was adult women being 
pre-admitted for gynaecological surgery at Christchurch Women’s Hospital. The exclusion 
criteria were not particularly limiting. The largest limiting factor in terms of the 
generalisability of the results was likely the ‘safety net’ put in place by the nurses to protect 
patients they felt were vulnerable from the study. However, given that recruitment for this 
study was undertaken over an 11-week period, it stands to reason that roughly one fifth of 
the patients who met the study’s criteria in 2014 were approached. In the absence of any 
explanation to the contrary, it seems likely that this cohort is representative of women 
undergoing moderate to major gynaecological surgery through the Christchurch Women’s 
Hospital Pre-Admissions Clinic. The sample size, as has been mentioned, is likely to have 
affected the results, and the conclusions and generalisability as a result. The participants did 
not appear to significantly differ from the New Zealand Census data in any aspect, and as 
such it is likely that these results could be cautiously applied to many of New Zealand’s 















8.4 Implications of the results, and recommendations for future research 
The results of this study have raised more questions: 
 A void in the literature seems to exist surrounding postoperative pain in gynaecological 
surgeries in New Zealand. For example, the rates of each route of performing a 
hysterectomy do not appear to have been published, nor has any data been published 
comparing the pain outcomes of the respective routes.  
 Gabapentin has shown promise in prevention of post-hysterectomy chronic pain (302). It 
is strongly believed that a randomised controlled trial of gabapentin or similar 
medications in the prevention of chronic post-operative pain should be conducted in 
future. 
 Further research is needed into subacute pain, and its relationship with peri-operative 
and chronic pain states dissected. At present it seems to be seen simply as an arbitrary 
half-way point between acute and chronic pain. However the biological and 
psychological changes that occur around this time have not yet been studied in-depth, 
and key pieces of this puzzle are still missing. 
 Further research is required into the relative merits and demerits of intra-operative 
administration of opioids. Particularly alarming was the statistically significant pattern of 
intra-operative tramadol being prescribed to those who would later develop prolonged 
pain states. It is unclear from our results exactly what role opioids play in the 
development of these states, be it a protective factor or a risk factor, but it seems clear 
that an effect is present. 
In terms of recommendations for carrying out future studies of this vein, the most 
prominent to have come out of this study is that: 
 The required sample size for studies such as this is larger than typically expected. A 
greater number of researchers collecting data (the nature of a university thesis restricts 
this to simply the student investigator) in a multi-centre manner would allow for many 
more participants to be recruited within a similar time-frame. 
 Record-keeping following surgery, particularly anaesthetic and PACU notes, is often not 
performed to the level required for high-quality research data. Although it would greatly 




real-time would be of much greater use. Perhaps recruiting individual anaesthetists and 
nurses as data collectors could assist with this. 
 A follow-up period of 6-12 months would likely be optimal for a study such as this. 
Within the restraints of the B.Med.Sc (Hons) programme this was not feasible, as 
increasing the follow-up period to 6 months would have almost halved the already 
limited sample size. 
8.5 Conclusion 
At 6 weeks and 3 months postoperatively, 15.7% and 8.2% of participants, respectively were 
deemed to be experiencing significant pain. The psychometric questionnaires used 
frequently detected differences between those experiencing pain and those not 
experiencing pain at given observation points. Only the BIPQ, however, appeared predictive 
of developing prolonged postoperative pain. The mean difference (7.4 on a 0 to 50) scale is 
even enough to see it used clinically alongside other predictive measures. 
The cold pressor test did not show any significant differences between ‘those in pain’ at 
baseline, and those ‘not in pain’ at baseline. However, pain threshold as measured by this 
test was shown to predict outcomes of persistent or prolonged pain. Pain tolerance and 
pain endurance followed the same trend, but were not statistically significant.  
No surgical approach or group was significantly more likely to develop a persistent or 
prolonged pain state than others. However, laparotomy seemed to be associated with 
poorer pain outcomes. This is supported by the literature. Intraoperatively, those who 
would later develop persistent or prolonged pain states were less likely to receive opioids, 
or more likely to receive larger doses when they did. Perhaps worryingly, those who would 
later develop persistent or prolonged pain states were significantly more likely to receive 
tramadol intraoperatively. There were no statistically significant trends in postoperative 
inpatient or discharge prescribing. In terms of prescription of specific NSAIDs and weak 
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Appendix one – Questionnaires 
 





Ethnicity/ethnicities: NZ Māori / NZ European / Other (please specify)  
 
 
Date of birth: 
 
 
Gender: M / F/ Other 
 
 
Have you ever suffered from any of the following? (Please circle, and give 
details):  
                Pain persisting for three months or longer 
 
                Mental illness 
 
                Other major medical condition 
 
                Any condition requiring surgery 
 
Are you a : Non-smoker 
 
                 : Former smoker* 
 





* For how many years did you smoke?       
 How many packs per day (on average) did you consume?   
 
** For how many years have you smoked?  
How many packs per day (on average) do you consume?  
 
How many standard drinks of alcohol would you consume on an average 
week?  
 









                     
 
Section 2: Pain Information 
 
(a) How severe is your pain? 
If zero (0) means ‘no pain’, and ten (10) means ‘the worst pain you can 
imagine’, what have been your levels of pain over the past week?   
 
 No pain Worst pain you can imagine 
Lowest pain 0          1          2          3          4          5          6          7          8          9          10 
  
Highest pain         0          1          2          3          4          5          6          7          8          9          10 
  
Usual pain         0          1          2          3          4          5          6          7          8          9          10 
 
Section 3: Healthcare and medications 
 
(a) How many times in the past 3 months have you seen any of 
the following for your pain? 
 
 
 Number of Times 
General Practitioner / family doctor 
 
Medical specialists (e.g. Orthopaedic surgeon, Neurologist, Rheumatologist) 
 






Alternative/Complementary health professionals (e.g. Homeopath, 
Massage Therapist, Acupuncturist) 
 
A hospital emergency department 
 




Section 4: Work and education status 
 
(a) What is your current work status? 
Please tick () one box below to show your current work status: 
(Work includes paid work, unpaid work, study and caring for others.)  
 
 1 I am working in paid or unpaid work, or studying 
 2 I am actively involved in the process of returning to paid or unpaid work 
 3 I plan to return to paid or unpaid work, but not right now 
 4 I am not planning on returning to paid or unpaid work 
 
(b) On the line below, please indicate how important working is to you 
 




      0        1        2        3        4        5        6        7        8        9        10 
 
(c ) On the line below, please indicate how confident you are about your ability to 
work 
 




      0        1        2        3        4        5        6        7        8        9        10 
 
 
If you are working, please answer the following questions: 
 
How many hours do you work each week?  
     
 
 
(g) Has this changed because of your pain? 
____________ hours paid work (d) 
____________ hours voluntary work (e) 
____________ hours education (f) 
Yes            No  
 
 
How many hours would you like to work 
each week?  
     
 
____________ hours paid work (d) 
____________ hours voluntary work (e) 










(Please tick the box 
the applies to you) 
 
1 WINZ benefit 
2 ACC Weekly Compensation 
3 Superannuation 




(l) What is your 
highest level of 
education? 
 
(Please tick the box 
the applies to you) 
 




5  University 






Short form McGill Pain Questionnaire (Ronald Melzack © 1984) 
Please indicate with a tick [√] the boxes that describe how your pain feels now: 




    
SHOOTING 
 
    
STABBING 
 
    
SHARP 
 
    
CRAMPING 
 
    
GNAWING 
 
    
HOT-BURNING 
 
    
ACHING 
 
    
HEAVY 
 
    
TENDER 
 
    
SPLITTING 
 
    
TIRING-
EXHAUSTING 







    
FEARFUL 
 




    
Please mark on the line below where you would rate your pain now 
NO I-----------------------------------------------------------------------I WORST 
PAIN                                                                                     PAIN POSSIBLE 






























Section 5:  Questionnaires 
 
DASS-21 
Please read each statement and circle a number 0, 1, 2 or 3 which indicates how much 
the statement applied to you over the past week.  There are no right or wrong answers.  Do 
not spend too much time on any statement. 




0 – Did not apply to me at all 
1 - Applied to me to some degree, or some of the time 
2 - Applied to me a considerable degree, or a good part of time 



























































































1 I found it hard to wind down  0            1             2             3    
   
2 I was aware of dryness of my mouth  0            1             2             3    
   
3 I couldn’t seem to experience any positive feeling at all 0            1             2             3    
   
4 I experienced breathing difficulty (eg excessively rapid breathing, 
breathlessness in the absence of physical exertion) 
0            1             2             3    
   
5 I found it hard to work up the initiative to do things 0            1             2             3    
   
6 I tended to over-react to situations 0            1             2             3    
   
7 I experienced trembling (eg in the hands) 0            1             2             3    
   
8 I felt that I was using a lot of nervous energy 0            1             2             3    
   
9 I was worried about situations in which I might panic and make a fool 
of myself 
0            1             2             3    
   
10 I felt that I had nothing to look forward to 0            1             2             3    
   
11 I found myself getting agitated 0            1             2             3    
   
12 I found it difficult to relax 0            1             2             3    
   
13 I felt down-hearted and blue 0            1             2             3    
   
14 I was intolerant of anything that kept me from getting on with what I 
was doing 
0            1             2             3    
   
15 I felt I was close to panic 0            1             2             3    
   
16 I was unable to become enthusiastic about anything 0            1             2             3    
   
17 I felt I wasn’t worth much as a person 0            1             2             3    
   
18 I felt that I was rather touchy 0            1             2             3    
   
19 I was aware of the action of my heart in the absence of physical 
exertion (eg sense of heart rate increase, heart missing a beat) 
0            1             2             3    




20 I felt scared without any good reason 0            1             2             3    
   
21 I felt that life was meaningless 0            1             2             3    













































Circle any number from 0 = “never” to 5 = “always” for each item. Never                         Always 
1. During painful episodes it is difficult for me to think of anything besides the pain 0      1       2       3       4      5 
   
2. I will stop any activity as soon as I sense pain coming on 0      1       2       3       4      5 
  
 
3. I worry when I am in pain 0      1       2       3       4      5 
4.  
 
4 Pain makes me nauseous. 0      1       2       3       4      5 
  
 
5. I avoid important activities when I hurt 0      1       2       3       4      5 
  
 
6. I can’t think straight when in pain 0      1       2       3       4      5 
  
 
7. Pain seems to cause my heart to pound or race 0      1       2       3       4      5 
  
 
8. When I feel pain I think that I might be seriously ill 0      1       2       3       4      5 
  
 
9. As soon as pain comes on, I take medication to reduce it 0      1       2       3       4      5 
  
 
10. When I feel pain, I am afraid that something terrible will happen 0      1       2       3       4      5 
  
 
11. I think that if my pain gets too severe, it will never decrease. 0      1       2       3       4      5 
  
 
12. I find it difficult to calm my body down after periods of pain 0      1       2       3       4      5 
  
 
13. When I hurt, I think about the pain constantly 0      1       2       3       4      5 
  
 
14. When pain comes on strong, I think that I might become paralysed or more 
disabled 
0      1       2       3       4      5 
  
 
15. Pain sensations are terrifying 0      1       2       3       4      5 
  
 
16. I find it hard to concentrate when I hurt 0      1       2       3       4      5 
  
 
17. I go immediately to bed when I feel severe pain. 0      1       2       3       4      5 
  
 
18. I try to avoid activities that cause pain 0      1       2       3       4      5 
  
 
19. I begin trembling when engaged in an activity that increases pain 0      1       2       3       4      5 
  
 
20. When I sense pain, I feel dizzy or faint 0      1       2       3       4      5 
 Circle any number from 0 = “never” to 5 = “always” for each item. 








Please note how confident you are that you can do the following things at present (despite 
the pain).  
Remember, this questionnaire is not asking whether or not you have been doing these 
things, but rather how confident you are that you can do them at present despite your 
pain. 
 
To answer, please circle one of the numbers on the scale beside each sentence, 
where 0 = not at all confident and 6 = completely confident. 
 
 Circle any number from 0 = “Not at all confident” to 6 = “Completely 
confident” for each item. 
Not at all                      Completely 
confident                         confident 
1 I can enjoy things, despite the pain. 0       1       2       3       4      5      6 
   
2 I can do most of the household chores (e.g. tidying-up, washing dishes, 
etc) despite the pain. 
0       1       2       3       4       5     6 
   
3 I can socialise with my friends or family members as often as I used to 
do, despite the pain. 
0       1       2       3       4       5     6 
   
4 I can cope with my pain in most situations. 0       1       2       3       4       5     6 
   
5 I can do some form of work, despite the pain.  (‘Work’ includes 
housework, paid and unpaid work). 
0       1       2       3       4       5     6 
   
6 I can still do many of the things I enjoy doing, such as hobbies or leisure 
activity, despite the pain. 
0       1       2       3       4       5     6 
   
7 I can cope with my pain without medication. 0       1       2       3       4       5     6 
   
8 I can still accomplish most of my goals in life, despite the pain. 0       1       2       3       4       5     6 
   
9 I can live a normal lifestyle, despite the pain. 0       1       2       3       4       5     6 
   











We would like to know how much your pain is preventing you from doing what you would 
normally do, or from doing it as well as you normally would.  Please think of the overall 
impact of your pain in your life, not just when the pain is at its worst.   A score of (0%) 
means no disability at all, and a score of (100%) signifies that all of the activities in which 
you would normally be involved have been totally disrupted or prevented by your pain. 
For each of the 7 categories of activity listed, please circle the number on the scale which 
describes your typical level of disability.   
1. Family/home responsibilities 
This category refers to activities related to the home or family.  It includes chores or duties performed around the house (e.g. 
gardening) and errands or favours for other family members (e.g. driving the children to school). 
0% 10 20 30 40 50% 60 70 80 90 100% 
no disability mild moderate severe total  
disability 
2. Recreation 
This category includes hobbies, sports, and other similar leisure time activities. 
0% 10 20 30 40 50% 60 70 80 90 100% 
no disability mild moderate severe total  
disability 
3. Social Activity  
This category refers to activities which involve participation with friends and acquaintances other than family 
members.  It includes parties, theatre, concerts, dining out, and other social functions. 
0% 10 20 30 40 50% 60 70 80 90 100% 
no disability mild moderate severe total  
disability 
4. Occupation 
This category refers to activities that are a part of or directly related to one’s job.  This includes non-paying jobs as 
well, such as household duties or volunteer work. 
0% 10 20 30 40 50% 60 70 80 90 100% 
no disability mild moderate severe total  
disability 
5. Sexual Behaviour 
This category refers to the frequency and quality of one’s sex life. 
0% 10 20 30 40 50% 60 70 80 90 100% 
no disability mild moderate severe total  
disability 
6. Self-care 
This category includes activities which involve personal maintenance and independent daily living (e.g. taking a 
shower, driving, getting dressed etc.) 
0% 10 20 30 40 50% 60 70 80 90 100% 
no disability mild moderate severe total  
disability 
7. Life-support activity 
This category refers to basic life-supporting behaviours such as eating, sleeping, and breathing.   
0% 10 20 30 40 50% 60 70 80 90 100% 







The following questions are designed to measure how satisfied you are with different 
aspects of your pain treatment.  Please circle the number that best describes the degree of 
satisfaction you have with the pain treatment you have received. 
 
1 How satisfied were you with the overall pain 
management you received whilst in hospital? 
 
Not satisfied                                                              Completely satisfied  
0         1         2         3         4         5         6         7         8         9         10 
2 How satisfied were you with staff warmth, 
respect, kindness and willingness to listen? 
 
0         1         2         3         4         5         6         7         8         9         10 
3 How satisfied were you with the competence 
of the staff? 
 
0         1         2         3         4         5         6         7         8         9         10 
4 How satisfied were you with the ease of 
getting to appointments, hours of treatment, 
etc? 
 
0         1         2         3         4         5         6         7         8         9         10 
5 Was the treatment you received in line with 
what you expected at the beginning of 
treatment? 
 
Yes                                   No 
6 How useful have you found any written 
resources you’ve been given? 
 
 
Not useful                                                                         Extremely useful 
0         1         2         3         4         5         6         7         8         9         10  
N/A 
7 Would you recommend this treatment to 
someone you know who has a similar 
problem? 
 















For the following questions, please circle the number that best corresponds to your views: 
How much does your illness affect your life? 
0              1              2             3             4              5              6             7              8              9              10 
no affect at all                                                                                                  severely affects my life  
 
How long do you think your illness will continue? 
0              1              2             3             4              5              6             7              8              9              10 
a very short time                                                                                                                        forever 
How much control do you feel you have over your illness? 
0              1              2             3             4              5              6             7              8              9              10 
absolutely no control                                                                               extreme amount of control 
 
How much do you think your treatment can help your illness? 
0              1              2             3             4              5              6             7              8              9              10 
not at all                                                                                                                      extremely helpful 
 
How much do you experience symptoms from your illness? 
0              1              2             3             4              5              6             7              8              9              10 
no symptoms at all                                                                                        many severe symptoms 
 
How concerned are you about your illness? 
0              1              2             3             4              5              6             7              8              9              10 
not at all concerned                                                                                           extremely concerned 
 
How well do you feel you understand your illness? 
0              1              2             3             4              5              6             7              8              9              10 





How much does your illness affect you emotionally? (e.g. does it make you angry, scared, 
upset or depressed?) 
0              1              2             3             4              5              6             7              8              9              10 
not at all affected emotionally                                                       extremely affected emotionally 
 
Please list in rank-order the three most important factors that you believe caused your illness. 




















For the following questions, please circle the number that best corresponds to your views: 
People aren’t taking my medical condition seriously enough 
0                                    1                                    2                              3                                  4 
Strongly disagree                                                                                                  Strongly agree 
 
My body is telling me I have something dangerously wrong 
0                                    1                                    2                              3                                  4 
Strongly disagree                                                                                                  Strongly agree 
 
My illness has put my body at risk for the rest of my life 
0                                    1                                    2                              3                                  4 
Strongly disagree                                                                                                  Strongly agree 
 
I am afraid I might injure myself accidentally 
0                                    1                                    2                              3                                  4 
Strongly disagree                                                                                                  Strongly agree 
 
If I were to try to overcome it, my pain would increase 
0                                    1                                    2                              3                                  4 
Strongly disagree                                                                                                  Strongly agree 
 
Simply being careful that I do not make any unnecessary movements is the safest thing I can do to 
prevent my pain from worsening 
0                                    1                                    2                              3                                  4 





I wouldn’t have this much pain if there weren’t something potentially dangerous going on in my 
body 
0                                    1                                    2                              3                                  4 
Strongly disagree                                                                                                  Strongly agree 
 
Pain always means I have injured my body 
0                                    1                                    2                              3                                  4 
Strongly disagree                                                                                                  Strongly agree 
 
Pain lets me know when to stop exercising so that I don’t injure myself 
0                                    1                                    2                              3                                  4 
Strongly disagree                                                                                                  Strongly agree 
 
It’s not really safe for a person with a condition like mine to be physically active 
0                                    1                                    2                              3                                  4 
Strongly disagree                                                                                                  Strongly agree 
 
I’m afraid that I might injure myself if I exercise 
0                                    1                                    2                              3                                  4 
Strongly disagree                                                                                                  Strongly agree 
 
I can’t do all the things normal people do because it’s too easy for me to get injured 
0                                    1                                    2                              3                                  4 
Strongly disagree                                                                                                  Strongly agree 
 
No-one should have to exercise when he/she is in pain 
0                                    1                                    2                              3                                  4 




Appendix two – Participant information sheet and 
consent form 
 
Participant Information Sheet 
Study title: The transition from acute to chronic post-surgical 
pain – a prospective cohort study 
Principal 
investigator: 
Name Professor Edward Shipton 
Department Anaesthesia 
Position Head of Department 
Contact phone 
number: 
 (03) 3641642 
 
Introduction 
Thank you for showing an interest in this project.  Please read this information sheet 
carefully. Take time to consider and, if you wish, talk with relatives or friends, before deciding 
whether or not to participate.  
If you decide to participate we thank you.  If you decide not to take part there will be no 
disadvantage to you and we thank you for considering our request.   
What is the aim of this research project? 
This project is a study of patients before and after surgery to determine those with risk of 
developing, and to develop strategies to help managing and preventing, acute persistent and 
chronic pain.  
Who is funding this project? 
This project is receiving funding from the University of Otago, Christchurch  
Why have you been asked to be a part of this study? 
For this study we hope to recruit women undergoing elective gynaecological surgeries at 
Christchurch Women’s Hospital. Some patients undergoing these types of surgery 




in this study, you must be sixteen years of age or older, able to give informed consent, and 
able to understand the English language without an interpreter.  
 
If you participate, what will you be asked to do? 
At the pre-admission assessment clinic you will be asked to provide written informed consent 
to take part in this project. Before your surgery, you will be asked to complete a number of 
questionnaires which explore your previous and recent health, and the impact on your life of 
the condition for which you are having an operation.   You will also be asked to undertake a 
‘cold pressor test’ to determine your pain tolerance. This test involves placing your hand or 
forearm in cold water. This will become more and more uncomfortable and when it becomes 
unbearable you can withdraw your hand and forearm from the water. Completing the 
questionnaires and the cold pressor test should take no more than 30 minutes. 
We will also ask for your consent to access your relevant medical records.  
At six weeks after your surgery, and at three months after your surgery, you will be 
telephoned at a time convenient to you (we will ask for suitable times at your first interview), 
and the questionnaires will be repeated, in order to assess changes in your functioning, 
mood, and other factors since your surgery. These telephone interviews should take no 
longer than 20 minutes. 
No aspect of your care will be affected by either refusal or agreement to participate.  
Participation is 100% voluntary.   
Is there any risk of discomfort or harm from participation? 
The validated questionnaires will explore you experiences of pain and your emotional and 
mental states. If the line of questioning develops in such a way that you feel hesitant or 
uncomfortable you may decline to answer any particular question(s).  
The cold pressor test will induce mild to moderate discomfort, ending when you voluntarily 
remove your hand from the water. In the very unlikely scenario that you have any major 
adverse reaction to the test, a clinician will be called to ensure your safety.  
What specimens, data or information will be collected, and 
how will they be used?  
Information recorded will be your NHI number (for medical records access), your responses 
to the questionnaires, and the results of your cold pressor test. These results, along with 
relevant information from your medical records, will be used along with the information from 
others participating in this study, to give the final results. 
You will be asked to indicate whether or not you would like to receive a copy of the results of 





What about anonymity and confidentiality? 
Every attempt will be made to preserve your anonymity. Only the researchers listed on this 
form will have access to the raw data collected in the course of this study. The data collected 
will be securely stored for at least 10 years in secure electronic servers, and locked physical 
cabinets, so that only those mentioned below will be able to gain access to it. Your data will 
have all factors which could potentially identify you removed before results are compiled, 
and published. 
If you agree to participate, can you withdraw later? 
You may withdraw from participation in the project at any time up until your de-identified data 
has been integrated into the study results, and without any disadvantage to yourself.  
 
Any questions? 
If you have any questions now or in the future, please feel free to contact either: 
Name Professor Edward Shipton 
Position Head of Department 
Department Anaesthesia 
Contact phone number: 
 (03) 3641642 
Name Associate Professor Peter Sykes 
Position Head of Department 
Department Obstetrics and Gynaecology 
Contact phone number: 
(03) 3641642 
Name Campbell MacLachlan 
Position Medical student 
Department Anaesthesia 
Contact phone number: 
(03) 3641642 
 
This study has been approved by the University of Otago Human Ethics Committee (Health). 
If you have any concerns about the ethical conduct of the research you may contact the 
Committee through the Human Ethics Committee Administrator (phone +64 3 479 8256 or 
email gary.witte@otago.ac.nz). Any issues you raise will be treated in confidence and 







The transition from acute to chronic post-
surgical pain – a prospective cohort study 
Principal Investigator: Professor Edward Shipton (ted.shipton@otago.ac.nz (03) 
3641642) 
CONSENT FORM FOR PARTICIPANTS 




1. I have read the Information Sheet concerning this study and understand the aims 
of this research project. 
2. I have, if I so desired, had sufficient time to talk with other people of my choice 
about participating in the study.   
3. I confirm that I meet the criteria for participation which are explained in the 
Information Sheet. 
4. All my questions about the project have been answered to my satisfaction, and I 
understand that I am free to request further information at any stage.  
5. I know that my participation in the project is entirely voluntary, and that I am free to 
withdraw from the project at any time without disadvantage. 
6. I know that as a participant I will be expected to complete the validated 
questionnaires and the cold pressor test. I also give consent for the researchers 
listed on the information sheet to access my medical records as relevant to this 
study. 
7. I appreciate that the cold pressor test that most likely will induce mild to moderate 
discomfort, ending when I remove my hand. 
8. I know that the validated questionnaires will explore my experiences of pain and 
my emotional and mental states, and that if the line of questioning  develops in 




particular question(s) , and /or may withdraw from the project without disadvantage 
of any kind. 
9. I understand the nature and size of the risks of discomfort or harm which are 
explained in the Information Sheet. 
10. I know that when the project is completed all personal identifying information will be 
removed from the paper records and electronic files which represent the data from 
the project, and that these will be placed in secure storage and kept for at least ten 
years.  
11. I understand that the results of the project may be published and be available in 
the University of Otago Library, but that any personal identifying information will 
remain confidential between myself and the researchers during the study, and will 
not appear in any spoken or written report of the study. 
12. I know that there is no remuneration offered for this study, and that no commercial 
use will be made of the data.  
Signature of participant:  Date: 
   
   
Signature and name of witness:  Date: 
   
   
   
 
